---
document_datetime: 2023-09-21 19:27:42
document_pages: 88
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/fulphila-public-assessment-report_en.pdf
document_name: fulphila-public-assessment-report_en.pdf
version: success
processing_time: 73.193911
conversion_datetime: 2025-12-23 08:18:15.34709
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

20 September 2018 EMA/724003/2018 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Fulphila

International non-proprietary name: pegfilgrastim

Procedure No. EMEA/H/C/004915/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

+44 (0)20 3660 6000

Facsimile

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure ..............................................7                                |                                                                                                          |
|---------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier......................................................................................7     |                                                                                                          |
| 1.2. Steps taken for the assessment of the product.........................................................8              |                                                                                                          |
| 2. Scientific discussion                                                                                                  | ................................................................................9                        |
| 2.1. Problem statement                                                                                                    | ...............................................................................................9         |
| 2.1.1. Disease or condition...........................................................................................9   |                                                                                                          |
| 2.1.2. Epidemiology and risk factors, screening tools/prevention                                                          | ......................................9                                                                  |
| 2.1.3. Biologic features, aetiology and pathogenesis........................................................9             |                                                                                                          |
| 2.1.4. Clinical presentation, diagnosis and stage/prognosis                                                               | ............................................10                                                           |
| 2.1.5. Management...................................................................................................10    |                                                                                                          |
| 2.2. Quality aspects                                                                                                      | ..................................................................................................11     |
| 2.2.1. Introduction....................................................................................................11 |                                                                                                          |
| 2.2.2. Active Substance.............................................................................................12    |                                                                                                          |
| 2.2.3. Finished Medicinal Product................................................................................16       |                                                                                                          |
| 2.2.4. Discussion on chemical, pharmaceutical and biological aspects..............................23                      |                                                                                                          |
| 2.2.1. Conclusions on the chemical, pharmaceutical and biological aspects                                                 | ......................24                                                                                 |
| 2.2.2. Recommendation for future quality development.................................................24                   |                                                                                                          |
| 2.3. Non-clinical aspects                                                                                                 | ............................................................................................24           |
| 2.3.1. Introduction....................................................................................................24 |                                                                                                          |
| 2.3.2. Pharmacology                                                                                                       | .................................................................................................25      |
| 2.3.3. Pharmacokinetics.............................................................................................27    |                                                                                                          |
| 2.3.4. Toxicology                                                                                                         | ......................................................................................................28 |
| 2.3.5. Ecotoxicity/environmental risk assessment                                                                          | .........................................................32                                              |
| 2.3.6. Discussion on non-clinical aspects......................................................................33         |                                                                                                          |
| 2.3.7. Conclusion on the non-clinical aspects................................................................33           |                                                                                                          |
| 2.4. Clinical aspects                                                                                                     | ..................................................................................................34     |
| 2.4.1. Introduction....................................................................................................34 |                                                                                                          |
| 2.4.2. Pharmacokinetics.............................................................................................35    |                                                                                                          |
| 2.4.3. Pharmacodynamics..........................................................................................42       |                                                                                                          |
| 2.4.4. Discussion on clinical pharmacology...................................................................50           |                                                                                                          |
| 2.4.5. Conclusions on clinical pharmacology.................................................................51            |                                                                                                          |
| 2.5. Clinical efficacy                                                                                                    | ..................................................................................................51     |
| 2.5.1. Dose response study(ies)                                                                                           | .................................................................................51                      |
| 2.5.2. Main study(ies)                                                                                                    | ...............................................................................................51        |
| 2.5.3. Discussion on clinical efficacy............................................................................66      |                                                                                                          |
| 2.5.4. Conclusions on the clinical efficacy.....................................................................67        |                                                                                                          |
| 2.6. Clinical safety                                                                                                      | ....................................................................................................67   |
| 2.6.1. Discussion on clinical safety                                                                                      | ..............................................................................79                         |
| 2.6.2. Conclusions on the clinical safety.......................................................................80        |                                                                                                          |
| 2.7. Risk Management Plan........................................................................................80       |                                                                                                          |
| 2.8. Pharmacovigilance..............................................................................................83    |                                                                                                          |
| 2.9. Product information                                                                                                  | ............................................................................................83           |
| 2.9.1. User consultation.............................................................................................83   |                                                                                                          |

<div style=\"page-break-after: always\"></div>

| 2.9.2. Additional monitoring.......................................................................................83   |
|-------------------------------------------------------------------------------------------------------------------------|
| 3. Biosimilarity assessment.......................................................................84                    |
| 3.1. Comparability exercise and indications claimed ......................................................84            |
| 3.2. Results supporting biosimilarity............................................................................85     |
| 3.3. Uncertainties and limitations about biosimilarity.....................................................86           |
| 3.4. Discussion on biosimilarity...................................................................................86   |
| 3.5. Extrapolation of safety and efficacy ......................................................................86      |
| 3.6. Additional considerations.....................................................................................86   |
| 3.7. Conclusions on biosimilarity and benefit risk balance ..............................................87             |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

a.u

Absorbance units

ADA

anti-drug antibodies

AE

adverse event

AET

Analytical evaluation threshold

AIEX

anionic exchange chromatography

ANC AUC0-t

above baseline levels of the subject's absolute neutrophil count

ANC Cmax

maximum absolute neutrophil count

ANC Tmax

time of maximum change from baseline of absolute neutrophil count

ANC

absolute neutrophil count

ANOVA

analysis of variance

ANS

1-anilinonaphthalene-8-sulfonate

APQR

Annual Product Quality Review

AR

Analytical Reagent

AS

active substance

ATR

Attenuated Total Reflectance

AUC

analytical ultracentrifugation

AUC0-∞

area under the curve extrapolated to infinity

AUC0-t

area under the curve from time zero to t

BPI

Brief Pain Inventory

BRL

Biocon Research Limited

BSC/LAF

Bio Safety Cabinet / Laminar Air Flow

CAS

Chemical Abstract Service

CD

Circular dichroism

CD34+ Cmax

maximum concentration change from baseline for CD34+ cell counts

CD34+ Tmax

time of maximum change from baseline for CD34+ cell counts

CD34+

hematopoietic progenitor antigen positive cells

CD34+AUC0-t  area under the curve from time zero to t from baseline for CD34+ cell counts CDS Coding DNA Sequence

CE-SDS

Capillary electrophoresis sodium dodecyl sulfate method

CHR

Chromatography

CI

confidence interval

cIEF

iso- electric focusing

CIEX

cation exchange chromatography

CIEX-HPLC

Cation-exchange-High performance liquid chromatography

Cmax

maximum concentration

CPP

Critical Process Parameter

CQA

Critical quality attribute

CSR

clinical study report

CSS

clinical summary of safety

CTCAE

common terminology criteria for adverse events

CV

coefficient of variation

Da

Daltons

DF

diafiltration

DLS

Dynamic light scattering

DP

Drug Product

DS

Drug Substance

DSC

Differential Scanning Calorimetry

DSN

duration of severe neutropenia

ECG

electrocardiogram

ECOG

Eastern Cooperative Oncology Group

EDTA

Ethylenediaminetetraacetic acid

ELISA

enzyme-linked immunosorbent assay

EMA

European Medicines Agency

EoPCB

End of Production Cell Bank

EP

Elution Pool

ESI

Electrospray Ionization

EU

European Union

EU

European Union

EU/ml

Endotoxin units/millileter

FDA

Food and Drug Administration

FMEA

Failure Modes Effect Analysis

FN

Febrile neutropenia

FTIR

Fourier Transform Infrared Spectroscopy FP finished product

GC

Gas Chromatography

GCSF

granulocyte colony-stimulating factor

GLM

general linear model

Glu-C

Endoproteinase Glu-C

GPP

cGMP Pilot Plant

HCDNA

Host Cell Deoxyribonucleic Acid

HCl

Hydrochloric acid

HCP

Host Cell Protein

HMW

high-molecular-weight

HMWP

high molecular weight proteins

HPLC

High Pressure Liquid Chromatography

IB

Inclusion Body

IEX

Ion Exchange Chromatography

INN

international non-proprietary name

IPC

In-Process Control

IPT

In-Process Test

IRS

Internal reference standard

ISR

Injection site reaction

ITT

intent-to-treat

JP

Japanese Pharmacopeia

kDa

kilo Dalton

Kel

terminal elimination rate constant

LB

Luria Bertani

LMW

low-molecular-weight

LMWP

low molecular weight proteins

LOD

Limit of detection

LOQ

Limit of quantitation

LS

least squares

MALDI-TOF

matrix-assisted laser desorption ionization time of flight mass spectrometry

MCB

Master Cell Bank

mdeg

Millidegree

MHRA

Medicines and Healthcare Products Regulatory Agency

MNFS-60

murine derived cells from a myelogenous leukemia

mPEG-AL

α-Methyl-ω-(3-oxopropoxy), polyoxyethylene

MS

Mass spectrometry

MYL-1401H

Pegylated Granulocyte Colony Stimulating Factor

N

number of patients in the sample

N

total number of patients with available data during Cycle 1

NA

Not Applicable

Nab

neutralizing antibodies

NCCN

National Comprehensive Cancer Network

NCI

National Cancer Institute

NIBSC

National Institute for Biological Standards and Control

NLT

Not Less Than

NMR

Nuclear Magnetic Resonance;

NMT

Not More Than

NTU

Nephelometric Turbidity Units

OD

Optical Density

PAR

proven acceptable ranges

PC

process characterisation

pCPP

Potential Critical Process Parameter

PD

pharmacodynamic(s)

PEG

Polyethylene Glycol propionaldehyde

PEG

polyethylene glycol

PEG-GCSF

Pegylated Granulocyte Colony Stimulating Factor

PFS

single-use prefilled syringe

Ph. Eur.

European Pharmacopeia

PI

Principle Investigator (if not Product Information)

PK

pharmacokinetic(s)

PMF

Peptide mass fingerprinting

PP

per-protocol (population)

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

PPCB Post Production Cell Bank PPM parts per million PPs process parameters PT preferred term PV process validation QA Quality Assurance QC Quality Control RCB Research Cell Bank RFU Relative fluorescence units rhG-CSF recombinant human granulocyte colony-stimulating factor rINN recommended International Non-proprietary Name r-met-HuG-CSF   recombinant methionyl human granulocyte colony-stimulating factor RP-HPLC Reverse Phase High-Performance Liquid Chromatography RRT Relative Retention Time RSD Relative standard deviation RT Retention Time SAP statistical analysis plan SBS Side by side SC subcutaneous SD Standard deviation SDS-PAGE Sodium Dodecyl Sulfate- Polyacrylamide Gel Electrophoresis SE standard error SEC-HPLC Size Exclusion High-Performance Liquid Chromatography Sl. Serial SLS Static light scattering SmPC summary of product characteristics SPR Surface plasmon resonance t1/2 apparent terminal elimination half-life TAC docetaxel, doxorubicin, and cyclophosphamide; a chemotherapy combination ('Taxotere'+'Adriamycine'+Cyclophosphamide) TEAE treatment-emergent adverse event TFF Tangential Flow Filtration Tmax time to maximum concentration TNM tumor-node-metastasis (disease stage of cancer diagnosis) TOF-MS Time-of-Flight Mass Spectrometry TSE Transmissible Spongiform Encephalopathy UF ultrafiltration ULT Ultra Low Temperature US United States (of America) USP United States Pharmacopeia USP upstream processing UV Ultraviolet VAS Visual analogue scale Vd/F apparent volume of distribution WCB Working Cell Bank WFI Water for injections λmax Wavelength maxima

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant MYLAN S.A.S submitted on 3 November 2017 an application for marketing authorisation to the European Medicines Agency (EMA) for Fulphila, through the centralised procedure falling within the Article 3(1) and point 1 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 14 September 2017.

The applicant applied for the following indication: reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

## The legal basis for this application refers to:

Article 10(4) of Directive 2001/83/EC - relating to applications for a biosimilar medicinal products

The application submitted is composed of administrative information, complete quality data, appropriate non-clinical and clinical data for a similar biological medicinal product.

The chosen reference product is:

Medicinal product which is or has been authorised in accordance with Union provisions in force for not less than 10 years in the EEA:

- Product name, strength, pharmaceutical form: Neulasta, 6mg, solution for injection
- Marketing authorisation holder: Amgen Europe B.V.
- Date of authorisation: 22/08/2002
- Marketing authorisation granted by:
- -Union
- Marketing authorisation number: EU/1/02/227/001-002-004

Medicinal product authorised in the Union/Members State where the application is made or European reference medicinal product:

- Product name, strength, pharmaceutical form: Neulasta, 6mg, solution for injection
- Marketing authorisation holder: Amgen Europe B.V.
- Date of authorisation: 22/08/2002
- Marketing authorisation granted by:
- -Union
- Marketing authorisation number: EU/1/02/227/001-002-004

Medicinal product which is or has been authorised in accordance with Union provisions in force and to which bioequivalence has been demonstrated by appropriate bioavailability studies:

- Product name, strength, pharmaceutical form: Neulasta, 6mg, solution for injection
- Marketing authorisation holder: Amgen Europe B.V.
- Date of authorisation: 22/08/2002
- Marketing authorisation granted by:
- -Union
- Marketing authorisation number: EU/1/02/227/001-002-004

<div style=\"page-break-after: always\"></div>

## Information on Paediatric requirements

Not applicable

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The applicant did not seek Scientific advice at the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Martina Weise Co-Rapporteur:  Alexandre Moreau

| The application was received by the EMA on                                                                                                                                                                                                                                                   | 3 November 2017                      |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|
| The procedure started on                                                                                                                                                                                                                                                                     | 23 November 2017                     |
| The Rapporteur's first Assessment Report was circulated to all CHMP members on                                                                                                                                                                                                               | 16 February 2018                     |
| The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on                                                                                                                                                                                                            | 14 February 2018                     |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC members on                                                                                                                                                                                                          | 19 February 2018                     |
| The CHMP agreed on the consolidated List of Questions to be sent to the applicant during the meeting on                                                                                                                                                                                      | 22 March 2018                        |
| The applicant submitted the responses to the CHMP consolidated List of Questions on                                                                                                                                                                                                          | 22 August 2018                       |
| The following GMP inspection was requested by the CHMP and their outcome taken into consideration as part of the Quality/Safety/Efficacy assessment of the product:                                                                                                                          |                                      |
| - A GMP inspection at one manufacturing site responsible for primacy packaging, processing operations for the medicinal product, quality control testing of the medicinal product and secondary packaging in India on 16 March 2018. The outcome of the inspection carried out was issued on | 18 July 2018                         |
| The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Questions to all CHMP members on                                                                                                                                                                      | 29 August 2018 and 13 September 2018 |

<div style=\"page-break-after: always\"></div>

| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                                 | 6 September 2018   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Fulphila on | 20 September 2018  |

## 2. Scientific discussion

## 2.1. Problem statement

## 2.1.1. Disease or condition

Fulphila is indented to be used for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

The Applicant claims the authorisation for Fulphila (also referred to as MYL-1401H in this report) as a similar product to Neulasta (EU) which was granted a marketing authorisation in the EU on 22 of August 2002. The proposed indication for Fulphila is the same as for the reference product Neulasta (EU).

## 2.1.2. Epidemiology and risk factors, screening tools/prevention

Chemotherapy-induced neutropenia and its subsequent infectious complications represent the most common dose-limiting toxicity of cancer therapy. Febrile neutropenia, FN, develops in 25% to 40% of treatment-naïve patients during common chemotherapy regimens depending on the patient population; the dosage, timing and type of chemotherapy used 1 . The severity of febrile neutropenia depends on the dose intensity of the chemotherapy regimen, the patient's prior history of either radiation therapy or use of cytotoxic treatment, and comorbidities.

## 2.1.3. Biologic features, aetiology and pathogenesis

The principal regulator of physiological granulopoiesis human G-CSF is a glycoprotein that has been shown to regulate the production and release of neutrophils from the bone marrow, mediated via a single affinity extracellular receptor. By binding and signalling through granulocyte colony-stimulating factor receptor (G-CSFR), G-CSF has multiple effects on circulating neutrophils and on neutrophil precursors in bone marrow 2 .

Stimulation of precursor cell proliferation in the bone marrow leads to an increase in the total mass of G-CSFR-expressing cells, which serves as a negative regulator of G-CSF levels through accelerated clearance of G-CSF 3 .

1  Dinan MA, Hirsch BR, Lyman GH. Management of chemotherapy-induced neutropenia: measuring quality, cost, and value. J Natl Compr Canc Netw. 2015 Jan;13(1):e1-7

2

3 recent findings and current challenges. Blood. 2008 Feb 15;111(4):1767-72

Roberts AW. G-CSF: a key regulator of neutrophil production, but that's not all! Growth Factors. 2005 Mar;23(1):33-41 Anderlini P, Champlin RE. Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals:

<div style=\"page-break-after: always\"></div>

## 2.1.4. Clinical presentation, diagnosis and stage/prognosis

Chemotherapy-induced neutropenia is a significant dose-limiting toxicity in cancer treatment and a major risk factor for infection-related morbidity and mortality. Febrile neutropenia, FN, develops in 25% to 40% of treatment-naïve patients during common chemotherapy regimens depending on the patient population; the dosage, timing and type of chemotherapy used. The occurrence of febrile neutropenia often necessitates chemotherapy delays or dose reductions. It may also lengthen hospital stay; increase monitoring, diagnostic, and treatment costs; and reduce patient quality of life.

## 2.1.5. Management

Primary prophylaxis with colony-stimulating factors, CSFs, reduces the frequency of chemotherapy induced neutropenia, all-cause mortality during chemotherapy, and need for hospital care e.g. in breast cancer 4  . The administration of G-CSF can accelerate the development of neutrophils from committed progenitors, thereby reducing the incidence, duration, and severity of neutropenia 5 . Forms of G-CSF such as filgrastim and lenograstim including biosimilars, are administered by a course of daily injections, whereas pegfilgrastim allows once-per-cycle administration and may avoid suboptimal daily dosing.

The European Organisation for Research and Treatment of Cancer ( EORTC) 2010 guidelines cover use of granulocyte-colony stimulating factor, G-CSF, to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Prophylaxis with a CSF is recommended for:

- Specified chemotherapy regimens with &gt;20% risk of FN
- Specified chemotherapy regimens with 10% to 20% risk of FN, subject to patient specific risk factors such as elderly age (≥65 years) and neutrophil count
- Patients with a previous episode of FN

Pegfilgrastim and filgrastim can accelerate neutrophil recovery, leading to a reduced duration of the neutropenic phase in patients receiving cytotoxic chemotherapy. Filgrastim was initially approved for the prevention of infection as manifested by febrile neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy. The pivotal study in patients with small cell lung carcinoma receiving cyclophosphamide, etoposide, and doxorubicin chemotherapy demonstrated an approximately 50% reduction in the incidence of febrile neutropenia and duration of Grade 4 neutropenia, as well as statistically significant reductions in the incidence of hospitalizations and IV antibiotic usage 6 . Subsequent indications for filgrastim included engraftment following bone marrow transplantation, mobilization of peripheral blood progenitor cells and engraftment following transplantation, induction or consolidation chemotherapy for acute myeloid leukemia, and severe chronic neutropenia. Because of its relatively short half-life of 3.5 hours, filgrastim is administered once daily by SC administration no less than 24 hours after chemotherapy and continuing until absolute neutrophil count (ANC) recovery within each cycle of treatment. Shortcomings of filgrastim include the requirement for either daily visits to the clinic or home injections by the patient during the period of administration, frequent ANC monitoring, the possibility of missed doses, and suboptimal duration of treatment (either too short or too long). Efforts to overcome these limitations led to the

4 Renner P, Milazzo S, Liu JP, Zwahlen M, Birkmann J, Horneber M. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients. Cochrane Database Syst Rev. 2012 Oct

17;10

5 Dale DC. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs. 2002;62 Suppl 1:1-15 6 Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991 Jul 18;325(3):164-70

<div style=\"page-break-after: always\"></div>

PEGylation of the G-CSF protein. The subsequent PEGylation of the G-CSF protein filgrastim altered the pharmacokinetic (PK) profile, resulting in slower clearance and a prolonged half-life (between 15 and 80 hours), thus permitting a single injection per cycle of chemotherapy 7 . Pegylation of filgrastim increases the size of filgrastim so that it becomes too large for renal clearance. Due to its high molecular weight, pegfilgrastim exhibits limited transport into the blood capillaries after SC administration and enters the systemic circulation via an indirect route, through the lymphatics.

With a long half-life and target-mediated clearance, pegfilgrastim remains in the circulation until the bone marrow neutrophil precursors start to come back after chemotherapy. Pegfilgrastim (Neulasta) was first authorized for marketing in the EU and US in 2002.

## About the product

The active substance is a recombinant human granulocyte colony-stimulating factor (G-CSF) with a single 20 kDa peg-filgrastim as active substance. This application is based on Article 10(4) of CD 2001/83/EC (similar to a reference biological product) claiming Fulphila being 'biosimilar' to Neulasta EU sourced (EU/1/02/227/001-002+004). The reference product is a pegylated (ATC code pegfilgrastim: L03AA13) filgrastim (ATC code filgrastim: L03AA02), thus a colony stimulating factor (CSF; L03AA).

## Type of Application and aspects on development

The current product specific (non-clinical/clinical) guidance document is the document 'Biosimilar medicinal products containing recombinant granulocyte-colony stimulating factor (Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues), EMEA/CHMP/BMWP/31329/2005'. This annex has been in effect since 01/07/2006 whereas the current overarching NfGs (i) Similar biological medicinal products, ii) Similar biological medicinal products containing biotechnology-derived proteins as active substance: nonclinical and clinical issues, iii) Similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues) are in effect since 2014-15.

The applicant did not seek Scientific Advice from the CHMP but had interactions with the Medicines and Healthcare Products Regulatory Agency (MHRA) on the clinical requirements.

## GMP

GMP compliance of all drug substance and drug product manufacturing sites was confirmed by either a valid  GMP  certificate  or  a  manufacturing  authorisation  (sites  located  in  the  EEA).  In  addition,  a confirmation was provided that the manufacturing authorisation (MIA) for the EU batch release site at McDermott Laboratories will  be  updated to  add the  new  medicinal  product  and  the  testing  sites  by variation to the MIA.

## 2.2. Quality aspects

## 2.2.1. Introduction

The finished product (FP) is presented as a solution for injection containing 6 mg pegfilgrastim (INN) as active substance. Other ingredients are: D-sorbitol, polysorbate 20 and sodium acetate.

7 Foley C, Mackey MC. Mathematical model for G-CSF administration after chemotherapy. J Theor Biol. 2009 Mar 7;257(1):27-44

<div style=\"page-break-after: always\"></div>

The product is available in a pre-filled syringe (Type I glass), with a bromobutyl rubber stopper and a stainless steel needle with or without an automatic needle guard.

Fulphila has been developed as biosimilar medicinal product to the reference product Neulasta.

The name Pegfilgrastim (MYL-1401H) is used to describe the active substance in this application.

## 2.2.2. Active Substance

## General information

Pegfilgrastim active substance (AS) is a conjugate of recombinant methionyl human granulocyte colony-stimulating factor (r-met-HuG-CSF; filgrastim), covalently linked to a 20 kDa monomethoxypolyethylene glycol (mPEG) .

Filgrastim is an E.coli -derived non-glycosylated rhG-CSF, consists of 175 amino acids and is identical to natural human G-CSF except for the presence of an additional methionine at the N-terminal end, which is covalently linked to a single 20 kDa PEG (overall relative molecular mass of approx. 40 kDa). Filgrastim has an α-helical structure and contains five cysteine residues, four of which form two intramolecular disulphide bonds required to maintain the biologically active conformation of the protein.

## Manufacture, characterisation and process controls

The active substance is manufactured at Biocon Limited, Electronics City, Bangalore, India.

## Description of manufacturing process and process controls

The Pegfilgrastim active substance manufacturing process has been adequately described.

The manufacturing process is a convergent process of the two critical intermediates recombinant filgrastim and activated mPEG.

The upstream process of GCSF manufacture is a high density E. coli cell culture process. The process ends with the harvest and cell lysis to gain the inclusion bodies (IB) containing the protein of interest. One batch of IBs (corresponding to the harvest of one upstream processing (USP) run) is further processed downstream by the purification process starting with thawing and solubilisation of the IBs followed by a refolding step and additional chromatographic and filtration purification steps. The intermediate is formulated and stored until PEGylation.

The manufacture and control of the activated mPEG has been adequately described.

Batches of the intermediate are pooled for PEGylation. The PEGylated GCSF is purified by a series of chromatography and filtration steps, including sterile filtration into appropriate containers. A batch numbering system is in place and has been described.

No reprocessing is claimed for AS manufacture. The bulk AS is shipped from the AS manufacturing site to the finished product (FP) manufacturing site for processing to finished product. The process has been adequately defined and in-process controls (IPCs) described to control the process.

## Control of materials

G-CSF is expressed in an E.coli expression system.

The generation of the expression plasmid and the production strain has been described. A synthetic GCSF gene has been prepared in order to optimise the codon usage for expression in E.coli .

<div style=\"page-break-after: always\"></div>

Characterisation data of the active substance show that the transcription of the synthetic gene results in the desired amino acid sequence. A standard two-tier cell banking system is used (master cell bankMCB and working cell bank-WCB) and cell banks and appropriate stability testing criteria are established for cell bank testing. The criteria applied for testing of the current WCB will be applied for future testing upon establishment of a new WCB.

Stability of the expression construct was investigated by generating and testing an end-of-production cell bank (EoPCB) and a post-production cell bank (PPCB).

Information on the raw materials is considered satisfactory. Compendial raw materials are tested in accordance with the corresponding monograph. If no compendial monograph is available, in-house specifications have been set.

Some column resins/filters contain specified materials of animal origin. Respective TSE certificates have been provided.

The synthesis of mPEG aldehyde is adequately described. The PEGylation reagent, activated mPEG has been classified as an intermediate.

## Control of critical steps and intermediates

The manufacturing process employs multiple controls to ensure consistent quality of the active substance. Critical process steps have been defined during development and process characterisation. Before initiation of the process characterisation experiments, a Failure Mode and Effect analysis (FMEA) risk assessment was conducted to identify which process parameters could have an impact on product quality. These parameters are termed potential critical process parameters (pCPP). Process characterisation experiments were performed to identify real CPPs from the list of pCPPs.

The manufacturing process description is very detailed. Critical and non-critical process parameters (PPs) are defined with their acceptable ranges. The classification of the PPs is considered conclusive and consistent.

In-process controls (IPC) and in-process tests (IPT) have been defined to ensure consistent quality of the active substance. Acceptance criteria, and relative ranges, have been adequately justified.

Overall, together with the non-critical PPs and the proposed IPCs and IPTs, the upstream process is considered adequately controlled. The composition of the media, feed solutions and buffers are stated. The downstream process is considered adequately described and controlled by the proposed in process controls and tests.

G-CSF is considered a critical intermediate. Appropriate tests for identity, purity, content and potency are included. Batch analysis and stability data of G-CSF are acceptable. The proposed storage condition and time for this intermediate in specified containers is accepted.

The activated PEG is declared as being manufactured under GMP conditions in compliance with ICH Q7. The QP declaration certificate confirming the GMP status is in order. The starting material has been defined. The manufacturing process has been elaborated in sufficient detail. All relevant information on mPEG-AL and the starting material is provided.

Release and stability specifications are provided.

## Process validation

The pegfilgrastim active substance manufacturing process has been validated adequately. Consistency in production has been shown  on an appropriate number of commercial batches. Appropriate protocols for the validation of i) the manufacture of the intermediate G-CSF and ii) PEGylation of G-CSF were

<div style=\"page-break-after: always\"></div>

provided. All acceptance criteria for the critical operational parameters and likewise acceptance criteria for the in-process tests are fulfilled demonstrating that the purification process consistently produces active substance of reproducible quality that complies with the predetermined specification and inprocess acceptance criteria. Hold periods for process intermediates have been qualified by data on physicochemical stability and bioburden for in-process stages and buffer solutions.

The clearance of process-related impurities (host cell proteins, DNA and other specified impurities) has been satisfactorily evaluated and supports the proposed control strategy. Chromatography resin and ultrafiltration cartridge lifetimes have been appropriately qualified. Validation also includes details of process plant cleaning validation, leachables and extractables evaluation for process plant contact materials and finished active substance shipping validation.

Column re-use is foreseen during the manufacture of G-CSF and the number of cycles is defined based on respective re-use validation studies included in the dossier which are considered acceptable. Specified membrane re-use is also suitably discussed.

## Manufacturing process development

The manufacturing process development of pegfilgrastim active substance was initially based on a manufacturing process which was then optimised to the commercial process.

A comparability study has been carried on pre- and post-change batches, and data provided demonstrated that the change did not have a significant influence on the quality of the product.

Comprehensive process characterisation (PC) studies have been performed for the single process steps and based on the results the process parameters were classified with respect to their criticality. The scaled-down models used for these studies were representative of the at scale manufacturing process.

## Characterisation

The active substance has been comprehensively characterised by orthogonal methods.

The Applicant has provided characterisation data on both pegfilgrastim and the protein backbone alone, G-CSF.

The intact molecular mass of the entire molecule was confirmed. The correct attachment of PEG to the primary PEGylation site was verified. The mass was within the expected range, substantiating the correct attachment of the PEG moiety. The disulphide bond structure of pegfilgrastim was shown to be consistent with the expected structure. Overall, the primary sequence of pegylated G-CSF was confirmed.

The apparent molecular weight was also analysed.The secondary and tertiary structure of pegfilgrastim was analysed. The size variants were analysed by various methods. Surface plasmon resonance (SPR) was used to determine the binding kinetics to the G-CSF receptor. The results were comparable within the batches of pegfilgrastim and to the reference product. The biological activity of pegfilgrastim was investigated using the compendial NFS-60 cell proliferation assay. The results were within the predefined acceptance criteria and confirm that pegfilgrastim possesses the correct three-dimensional structure and exhibits qualitatively and quantitatively the expected biological activity.

The G-CSF (before the PEGylation step) was characterised with respect to intact mass, primary structure, confirmation of the disulphide bonds, higher order structure, and biological activity. Qualification data for the potency assay were provided substantiating its suitability. Overall, the identity and the expected structure of the G-CSF could be confirmed.

The PEG moiety was characterised. These data confirm the expected molecular mass and distribution.

<div style=\"page-break-after: always\"></div>

Orthogonal chromatographic methods were applied to analyse purity and impurities. Characterisation of the impurities was performed thoroughly with respect to identification of the impurities and their stability indicating properties. Size-related variants were identified. The main degradation pathways of Pegfilgrastim are dimerisation/ oligomerisation, truncation and Des-PEGylation and oxidation, as confirmed by stress studies. Overall, the characterisation of product-related impurities is considered comprehensive and the results are consistent across the orthogonal methods.

Process-related impurities were monitored during manufacture of the consistency batches. The small molecule impurities were consistently below the detection level. Data for HCP and DNA were below the detection levels. Free PEG was detectable at consistently low levels in the more concentrated AS solution. Bacterial endotoxin was below detection level in the finished AS.

In summary, the characterization is considered appropriate for this type of molecule.

## Specification

The active substance specification includes test parameters on identity, potency and content, purity, impurities, excipients, microbiological safety. The list of parameters is considered comprehensive. The active substance release and shelf-life specifications are identical overall (and contain the same number of parameters) but differ in the acceptance limits for AS-related impurities.

Biological activity (potency) of the active substance is determined by parallel line assay using M-NFS60 cells. The cells depend on the presence of growth factors like G-CSF for their viability and proliferation. The potency assay mimics the functioning of Pegfilgrastim (MYL-1401H) based on the purported mechanism of action in vivo. There is a defined concentration range of G-CSF in which a linear correlation between the proliferation of the cells when stimulated with growth factor is observed. Determination of proliferation is carried out by photometric measurement of absorption observed from the reduction of tetrazolium compound (formazan) which produces colour under assay conditions.

The release specification limits for post peaks by RP-HPLC and HMWP by SE-HPLC were established in consideration of the proposed shelf life limits and the rate of degradation observed for these species over the proposed shelf life.

## Analytical methods

The descriptions of non-compendial analytical methods used in the control of the active substance have been provided and are found to be acceptable in the level of detail.

Residual DNA is an in-house method using commercial extraction and quantitative kits. Residual HCP is determined by a commercial ELISA kit. Overall, sufficiently detailed information has been provided with regard to the validation of the proposed in-house analytical procedures. The analytical methods used have been adequately described and (non-compendial methods) appropriately validated in accordance with ICH guidelines.

## Batch analysis

Batch release results have been provided for AS batches, that were included in clinical studies, process validation and stability studies. All batches comply with the predefined specification acceptance criteria in place at the time of analysis.

Batch release results have been provided for several batches of AS, that were included in clinical studies, process validation and stability studies. The batches were produced at commercial scale. All batches comply with the predefined specification acceptance criteria in place at the time of analysis. In addition, batch data provided represent the early and final commercial processes.

<div style=\"page-break-after: always\"></div>

## Reference materials

Sufficient details have been provided on the reference standard system established for AS manufacture. In-house laboratory standards (internal reference standards, IRS) and certified reference materials are used. The currently used primary IRS used for PEG-GCSF potency measurement has been adequately qualified. Any secondary IRS will be qualified against the primary IRS in terms of potency which is considered adequate.

## Stability

A suitable 24 months shelf life is proposed for active substance when stored at 2-8 o C in Type I glass bottles.

Stability data are provided for several commercial AS batches which have been stored for the proposed shelf-life at the proposed long-term storage condition and for a specified period at accelerated conditions  which is in accordance with ICH requirements. The stability protocols comprise all AS release test parameters and are therefore considered appropriate. Stability-indicating methods have been used in investigations. The data provided show that the batches complied with limits in force at that time although the specifications have been updated during the study but also with the proposed AS specification containing tighter limits for the product-related substances.

The stability data provided is supportive of the proposed shelf life for active substance stored in the proposed packaging.

## 2.2.3. Finished Medicinal Product

## Description of the product and pharmaceutical development

Fulphila finished product consists of MYL-1401H pegfilgrastim as active substance, D-sorbitol (tonicity agent), polysorbate 20 (stabilising agent) and sodium acetate buffer (Buffering agent) is obtained by titrating acetic acid and sodium hydroxide.

Fulphila is supplied in a single-use prefilled syringe (PFS)  containing 0.6 mL of the solution at a protein concentration of 10 mg/mL resulting in 6 mg pegfilgrastim per syringe. A specified overfill is included to ensure a withdrawal of 0.60 mL. The qualitative composition of Fulphila is the same as that of the reference product Neulasta

All excipients comply with the specifications described in the respective Ph. Eur. monographs.

It has been confirmed that the excipients used during the production of the medicinal product are not of animal origin and all excipients are well known and widely used in pharmaceutical products.

The intended commercial formulation is the same as that used in clinical trials.Despite identical target concentrations with the reference product, various studies were performed during pharmaceutical development to further support the proposed final composition of Fulphila.

Taking all study results together the qualitative and quantitative composition of Fulphila is sufficiently justified with regard to finished product stability.

Adequate characterisation studies were performed on the FP manufacturing process. The acceptable ranges of the process parameters were appropriately evaluated with regard to product quality and stability Finally, compatibility of all materials of construct used for FP manufacture and product stability was confirmed.

<div style=\"page-break-after: always\"></div>

The finished product is filled into a Ph. Eur. Type I glass PFS closed with a bromobutyl elastomer with a Fluorotec coating and fitted with a staked hypodermic needle. The PFS is presented with or without a needle guard. Appropriate compatibility studies were also conducted with Fulphila formulation and the selected primary packaging system including a thorough evaluation of extractables and leachables. Overall it can be concluded that there is no impact of the container closure materials on protein stability at the recommended storage conditions. The suitability of the selected container closure system and its compatibility with Fulphila FP is satisfactorily demonstrated. Container closure integrity test used during stability studies to replace sterility testing and during manufacturing process validation was appropriately validated.

A risk assessment on elemental impurities in Fulphila FP was conducted in line with ICH Q3D. Subsequent analysis of FP lots confirmed the absence of metal residues.

## Manufacture of the product and process controls

Batch release for the finished product is performed at McDermott Laboratories, Malahide Road, Dublin, Ireland.

Batch formula for a representative FP batch is provided. The manufacturing process is depicted in detail. The entire manufacturing process is separated in three stages. Stage A includes all steps up to the final formulated FP. Stage B comprises filtration and filling. In stage C the filled syringes are visually inspected and then assembled with the plunger rod and a needle guard. In addition, the single process steps are additionally described along with the in-process controls (IPC)/tests (IPT) performed at this stage.

The process description is satisfactory. The final formulated bulk is controlled for bioburden and subsequently sterile filtered.  A major objection was raised during the evaluation procedure with regard to the adequacy of some of the controls proposed during this step of the manufacturing process, as they would not provide sufficient assurance in the control of sterility of the finished product. The Applicant has satisfactorily addressed this point and revised the application accordingly.

All process parameters applied during manufacture are listed together with their target value and the proven acceptable ranges (PAR) as evaluated during pharmaceutical development or process validation. The Applicant's designation to critical and non-critical process parameters is acceptable.

The maximum hold times are supported by appropriate data generated in hold time studies.

Manufacturing process validation was performed by the manufacture of an adequate number of consecutive FP batches. The process parameters applied during the manufacture were kept within their PARs. Overall, the process validation program applied was adequate to evaluate process consistency. All parameters checked during manufacture or at release were within the pre-defined ranges and all results of the IPCs met the predefined acceptance criteria. The batch release results complied with the FP specification acceptance criteria. Hence, the FP manufacturing process can be considered validated.

Validation of the aseptic conditions during FP filling was demonstrated by media fill runs. Impact of shipping on Fulphila stability was adequately studied by various storage and shipping studies conducted with AS and FP samples. Evidence was provided that the routine conditions during shipment can maintain the desired temperature range.

Finally, it was demonstrated that the technical properties of the PFS and the product quality characteristics are not negatively affected by the assembly process of the PFS with the needle guard.

The container closure components are purchased pre-sterilised.

<div style=\"page-break-after: always\"></div>

## Product specification

The FP specification includes test parameters on identity, potency and content, purity and impurities, pharmaceutical properties, microbiological safety, pre-filled syringe functionality and safety device testing.

All acceptance limits are adequately justified.

The Applicant is recommended to revise the FP shelf-life specification for the parameter  'aggregates', as well as for the impurities quantified by RP-HPLC, when data from further batches are available (see recommendation).

## Analytical methods

In-house analytical methods used in the control of finished product are common with those of the active substance with the exception of product-specific parameters. Methods are appropriately validated in accordance with ICH guidelines. The analytical methods are shown to be stability indicating. The protocol and the report on method transfer of the potency assay used at the site responsible for QC testing on importation into the EU has been provided.

## Batch analysis

Batch release results of several FP batches are presented, manufactured at commercial scale and which were used in clinical studies/ process validation/ stability studies. All results comply with the specification acceptance criteria applicable at the time of testing but also comply with the currently proposed tighter limits for impurities and product-related substances, and confirm consistency of the manufacturing process. In addition, analysis of FP batches in comparison to Neulasta batches did not reveal any new unknown impurities.

## Reference materials

FP is released against the same reference standards and control materials described for AS.

## Post-Approval Change Management Protocol (PACMP)

In preparation for Brexit, the applicant included a PACMP covering the addition of test sites for finished product release to ensure uninterrupted EU importation testing. No changes are being made to the analytical  methods.  The  only  change  being  made  is  to  the  location  of  the  testing  laboratories.  The additional  laboratories  all  hold  GMP  Certificates.  The  new  sites  will  be  qualified  according  to  a  preapproved method transfer protocol. The data from the analytical method transfer will be submitted as a Type IB variation.

The proposed PACMP is deemed acceptable.

## Stability of the product

The proposed FP shelf-life in the commercial container system is 36 months when stored at 5±3 °C.

Stability studies have been initiated in accordance to ICH requirements with Fulphila FP batches at commercial scale. Stability-indicating methods have been used in investigations. Stability data at recommended storage temperature have been presented for a suitable number of FP lots packaged in the proposed container closure system, as well as for process validation batches.    Here, not only physicochemical parameters but also functional stability has been tested. No out-of-specification results have been reported. Under accelerated conditions, an increase in some of the impurities could be observed in the FP.

<div style=\"page-break-after: always\"></div>

The parameters 'extractable volume' and 'actuation of safety device' were checked in a separate functional stability study. The results obtained so far do not show any impact on extractable volume and actuation of the safety device of the PFS.

Forced degradation studies were performed in the course of analytical comparability evaluation against Neulasta.

These data confirm that Fulphila FP is susceptible to degradation when subject to several stress agents (e.g. photo exposure, mechanical stress, acidic and alkaline pH).

For long-term storage, appropriate instructions are included in the SmPC section 6.4 ('store in a refrigerator (2°C-8°C))'. Moreover, the warning to keep the container in the outer carton is supported by the results of the photo-stability study. The SmPC storage instruction that Fulphila may be exposed to not more than 30°C for a maximum of 72 hours is supported by stability data.

Fulphila PFS stability after freezing has been demonstrated with the applicants own data. However, in view of a potential impact on container closure integrity freezing of the PFS is not recommended.

In conclusion, appropriate stability studies on Fulphila FP have been conducted. The claimed FP shelf life of 36 months when stored at 2-8°C is supported by sufficient data and is approvable.

## Adventitious agents

Contract vendors are stated as having been audited and only animal origin-free materials procured for cell banking and manufacture of bulk AS. Raw materials are confirmed free of Transmissible Spongiform Encephalopathies and Bovine Spongiform Encephalopathies and in compliance with the Note for guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products (EMA/410/01). All have been confirmed as being of yeast or vegetable origin.

TSE certificates provided for materials of biological and non-biological origin used throughout active substance and finished product manufacture have been provided

The control of microbial contamination has been evaluated elsewhere in the dossier.

Viral adventitious agents are not applicable for the E.coli cell line. Cell banks have been satisfactorily evaluated for presence of bacteriophage.

## Biosimilarity

Overall, the analytical data package comprehensively covers the quality attributes that need to be compared for demonstration of analytical similarity. Orthogonal methods have been applied to assess the individual parameters.

The number of batches of EU-sourced Neulasta as well as of Fulphila were considered adequate for the analytical comparability analysis.

The Applicant executed a risk assessment of the critical quality attributes of Neulasta and ranked the CQAs according to their potential influence on efficacy and safety of the product. The Applicant consequently thoroughly investigated these attributes and the test and reference product were highly similar if not identical in this respect.

Analytical similarity was evaluated based on a straight-forward statistical approach.

The approach to evaluating comparability by comparing individual data from multiple batches of test product with individual data from multiple batches of US and EU reference product is acceptable

<div style=\"page-break-after: always\"></div>

although the statistical approach proposed for acceptance criteria is not accepted as the primary measure of comparability - assessment has primarily based comparison on the actual data ranges observed.

The primary sequence has been confirmed by peptide mass fingerprinting (ESI MS) after either Glu-C or Trypsin digest. Intact mass and the N-terminal PEGylation were confirmed by MALDI-TOF MS. The results confirm the desired amino acid sequence, PEGylation at the N-terminal methionine and similarity of the intact molecular mass.

SEC-MALS was used as an orthogonal method to determine the molar mass and hydrodynamic radius and also polydispersity. The data show a high level of conformity of the products regarding polydispersity thus confirming analytical similarity.

Secondary and higher order structures were investigated by various orthogonal analytical methods. SS-bonds could be confirmed by the peptide map, the secondary structure was analysed using far UV CD and fourier transformed infrared spectroscopy (FTIR). The levels of α -helix, β -sheet, β -turn and random coils were comparable between the products within a given method. Levels of free cysteine were determined and again, the results were within the predefined acceptance criteria. No considerable differences were detected when subjecting the biosimilar and the reference product to near UV CD, differential scanning calorimetry (DSC), intrinsic and extrinsic fluorescence spectrometry. The NMR spectroscopy was used for a comparative fingerprint analysis only which is considered appropriate taking into account the challenges associated with the PEG-moiety. Overall, it can be concluded that the biosimilar Fulphila is highly similar to the reference product in terms of primary, secondary and tertiary structure.

This was further confirmed by the data showing similarity with respect to relative potency as measured by the compendial NFS-60 cell proliferation assay and with respect to GCSF-receptor affinity as measured by surface plasmon resonance.

The protein content data show that Fulphila meets this requirement for analytical similarity to Neulasta.

Purity and impurities were investigated applying the chromatographic methods used for release, i.e. CIEX, RP-HPLC and SE-HPLC. The risk associated with aggregates and dimers was classified as 'high' due to the potential impact on clinical safety (immunogenicity risk) whereas the Di-PEGylated species and deamidated species are considered having a 'moderate risk'.

The aggregates and dimers were analysed by SE-HPLC (aggregates, dimers+Di-PEGylated GCSF), analytical ultracentrifugation- AUC (aggregates), SEC-MALS (aggregates) and RP-HPLC (dimers). DiPEGylated species were also analysed by CIEX by which they can be separated from the dimers. The average level of aggregates is slightly higher in Fulphila compared to Neulasta with two single values outside the similarity range. As the amount of Di-PEGylated species is lower than in Neulasta, the average sum of HMWPs as measured by SE-HPLC is still below the average sum of HMWPs in Neulasta. Taking additionally into account the relatively low absolute level of aggregates found in Fulphila, the biosimilarity is not considered impaired by this issue. Aggregates were additionally analysed by CESDS and AUC and the results were consistent among batches showing similarity of biosimilar and reference product in this respect, too.

LMWP include Des-PEG pegfilgrastim and N-terminal truncated species without PEG. SE-HPLC data show that the LMWP content determined in the biosimilar product is well below the amount of LMWP in Neulasta.

The RP-HPLC data show slight differences in the profiles of test and reference product. The amount of Q108 deamidated pegfilgrastim is slightly higher in Fulphila than in EU-Neulasta. However, the

<div style=\"page-break-after: always\"></div>

absolute value is still rather low and no impact on safety is expected; thus, this difference is not considered precluding biosimilarity. The amount of M138 oxidised species is highly similar in biosimilar and reference products. The amount of dimer as measured by RP-HPLC is lower in Fulphila which is in agreement with the findings in the SE-HPLC analysis.

Comparability of biosimilar and reference product in terms of stability has been investigated by forced degradation studies under various stress conditions: acidic and alkaline conditions, oxidative stress, light exposure, accelerated, temperature stress conditions and mechanical stress by agitation. Even though slight differences in the degradation rates occurred, the degradation pathways were the same. The Applicant discussed the differences and postulates that the observed differences may be ascribed to the different age of the finished products when starting the stress studies and to the non-linear kinetics of degradation. Overall, the analytical similarity of MYL-1401H to Neulasta EU is considered proven.

The primary sequence has been confirmed as has the site of PEGylation. Secondary and higher order structures were investigated by various orthogonal analytical methods. Overall, it can be concluded that the biosimilar MYL-1401H is highly similar to the reference product in terms of primary, secondary and tertiary structure. This was further confirmed by the data showing similarity with respect to potency.

Purity and impurities were investigated. High and Low-molecular -weight species were analysed. Comparability of biosimilar and reference product in terms of stability has been investigated and no particular issues regarding the stability of MYL-1401H arose during DS and DP stability studies.

The similarity of EU to US-Neulasta is considered sufficiently demonstrated. This is of importance since several clinical studies were performed using the US-derived reference product. A summary of the biosimilarity studies is shown in Table 1 .

Table 1: Summary of biosimilarity studies

| Molecular parameter   | Attribute           | Methods for control and characterization                     | Key findings                                    |
|-----------------------|---------------------|--------------------------------------------------------------|-------------------------------------------------|
| Primary structure     | Amino acid sequence | Peptide mass fingerprinting (Glu-C digest)                   | Identical primary sequence to reference product |
| Primary structure     | Amino acid sequence | Peptide mass fingerprinting (Trypsin digest)                 | Identical primary sequence to reference product |
| Primary structure     | Amino acid sequence | Intact MALDI TOF MS                                          | Highly similar to reference product             |
| Primary structure     | Pegylation site     | N-terminal Pegylation by GluC digestion - MALDI- TOF MS      | Highly similar to reference product             |
| Primary structure     | Pegylation site     | N-terminal Pegylation by CNBr/trypsin digestion - ESI-TOF MS | Highly similar to reference product             |
| Primary structure     | Pegylation site     | N-terminal Pegylation by Trypsin digestion - MALDI-TOF MS    | Highly similar to reference product             |

<div style=\"page-break-after: always\"></div>

| Molecular parameter    | Attribute                        | Methods for control and characterization                       | Key findings                                                                                             |
|------------------------|----------------------------------|----------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
|                        | Polydispersity                   | MALDI-TOF                                                      | Highly similar to reference product                                                                      |
| Higher order structure | Secondary and tertiary structure | Non-reduced peptide mass fingerprint Glu-C Digest (disulphide) | Identical to reference product                                                                           |
|                        |                                  | Far UV CD spectroscopy                                         | Highly similar to reference product                                                                      |
|                        |                                  | FTIR                                                           | Highly similar to reference product                                                                      |
|                        |                                  | Ellman's reagent (free Cysteine)                               | Highly similar to reference product                                                                      |
|                        |                                  | Extrinsic Fluorescence                                         | Highly similar to reference product                                                                      |
|                        |                                  | Near UV CD spectroscopy                                        | Highly similar to reference product                                                                      |
|                        |                                  | Differential scanning calorimetry                              | Highly similar to reference product                                                                      |
|                        |                                  | Intrinsic Fluorescence                                         | Highly similar to reference product                                                                      |
|                        |                                  | 1D NMR                                                         | Highly similar to reference product                                                                      |
| Biological Activity    | Potency                          | MNFS-60 cell proliferation                                     | Highly similar to reference product                                                                      |
|                        | Receptor Binding                 | Surface Plasmon Resonance                                      | Highly similar to reference product                                                                      |
| Charge                 | Isoelectric point                | cIEF                                                           | Highly similar to reference product                                                                      |
| Purity/Impurities      | HMWP-1 (Aggregates)              | SEC-UV AUC SEC-MALS                                            | Marginally higher than reference product Highly similar to reference product Highly similar to reference |
|                        | Di-PEG-G-CSF                     | SEC-UV CIEX                                                    | Lower than reference product Lower than reference product                                                |

<div style=\"page-break-after: always\"></div>

| Molecular parameter         | Attribute                   | Methods for control and characterization   | Key findings                                                                                                          |
|-----------------------------|-----------------------------|--------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|
|                             | Dimer                       | SEC-UV RP-HPLC                             | Lower than reference product Lower than reference product                                                             |
|                             | Des-PEG-G-CSF               | RP-HPLC SEC-UV                             | Marginally higher than reference product Highly similar to reference product                                          |
|                             | M138 Oxidation              | RP-HPLC                                    | Highly similar to reference product                                                                                   |
|                             | Q108 Deamidation            | RP-HPLC                                    | Marginally higher than reference product                                                                              |
|                             | Total hydrophobic pre-peak  | RP-HPLC                                    | Highly similar to reference product                                                                                   |
|                             | Total hydrophobic post-peak | RP-HPLC                                    | Marginally higher than reference product                                                                              |
|                             | Purity by                   | RP-HPLC CIEX SEC-UV                        | Highly similar to reference product Marginally higher than reference product Marginally higher than reference product |
| Finished product attributes | Composition                 |                                            | Identical to reference product                                                                                        |
|                             | Protein content             | UV280                                      | Highly similar to reference product                                                                                   |
|                             | Subvisible particles        | Micro-flow imaging                         | Lower than reference product                                                                                          |

## 2.2.4. Discussion on chemical, pharmaceutical and biological aspects

The development, characterisation, manufacture and control of MYL-1401H active substance and finished product are adequately described, and questions raised during the procedure were adequately solved. Analytical similarity of MYL-1401H finished product to the reference product Neulasta (EU) has been satisfactorily demonstrated. Likewise, analytical similarity of Neulasta sourced from EU and US was proven.

At D120, a major objection has been raised as EU GMP compliance had not yet been confirmed for the finished product manufacturing site Biocon Limited, Plot No. 2-4, Phase IV, Bommasandra-Jigani Link

<div style=\"page-break-after: always\"></div>

Road, Bangalore, India. A second major objection had been raised on the control of the FP sterile filtration step.

Both major objections have been satisfactorily solved.

As regards the finished product specifications, the Applicant is expected to revise the FP shelf-life specification for the parameter  'aggregates', as well as for the impurities quantified by RP-HPLC, when data from further batches are available (see recommendation).

## 2.2.1. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way. Data have been presented to give reassurance on TSE safety.

In conclusion, based on the review of the quality data provided, the CHMP considers that the marketing authorisation application for Fulphila is approvable from the quality point of view.

Analytical similarity of MYL-1401H finished product to the reference product Neulasta (EU) has been satisfactorily demonstrated. Likewise, analytical similarity of Neulasta sourced from EU and US was proven.

Based on the review of the data the CHMP considers that the active substance Pegfilgrastim contained in the medicinal product Fulphila is not to be qualified as a new active substance.

## 2.2.2. Recommendation for future quality development

In the context of the obligation of the MAHs to take due account of technical and scientific progress, the CHMP recommended additional points for investigation:

- The Applicant is recommended to revise the FP shelf-life specification for the parameter 'aggregates', as well as for the impurities quantified by RP-HPLC, when data from further batches are available. Revised specification acceptance criteria should then be introduced into the finished product shelf life specification via a variation application if appropriate.

## 2.3. Non-clinical aspects

## 2.3.1. Introduction

The functionality of MYL-1401H was compared to that of EU- and US-Neulasta with two in vitro assays, namely with the cell proliferation assay and the binding to target receptor by the SPR method. The binding affinity to the G-CSF receptor of MYL-1401H and EU- as well as US-Neulasta was also investigated using Surface Plasmon Resonance (SPR). The in vitro functionality assays were completed by a GLP-compliant in vivo study performed in chemically-induced neutropenic rats. A toxicokinetic study was included in the GLP compliant comparative 28 day repeat-dose toxicity study. The toxicological program included a single, GLP-compliant 28 day repeat-dose toxicity study in Sprague Dawley rats.

<div style=\"page-break-after: always\"></div>

## 2.3.2. Pharmacology

## Primary pharmacodynamic studies

## In vitro

Receptor binding by SPR (Studies BDL/TR/BR.14.5003/15/001 and BDL/TR/BR.14.5003/16/001)

A summary of the kinetic data were provided in Table 2.

Table 2: Summary of Binding Kinetics of MYL-1401H and EU- and US-Neulasta to GCSF-R

<!-- image -->

## Cell proliferation assay (Study DDL/TR/BR.14.5003/16/003)

M-NFS-60 cells were exposed to MYL-1401H, EU-Neulasta, or US-Neulasta for 44 to 50 hours. Proliferation was measured using a spectrophotometer after adding 3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) reagent, which is reduced to a soluble formazan product by living cells. The absorbance at 490 nm is proportional to the number of live cells. The geometric mean relative potencies ranged from 0.91 to 1.12 with a mean (± SD) of 1.05 ± 0.08 for MYL-1401H, from 0.91 to 1.07 with a mean of 1.00 ± 0.05 for EU-Neulasta, and from 1.03 to 1.16 with a mean of 1.07 ± 0.04 for US-Neulasta.

## In vivo

Male CD / Crl:CD(SD) rats (10 animals per group) were treated once subcutaneously with MYL-1401H, EU- or US-Neulasta at dose levels of 100, 300, 1000 and 3000 mg/kg on 12 consecutive days. The results  of  the  pharmacodynamics  analysis  of  the  neutrophilic  granulocytes  responses  between  the three products are given in Table 3 and of the ANC responses in Table 4:

<div style=\"page-break-after: always\"></div>

Table 3: Pharmacodynamic Analysis of Neutrophilic Granulocyte Response Following Administration of MYL-1401H, EU-Neulasta, and USNeulasta in Chemically-Induced Neutropenic Rats

<!-- image -->

effective AUEC of the dose level groups 3 to 14: AUECor.st+1 - AUECar.2

<div style=\"page-break-after: always\"></div>

Table 4: Pharmacodynamic Analysis of Leucocyte response Following Administration of MYL-1401H, EU-Neulasta, and US-Neulasta in Chemically-induced Neutropenic Rats

<!-- image -->

## Secondary pharmacodynamic studies

The applicant did not submit secondary pharmacodynamic studies (see non-clinical discussion).

## Safety pharmacology programme

The applicant did not submit safety pharmacology studies (see non-clinical discussion).

## Pharmacodynamic drug interactions

The applicant did not submit pharmacodynamic drug interaction studies (see non-clinical discussion).

## 2.3.3. Pharmacokinetics

The applicant did not submit pharmacokinetic studies regarding absorption, distribution, metabolism, excretion,  pharmacokinetic  drug  interaction  and  other  pharmacokinetic  studies  conducted  for  MYL1401H (see non-clinical discussion).

<div style=\"page-break-after: always\"></div>

## 2.3.4. Toxicology

## Single dose toxicity

The applicant did not submit single dose toxicity studies (see non-clinical discussion).

## Repeat dose toxicity

The applicant provided data from one comparative in vivo study in rats (Study TOX-071-001). MYL1401H was administered subcutaneously once weekly at 0.15 mg/kg (low dose), 0.65 mg/kg (mid dose), and 1.5 mg/kg (high dose and high-dose recovery) to male and female Sprague Dawley rats for 28 days. These doses were equivalent to approximately 0.24, 1.05, and 2.43 times (respectively) the intended dose in humans (6 mg/chemotherapy cycle) based on body surface area. Animals in the recovery groups received no treatment for an additional 14 days after the 28-day treatment period.

| Parameters                                   | Main findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|----------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pharmacodynamic effect                       | Neutrophil counts increased in a dose-proportionate manner with both MYL-1401H and EU-Neulasta. Dose-proportionate changes to red blood cells, reticulocytes, lymphocytes, monocytes, eosinophils, and basophils were also seen for both MYL-1401H- and EU- Neulasta-treated animals. However, these changes were not of the magnitude of the neutrophil counts.                                                                                                                                                                                                                                                                                                                                                                      |
| Injection site effects                       | At the injection sites, minimal fasciitis/fibrosis and occasional hemorrhage were recorded in animals administered MYL-1401H, animals administered EU-Neulasta, and in the controls.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Immunogenicity                               | No assessment of anti-drug antibody formation (binding and neutralizing capacity) of the test or reference product was performed. No significant differences in toxicokinetics were observed, anaphylactic reactions were absent, and the expected increases in pharmacodynamic markers were observed. Therefore, there was no indication that anti- drug antibody was present.                                                                                                                                                                                                                                                                                                                                                       |
| Mortality and clinical signs                 | There was 1 mortality during the study, at Day 28. A female in the high dose EU- Neulasta group was removed from the study due to clinical signs related to granulocytic leukemia characterized by a widespread, diffusely invasive proliferation of granulocytes (myeloid cells) in the spleen, bone marrow, and multiple other organs, including non- hematopoietic tissues. The following observations seen were across several dose groups in one or both sexes, with no apparent dose response. Several male animals across all dose groups (except Group 4) had hair loss, sores, or lesions to their neck, while several female animals across all dose groups showed signs of thinning neck fur and red staining to the neck. |
| Ophthalmological examination                 | There were no remarkable ophthalmic changes in animals given MYL-1401H or EU- Neulasta.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Body weights and cumulative net weight gains | All animals given MYL-1401H or EU-Neulasta had comparable weight gain during the dosing phase and treatment-free phase of the study.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Food consumption                             | Food consumption throughout the pre-dose, dosing, and treatment-free phases was                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|                                       | comparable across all dose groups.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Hematology                            | Dose-proportional increases in white blood cell counts (in particular, absolute neutrophil counts) were seen in all MYL-1401H- and EU-Neulasta-treated animals. In males receiving 1.5 mg/kg MYL-1401H or EU-Neulasta, maximal neutrophil counts were 80.45 and 73.68 × 109/L, respectively, and occurred 48 hours post dose (Day 22 administration) on Day 24. In females receiving 1.5 mg/kg MYL-1401H or EU-Neulasta, maximal neutrophil counts of 50.96 and 53.54 × 109/L, respectively, were seen at 72 hours post dose (Day 22 administration) on Day 25. Additionally, there were smaller dose-proportional statistical changes (ANOVA and Dunnet ' s; P ≤ 0.001 to 0.05) in numbers of red blood cells, reticulocytes, lymphocytes, monocytes, eosinophils, and basophils in both MYL-1401H- and EU-Neulasta-treated animals. There were no other statistically significant (P ≤ 0.05) treatment-related changes in hemoglobin, packed cell volume, mean cell volume, mean cell hemoglobin, mean cell hemoglobin concentration, red cell distribution width, hemoglobin distribution width, total and differential white cell count, platelet count, plateletcrit, mean platelet volume, platelet distribution width, or coagulation (prothrombin time). |
| Clinical chemistry                    | Alkaline phosphatase levels increased in treated males and females in a dose-dependent manner. Similar increases were seen with MYL-1401H and EU-Neulasta. Males given 0.15 mg/kg MYL-1401H or EU-Neulasta showed comparable levels of alkaline phosphatase elevation above control; approximately 2.4 and 2.3 times higher, respectively. Similarly, males given 1.5 mg/kg MYL-1401H or EU-Neulasta showed elevation of alkaline phosphatase approximately 5 times higher than males given placebo (controls). Females showed a comparable trend, with elevation of alkaline phosphatase in animals given 0.15 mg/kg or 1.5 mg/kg MYL-1401H or EU-Neulasta (3 and 5 times, respectively, the level of controls). No statistically significant (P ≤ 0.05) changes in other clinical chemistry parameters were observed following treatment with either MYL-1401H or EU-Neulasta, including aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, total cholesterol, total bilirubin, total protein, albumin, globulin, albumin/globulin ratio, sodium, potassium, chloride, calcium, inorganic phosphate, creatinine, urea, and glucose.                                                                                                   |
| Urinalysis                            | No treatment-related differences from control were seen for volume, color, turbidity, specific gravity, pH, protein, glucose, ketones, urobilinogen, bilirubin, blood, and microscopic observation of sediment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Organ weights and organ weight ratios | Group mean spleen weights (adjusted for terminal body weight) were increased by 46%, 80%, and 115% in males and 33%, 54%, and 77% in females given 0.15, 0.65, or 1.5 mg/kg MYL-1401H, respectively, compared with those in males and females given placebo (controls). Similar increases were observed in animals given EU-Neulasta; group mean spleen weights (adjusted for terminal body weight) were increased by 44% and 116% in males and 8% and 67% in females given 0.15 or 1.5 mg/kg EU-Neulasta.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Gross pathology                       | Large spleen was recorded for most animals given 0.65 or 1.5 mg/kg MYL-1401H and for most animals given 1.5 mg/kg EU-Neulasta. These findings correlated with increased spleen weight at necropsy. There were no other macroscopic findings considered related to test article administration. Other tissues were either macroscopically unremarkable or the findings were typical for animals of this strain and age.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Histopathology                        | Histopathological changes attributable to test article administration were observed in the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| bone marrow, spleen, and liver. Microscopic findings in other tissues and at the injection site were generally infrequent, minor, and typical for animals of this strain and age. Increased granulopoiesis was seen in the bone marrow of the femur and sternum, in animals given 1.5 mg/kg MYL-1401H or EU-Neulasta. This was characterized by increased cellularity and decreased basophilia of the bone marrow due to an increased proportion of white cell precursors. This was also associated with a reduction in marrow fat spaces. In the spleen, an increase in the severity of hematopoiesis was recorded for animals given 1.5 mg/kg MYL-1401H or EU-Neulasta. This was characterized by increased hematopoietic cells in the red pulp and correlated with large spleen visible macroscopically. In the liver, an increase in the incidence and severity of hematopoiesis was recorded for animals given 1.5 mg/kg MYL-1401H or EU-Neulasta. Hematopoiesis was characterized by foci of predominantly myeloid cells in the periportal areas and in the liver parenchyma with small foci of hyperchromatic erythroid cells and occasional megakaryocytes also in the liver parenchyma.   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

## Genotoxicity

The applicant did not submit genotoxicity studies (see non-clinical discussion).

## Carcinogenicity

The applicant did not submit carcinogenicity studies (see non-clinical discussion).

## Reproduction Toxicity

The applicant did not submit reproduction toxicity studies (see non-clinical discussion).

## Toxicokinetic data

Toxicokinetic and statistical analysis for MYL-1401H and EU-Neulasta were performed and included:

AUC0-t:  Area  under  the  concentration-time  curve  from  hour  0 to the last  measurable  concentration, estimated by the log/linear trapezoidal rule

Cmax: Maximum observed concentration from the concentration/time graphs tmax: Time of maximum concentration from the concentration/time profile

Other  parameters,  including  dose  normalized  Cmax  (Cmax/D)  and  AUC0-t  (AUC0-t/D),  area  under  the concentration-time  curve  extrapolated  to  infinity  (AUC0-∞),  terminal  plasma  half-life  (t1/2),  and accumulation ratios based on Cmax (RACmax) and AUC (RAAUC).

Blood samples for toxicokinetics (1 mL nominal) were taken from all toxicokinetic animals on Day 1 and Week 4 at pre-dose, 4, 8, 12, 24, 48, 72, 96, 120 and 144 hours after dosing.

<div style=\"page-break-after: always\"></div>

Table 5: Summary of Toxicokinetic Parameters of MYL-1401H in Rat Plasma

| Day   |                         | 0.15 mg/kg/week   | 0.15 mg/kg/week   | 0.65 mg/kg/week   | 0.65 mg/kg/week   | 1.5 mg/kg/week   | 1.5 mg/kg/week   |
|-------|-------------------------|-------------------|-------------------|-------------------|-------------------|------------------|------------------|
|       | Parameter               | Male              | Female            | Male              | Female            | Male             | Female           |
|       | Cx (pg/mL)              | 86900             | 258000            | 1010000           | 1590000           | 2340000          | 4200000          |
|       | tmx (h)                 | 12.0              | 12.0              | 24.0              | 12.0              | 12.0             | 12.0             |
|       | t12 (h)                 | 6.98              | 4.93              | 4.91              | 4.83              | 4.74             | 4.73             |
| Day1  | AUC(o-) (pg.h/mL)       | 1700000           | 5190000           | 33000000          | 48600000          | 113000000        | 170000000        |
|       | AUC(o-) (pg.h/mL)       | 1710000           | 5190000           | 33000000          | 48600000          | 113000000        | 170000000        |
|       | CD                      | 580000            | 1720000           | 1550000           | 2450000           | 1560000          | 2800000          |
|       | AUC(o-gD                | 11300000          | 34600000          | 50800000          | 74700000          | 75200000         | 113000000        |
|       | Cx (Pg/mL)              | 98900             | 315000            | 565000            | 1380000           | 2410000          | 4260000          |
|       | tmx (h)                 | 12.0              | 12.0              | 24.0              | 12.0              | 24.0             | 12.0             |
|       | tn (h)                  | NR                | NR                | 10.1              | 5.32              | 8.31             | 6.00             |
|       | AUC(o-q) (Pg.h/mL)      | 1570000           | 4860000           | 13200000          | 38600000          | 83600000         | 148000000        |
|       | Day22 AUC(o-) (Pg.h/mL) | NR                | NR                | 13200000          | 38600000          | 83600000         | 148000000        |
|       | CD                      | 660000            | 2100000           | 870000            | 2120000           | 1600000          | 2840000          |
|       | AUC(o-D                 | 10500000          | 32400000          | 20300000          | 59300000          | 55700000         | 98600000         |
|       | RAC.                    | 1.14              | 1.22              | 0.562             | 0.865             | 1.03             | 1.01             |
|       | RAAUC                   | 0.922             | 0.938             | 0.399             | 0.794             | 0.741            | 0.869            |

AUCo: area under the concenhation-time cuwve mil the last measurable concentation; AUC(o-/D: dose-normalized AUC(o-q, caleulated by dividing the AUC(or) value by the nominal dose; AUCo-z- area umder the concentation-time cwve by the nominal dose; NR: not reported; RAAuc: acecumulation ratio based on AUCqon; RACm: accumulation ratio based on Cms; tin: terminal plasma half-life; tmw: time to reach peak plasma concenhration.

All reported values are individual values derived from composite data (ie, anithmetic mean of concentrations from 3 rats at each time point).

Table 6: Summary of Toxicokinetic Parameters of EU-Neulasta in Rat Plasma

| Day   | Parameter          | 0.15 mg/kg/week   | 0.15 mg/kg/week   | 1.5 mg/kg/week   | 1.5 mg/kg/week   |
|-------|--------------------|-------------------|-------------------|------------------|------------------|
|       |                    | Male              | Female            | Male             | Female           |
|       | C. (pg/mL)         | 140000            | 268000            | 2280000          | 4030000          |
|       | t. (h)             | 12.0              | 24.0              | 24.0             | 12.0             |
|       | tn (h)             | 6.20              | NR                | NR               | 4.13             |
|       | AUC(o- (pg.h/mL)   | 2640000           | 6020000           | 106000000        | 158000000        |
| Day 1 | AUC(o-=) (pg.h/mL) | 2640000           | NR                | NR.              | 158000000        |
|       | \"                  | 931000            | 1780000           | 1520000          | 2690000          |
|       | AUC(o-D            | 17600000          | 40100000          | 70500000         | 106000000        |
|       | C. ratio*          | 0.623             | 0.964             | 1.03             | 1.04             |
|       | AUC(o-) ratio*     | 0.645             | 0.862             | 1.07             | 1.07             |

<div style=\"page-break-after: always\"></div>

| Day   | Parameter         | 0.15 mg/kg/week   | 0.15 mg/kg/week   | 1.5 mg/kg/week   | 1.5 mg/kg/week   |
|-------|-------------------|-------------------|-------------------|------------------|------------------|
|       |                   | Male              | Female            | Male             | Female           |
|       | Cmx (Pg/mL)       | 269000            | 437000            | 2500000          | 2900000          |
|       | tmx (h)           | 12.0              | 12.0              | 12.0             | 24.0             |
|       | tin (h)           | 8.29              | 4.99              | NR               | 6.18             |
|       | AUC(o-g (Pg.h/mL) | 4080000           | 6860000           | 79500000         | 124000000        |
|       | AUC(o-) (pg.h/mL) | 4080000           | 6860000           | NR               | 124000000        |
|       | Day 22 CmD        | 1800000           | 2920000           | 1670000          | 1930000          |
|       | AUC(o-qD          | 27200000          | 45700000          | 53000000         | 82400000         |
|       | RACm              | 1.93              | 1.63              | 1.10             | 0.719            |
|       | RAAUC             | 1.55              | 1.14              | 0.752            | 0.780            |
|       | Cmx Iatioa        | 0.367             | 0.721             | 0.963            | 1.47             |
|       | AUC(o-q ratio*    | 0.384             | 0.709             | 1.05             | 1.20             |

a MYL-1401H/Neulasta ratio

AUCo.: area umder the concenhation-time cwve umtil the last measurable concenhation; AUCo.r/D: dose normalized AUC(oq), caleulated by dividing the AUC(o-q value by the nominal dose; AUCp: area mder the concentration-time cwve extrapolated to infinity;, Cmx peak plasma concentation; Cmw/D: dose normalized Cmx, caleulated by dividing the Cmn by the nominal dose; EU: Euopean Union; NR: not reported; RAAuc: aceumulation ratio based on AUC(ot; RACmm· accumulation ratio based on Cmm: tio: teminal plasma half-life; tmw: time to reach peak plasma concenhation.

All reported parameters are individual values derived from composite data (ie, anithmetic mean of concenhations from 3 rats at each time point).

The NOAEL was considered to be 1.5 mg/kg in male and female rats for both MYL-1401H and EUNeulasta in this study. This dose is equivalent to approximately 2.4 times the intended therapeutic dose in humans (6 mg/chemotherapy cycle) based on body surface area.

## Local Tolerance

Comparative local tolerance assessments between MYL-1401H, EU-Neulasta, and US-Neulasta were made in the in vivo pharmacodynamic study and in the repeat-dose toxicity study. No injection site reactions were observed in the pharmacodynamic study. In the toxicity study, minimal fasciitis/fibrosis and occasional hemorrhage were observed.

## Other toxicity studies

The applicant did not submit reproduction toxicity studies (see non-clinical discussion).

## 2.3.5. Ecotoxicity/environmental risk assessment

The applicant provided a justification for waiving ERA studies in accordance with the guideline on the environmental risk assessment of medicinal products for human use (EMEA/CHMP/SWP/4447/00 Corr 2).

It  is  considered  that  Fulphila  will  not  pose  any  greater  risk  to  the  environment  than  Neulasta. Pegfilgrastim  is  extensively  metabolised  in  man  and  predicted  to  be  rapidly  biodegraded  in  the environment.  Furthermore,  it  is  considered  that  Fulphila  will  replace  other  similar  pegfilgrastim products  on  the  market.  Hence,  it  is  expected  that  the  total  amount  of  pegfilgrastim  will  not  be substantially  increased  and  no  additional  environmental  burden  is  envisaged.  Furthermore,  proteins

<div style=\"page-break-after: always\"></div>

and peptides are excluded from the need for an environmental risk assessment in accordance with the respective guideline.

## 2.3.6. Discussion on non-clinical aspects

MYL-1401H was developed as a biosimilar biological medicine to Neulasta. As such, according to the guideline  EMEA/CHMP/42832/05,  a  reduced  preclinical  program  is  acceptable  in  order  to  show comparability  of  test  and  reference  product.  Mylan  provided  comparative in  vitro and in  vivo pharmacodynamic studies as well as one comparative 28 day repeat dose toxicity study in neutropenic rats.

The in  vitro cell  based  proliferation  assay  using  the  murine  NFS  60  cell  line  demonstrated  similar relative  potencies.  The  binding  activity  using  receptor-binding  Surface  Plasmon  Resonance  showed comparable  binding  characteristics  for  Association  rate  constant,  Dissociation  rate  constant  and Equilibrium dissociation constant. Pharmacodynamic responses of the in vivo study showed comparable number of leucocytes and neutrophilic granulocytes with higher values of MYL-1401H compared to the reference product (EU-Neulasta).

The toxicological profile of MYL-1401H in comparison to EU-Neulasta was evaluated in a 28-day repeat dose toxicity study in rats. This study included toxicokinetic analysis. Dose-proportional increases in mean maximal concentration exposures and comparable half-lives were seen with both products. Minor gender  differences  were  observed,  with  males  having  higher  exposure  levels  than  females.  As expected,  neutrophil  counts  increased  in  a  dose-proportional  manner  across  all  treated  groups. Expected and treatment related increases in spleen weight as well as elevated and comparable alkaline phosphatase levels were observed. Splenomegaly is an expected finding of pegfilgrastim therapy and therefore  a  known  adverse  effect.  The  toxicokinetic  data  from  this  study  showed  comparability between doses of 0.15 and 1.5 mg/kg Myl-1401H and EU-Neulasta with the exception of the low dose in males, where systemic exposure to MYL-1401H was notably lower than EU-Neulasta, suggesting that there may be a gender difference. However, the gender difference may be a chance findings and is not considered relevant.

According to the guideline EMEA/CHMP/BMWP/31329/2005 as well as the concept paper published on 27/07/2015, studies on single dose toxicity, reproduction, genotoxic, carcinogenic potential are not required for the development of biosimilar G-CSF products.

A justification for waiving ERA studies had been provided. This is considered acceptable, given that the active substance pegfilgrastim is a polypeptide which is exempted from an ERA as per guideline on the environmental risk assessment of medicinal products for human use (EMEA/CHMP/SWP/4447/00 Corr 2). Pegfilgrastim is not expected to pose a risk to the environment.

## 2.3.7. Conclusion on the non-clinical aspects

The non-clinical aspects of pharmacology, pharmacokinetic and toxicology for Fulphila have been well characterised and are considered acceptable. There were no further changes to the SmPC and the product information is aligned with the reference product Neulasta.

<div style=\"page-break-after: always\"></div>

## 2.4. Clinical aspects

## 2.4.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the Community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

| Type of Study                      | Study Number    | Study Objective(s)                                                                                                                                                                         | Study Design                                                                                                               | Test Product(s), Dosage, Regimen, Route of Administration                              | Number of Subjects/ Diagnosis                                                                                            | Duration of Treatment                                                                                               |
|------------------------------------|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| PK/PD, safety                      | MYL-1401H- 1001 | To compare the PK, PD, safety, and tolerability of MYL-1401H and NEULASTA                                                                                                                  | Single-center, randomized, double-blind, 3-period, 3-treatment, 3-way crossover study                                      | MYL-1401H or NEULASTA (EU-approved NEULASTA or US-licensed NEULASTA) 2-mg SC injection | 216 healthy adult subjects                                                                                               | Single dose                                                                                                         |
| Immuno- genicity, safety           | MYL-1401H- 1002 | To descriptively compare immunogenicity between 2 SC injections of MYL-1401H and NEULASTA To evaluate the safety and tolerability of MYL-1401H and NEULASTA after 2 injections (6 mg each) | Single-center, randomized, open-label, 2- dose, parallel study                                                             | MYL-1401H or NEULASTA (US-licensed NEULASTA) 6-mg SC injection                         | 50 healthy adult subjects                                                                                                | 2 doses                                                                                                             |
| Efficacy, safety, immuno- genicity | MYL-1401H- 3001 | To compare the efficacy, safety, and immunogenicity of MYL-1401H and NEULASTA                                                                                                              | Multicenter, randomized, double-blind, therapeutic- equivalence study Subjects were randomly assigned (2:1) to either MYL- | MYL-1401H or EU- approved NEULASTA 6-mg SC injection                                   | 194 adult patients with Stage II/III invasive breast cancer in the adjuvant/neo- adjuvant setting who were receiving TAC | Single dose of MYL-1401H or EU- approved NEULASTA on Day 2 of each chemotherap y cycle. Each cycle was approximatel |

<div style=\"page-break-after: always\"></div>

| 1401H or EU-NEULASTA and were stratified based on their age and country.   | chemotherapy   | y 3 weeks (from the first day of chemotherap y [Day 1 Cycle 1] to the last scheduled assessment in Cycle 1). Study treatment duration was up to 6 cycles of chemotherap y.   |
|----------------------------------------------------------------------------|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

Abbreviations: EU = European Union; PD = pharmacodynamics; PK = pharmacokinetics; SC = subcutaneous; TAC = docetaxel, doxorubicin, and cyclophosphamide; US = United States.

## 2.4.2. Pharmacokinetics

## Absorption

The pivotal cross-over PK/PD study MYL-1401H-1001 investigated single 2 mg doses of MYL-1401H, EU- and US-Neulasta (0.2 mL of 10 mg/mL dose strengths based on protein content with all 3 drug products being transferred into identical 0.3-mL syringes), whereas the parallel-design study 1002 used single 6 mg doses and primarily investigated immunogenicity in healthy subjects.

Also in trial MYL-1401H-1002 concentrations of the analyte PEG GCSF were determined but analysed only descriptively (for the means of the primary objective of this trial immunogenicity).

Thus, trial MYL-1401H- 1001 is the pivotal BE (and equivalent PD) study of this application:

Trial MYL-1401H-1001 was a single centre, randomized, double-blind, 3-period, 3 treatments, 3-way crossover trial to evaluate the PD, PK, safety and tolerability of pegfilgrastim from a test product (MYL1401H) compared to reference products EU- and US-Neulasta in 216 healthy volunteers intended to be in accordance with EU and US biosimilar guidelines.

After randomization to one of six possible treatment sequences, subjects were administered MYL1401H or one of two reference products in Period 1. After the 1 st crossover, subjects received one of the remaining alternate treatments in Period 2.

After the 2 nd crossover, subjects received the other alternate treatment in Period 3. The washout between drug administrations was at least 4 weeks.

<div style=\"page-break-after: always\"></div>

Figure 1: Overview of Study Design MYL-1401H-1001

<!-- image -->

The inclusion and exclusion criteria can be briefly summarized as selecting for healthy adults (18-65 years of age) of both genders. Specific for the scope of the trial are only the two exclusion criteria:

- Known history of previous exposure to filgrastim, pegfilgrastim, GCSF or any analogue of these.
- Hypersensitivity to the constituents of Neulasta (sorbitol E420, polysorbate 20 and acetate or acetic acid) or hypersensitivity to E. coli derived proteins.

## Methods

- ELISA Assay for the Quantitation of MYL-1401H/Neulasta in Human Serum (has been satisfactorily validated and considered suitable for its intended use)
- Neutrophils and CD34+ cells were counted via flow cytometry (Validation reports have not been submitted. Flow cytometry is considered a standard approach so that validation of this method is not needed for this application)
- Analysis of Normal Human Serum Samples for detection of Anti-Drug Antibodies against MYL1401H and Neulasta (EU and US) to support Phase 1 Clinical Study (MYL-1401H-1001) using the Mesoscale Discovery Platform
- Cell-Based Assay to Detect Neutralizing Antibodies (NAb) Against MYL-1401H and Neulasta (EU and US) in Normal Human Serum.

## Pharmacokinetic Measurements

At the time points defined blood samples of 2.5 m each were taken for the analysis of PEG-GCSF concentration in serum samples.

## Pharmacodynamic Measurements

At the time points defined, blood samples of 3 mL each were taken for the analysis of ANC and CD34+. Both ANC and CD34+ cell count was determined with flow cytometry by the clinical safety laboratory of the centre.

<div style=\"page-break-after: always\"></div>

## Safety and Tolerability Measurements

Safety and tolerability assessments consisted of AEs, clinical laboratory, vital signs, 12-lead ECG, local tolerability, physical examination and immunogenicity and were performed as scheduled.

## Primary PK Parameters

The primary PK parameters to be determined or calculated from the serum-concentration time data for PEG-GCSF were:

- Cmax = Observed maximum serum concentration
- AUC0-inf = Area under the serum concentration-time curve (time 0 to infinity)

Bioequivalence was to be concluded if the 90% CI for the ratio of geometric means of two treatments falls completely within the limits of 0.8000-1.2500 for the primary PK parameters.

## Secondary PK Parameters

The secondary PK parameters to be determined or calculated from the serum-concentration time data for PEG-GCSF were:

- AUC0-t = Area under the concentration-time curve (time 0 to time of last quantifiable concentration)
- Tmax = Time to attain maximum serum concentration
- kel = Terminal elimination rate constant
- t1/2 = Apparent terminal elimination half-life
- Vd/F = Apparent volume of distribution

An additional PK parameter to be determined or calculated from the serum-concentration time data for PEG-GCSF was:

- %AUCextra = Percentage of estimated part for the calculation of AUC0-inf of serum PEG-GCSF: ([AUC0-inf - AUC0-t]/AUC0-inf)*100%.

The chosen PK parameters are standard parameters for BE trials and accepted for demonstration of similar PK profiles of two pegfilgrastims.

## Primary PD Parameters

The primary PD parameters to be determined or calculated from the cell count-time data for ANC were:

- ANC AUC0-t = Area under the ANC above baseline values versus time curve (time 0 to time of last data collection point)

- ANC Cmax = Maximum change from baseline for ANC*

* ANC Cmax was changed from secondary PD parameter to primary PD parameter after completion of the study, as documented in CSP Version 3.0.

Equivalence was to be concluded if the 95% CI for the ratio of geometric means of two treatments fell completely within the limits of 0.8500-1.1765 for the primary PD parameters.

<div style=\"page-break-after: always\"></div>

## Secondary PD Parameters

The secondary PD parameter to be determined or calculated from the cell count-time data for ANC was:

- ANC Tmax = Time of maximum change from baseline for ANC

The secondary PD parameters to be determined or calculated from the cell count-time data for CD34+ cell counts were:

- CD34+ AUC0-t = Area under the CD34+ cell counts above baseline versus time curve
- CD34+ Cmax = Maximum change from baseline for CD34+ cell counts
- CD34+ Tmax = Time of maximum change from baseline

The choice of the primary and secondary PD parameters is in line with the respective guideline and acceptable.

## Determination of Sample Size

The actual sample size of 216 healthy volunteers was based on the following assumptions laid down in the protocol:

- -Intrasubject variability from the MYL-PER-0001 pilot study11 8 :
- ANC AUC0-t = 14%
- PEG-GCSF AUC0-t and AUC0-inf = 36%
- PEG-GCSF Cmax = 50%
- 95% CI
- equivalence range [0.8500-1.1765]
- ratio of geometric means in interval [0.95-1.05]
- -PEG-GCSF AUC0-t, AUC0-inf and Cmax
- 90% CI
- equivalence range [0.8000-1.2500]
- ratio of geometric means in interval [0.95-1.05]

It was estimated that with 180 evaluable subjects the study will have a combined power for PD and PK of over 90% to establish equivalence for each of the 3 pairwise comparisons.

According to the applicant, the sample size estimation was not literature derived but was based on a pilot study with Neulasta.

## Results

- Disposition of Subjects and Data Sets analysed

8 A pilot phase 1, repeated single dose study evaluating the variability of pharmacokinetics and pharmacodynamics of long acting filgrastim  following subcutaneous administration to healthy volunteers. Myl-Per0001/MYB262EC-122621. Final Clinical Study Report. 18 June 2013.

- -ANC AUC0-t:

<div style=\"page-break-after: always\"></div>

372 subjects were screened and 216 subjects were included in the study. All of these 216 subjects were randomized and received at least one dose of 2 mg pegfilgrastim. The doses of pegfilgrastim were administered at least 4 weeks apart. All 216 subjects were included in the safety analysis set.

Twenty subjects discontinued the study for the following reasons:

8 subjects were withdrawn because of a protocol violation (tested positive for cannabinoids and cocaine; inability to follow protocol instructions).

8 subjects withdrew consent for personal reasons.

3 subjects were withdrawn due to AEs (1 SAE).

1 subject dropped out after dosing in Period 2 because he missed too many visits due to illness.

A total of 196 subjects completed the study as per protocol. All of these subjects were part of the 208 subjects who were included in both the PK and PD analysis sets.

Number and reasons for withdrawal were as expected. The about 10% withdrawal rate seems to equally distribute over the 6 sequences. As to the subjects withdrawn due to AEs or SAEs  see safety assessment.

## · Baseline characteristics

Table 7: Summary of Demographic Characteristics (MYL-1401H-1001)

| Parameter               | Parameter                     | Statistic/ Category      | Safety Set (N =216)         | PKandPD Set (N=208)           |
|-------------------------|-------------------------------|--------------------------|-----------------------------|-------------------------------|
| Gender                  | -Male                         | n (%)                    | 170 (79%)                   | 163 (78%)                     |
|                         | -Female                       | n (%)                    | 46 ( 21%)                   | 45 (22%)                      |
| Ethnicity               | -Hispanic or Latino           | n (%)                    | 3( 1%)                      | 3( 1%)                        |
|                         | -NotHispanicorLatino          | n (%)                    | 213 ( 99%)                  | 205 (99%)                     |
| Race                    | -AmericanIndianOrAlaskaNative | n (%)                    | 2( 1%)                      | 2( 1%)                        |
|                         | -Asian                        | n (%)                    | 5 ( 2%)                     | 5 ( 2%)                       |
|                         | -Black                        | n (%)                    | 6 ( 3%)                     | 5 ( 2%)                       |
|                         | -White                        | n (%)                    | 196 (91%)                   | 189 (91%)                     |
|                         | -Multiple                     | n (%)                    | 7 ( 3%)                     | 7 ( 3%)                       |
| Age (years)             |                               | mean (SD) median min-max | 37 (14) 33 18-65            | 37 (14) 33 18-65              |
| Weight (kg)             |                               | mean (SD) median min-max | 78.5 (10.7) 78.3 59.4-106.5 | 78.4 (10.8) 78.0 59.4 - 106.5 |
| Height (cm)             |                               | mean (SD) median         | 178 (9) 179                 | 178 (9) 179                   |
| Body Mass Index (kg/m²) |                               | min-max mean (SD)        | 156-201 24.6 (2.6)          | 156-201 24.6 (2.6)            |
|                         |                               | median                   | 24.4                        | 24.4                          |
|                         |                               | min-max                  | 19.5-30.4                   | 19.5-30.4                     |

PK=pharmacokinetics;SD=standarddeviation

Source:Table15.1-2,Table15.1-3andTable15.1-4

## · Pharmacokinetic Results

## Concentration Data of PEG-GCSF in Serum

After administration of a single sc injection of 2 mg pegfilgrastim, PEG-GCSF (analyte) appeared in serum within 2 to 4 hours post-dose. Only for 2 of the 216 subjects, PEG-GCSF concentrations were first observed at 6 hours after dosing with EU-Neulasta.

The concentrations of PEG-GCSF in serum increased slowly, with maximum mean concentrations reached at approximately 12 hours post-dose.

Mean PEG-GCSF concentrations could be determined in serum up to 144 hours post-dose for all 3 treatments.

<div style=\"page-break-after: always\"></div>

## Pharmacokinetic Parameters of PEG-GCSF in Serum

The exposure to PEG-GCSF (in terms of Cmax, AUC0-inf and AUC0-t) was most similar between MYL1401H and US-Neulasta, whereas the exposure of EU-Neulasta appeared to be slightly lower than the other 2 treatments (Table 8).

The median Tmax of PEG-GCSF in serum was 12 hours for all 3 treatments.

The geometric mean t1/2 of PEG-GCSF varied minimally between 49.3 and 51.1 hours across treatments.

The %AUCextra, Vd/F and kel were comparable between the 3 treatments.

Considerable inter-subject variability was observed for the primary PK parameters Cmax and AUC0-inf of PEG-GCSF (CV% ~70%).

Table 8: Summary of PK Parameters for PEG-GCSF in Serum (Geometric Mean [CV%]) (MYL-1401H-1001)

| Parameter          | MYL-1401H N=204    | EU-Neulasta N=203   | US-Neulasta N=207   |
|--------------------|--------------------|---------------------|---------------------|
| Cmax (pg/mL)       | 36.7 (72.1%)       | 34.2 (72.1%)        | 37.3 (67.6%)        |
| AUCo-int (h·ng/mL) | 869 (69.1%)        | 833 (70.1%)         | 876 (66.3%)         |
| AUCot(h·ng/mL)     | 827 (71.4%)        | 787 (72.7%)         | 832 (68.6%)         |
| %AUCextra (%)      | 3.2 (97.2%)        | 3.6 (97.9%)         | 3.2 (105.9%)        |
| Tmax (h)           | 12.00 (6.00-24.02) | 12.00(6.00-48.00)   | 12.00 (4.02-24.02)  |
| kel (1/h)          | 0.014 (31.0%)      | 0.014 (39.1%)       | 0.014 (40.1%)       |
| Va/F (L)           | 164 (100%)         | 177 (101%)          | 168 (113%)          |
| t12 (h)            | 49.3 (36.5%)       | 51.1 (48.9%)        | 51.0 (42.5%)        |

CV%=coefficientofvariation;PK=pharmacokinetic

ForTmaxthe median(range) ispresented.

## Statistical Analysis of Pharmacokinetic equivalence

When comparing the primary PK parameters Cmax and AUC0-inf of PEG-GCSF between MYL-1401H, EU-Neulasta and US-Neulasta, GLM ANOVA results showed that the 90% CIs of the ratios of geometric means for these PK parameters ranged between 0.907 and 1.18. The 90% CIs were therefore well contained within the standard bioequivalence interval of 0.8000 - 1.2500 for each of the comparisons.

These results demonstrate similar PK profiles of MYL-1401H, EU-Neulasta and US-Neulasta. The intrasubject CV% (within-subject variability) for the primary PK parameters Cmax and AUC0-inf was 54.8% and 41.8%, respectively, across the 3 treatments.

<div style=\"page-break-after: always\"></div>

Table 9: Summary of Bioequivalence Analysis on Primary PK Parameters of PEG-GCSF in Serum (Geometric Mean [CV%]) (MYL-1401H-1001)

|                         |                    | GeometricLS means   | GeometricLS means   | RatioTest/Reference   | RatioTest/Reference   | RatioTest/Reference   |       |
|-------------------------|--------------------|---------------------|---------------------|-----------------------|-----------------------|-----------------------|-------|
| TreatmentComparison     | PK                 |                     |                     |                       | #13 %06               | #13 %06               | Intra |
| (TestversusReference)   | Parameter          | Test                | Reference           | Estimate              | Lower                 | Upper                 | CV%   |
| MYL-1401H/EU-Neulasta°  | Cmax (pg/mL)       | 36.6                | 34.2                | 1.07                  | 0.984                 | 1.16                  | 54.8* |
|                         | AUCo-inf (h-ng/mL) | 871                 | 835                 | 1.04                  | 0.977                 | 1.11                  | 41.8* |
| MYL-1401H /US-Neulasta  | Cmax (pg/mL)       | 36.6                | 37.2                | 0.986                 | 0.907                 | 1.07                  |       |
|                         | AUCo-inf (h·ng/mL) | 871                 | 873                 | 0.998                 | 0.935                 | 1.07                  |       |
| US-Neulasta/EU-Neulasta | Cmax (pg/mL)       | 37.2                | 34.2                | 1.09                  | 0.998                 | 1.18                  |       |
|                         | AUCo-if (h-ng/mL)  | 873                 | 835                 | 1.05                  | 0.979                 | 1.12                  |       |

CI=confidence interval;intra CV%= intra-subject coeficient of variation;LS=least squares;

PK=pharmacokinetic

Natural logtransformationofCmaxandAUCo-inr wasusedforanalysis.UsingPROCgeneral linearmodel (GLM) analysis of variance (ANOVA) with treatment,sequence and period as fixed effects,and subject withinsequenceasarandomeffect.

(0.800 - 1.2500).

# Bioequivalence is established if the 90% Cl of the ratio is contained completely within acceptance range

*TheintraCV%(within-subjectvariability)isdisplayedonlyonceforeachparameter,asitisequal for eachcomparison.

Source:Table15.2-5

Relationship between Pharmacokinetics and Anti-Drug Antibodies

Descriptive statistics were used to summarize the serum PEG-GCSF concentrations and PK parameters by treatment and ADA status as defined as follows.

- ADA positive: Subjects with any confirmed positive ADA response against PEG G-CSF at any point during the study
- ADA negative: Subjects with no confirmed positive ADA response against PEG G-CSF at any point during the study

In addition, geometric mean ratios and corresponding 90% CIs for the 3 pairwise comparisons between 2 treatments were repeated by ADA status for the primary and secondary PK parameters.

Minimal differences (≤10%) in the exposure to PEG-GCSF were observed between ADA positive and negative subjects. For MYL-1401H treatment the geometric mean AUC0-inf was approximately 1.1-fold higher in ADA positive subjects (932 h·ng/mL; n=62) than in ADA negative subjects (843 h·ng/mL; n=142), whereas for EU-Neulasta the AUC0-inf was approximately 1.1-fold lower in ADA positive (775 h·ng/mL; n=62) than in ADA negative subjects (860 h·ng/mL; n=141). For US-Neulasta the differences in exposure were less than 5% between ADA positive (857 h·ng/mL; n=64) and negative subjects (885 h·ng/mL; n=143).

When excluding the ADA positive subjects from the comparison of the primary PK parameters Cmax and AUC0-inf of PEG-GCSF between the 3 treatments, results showed that the upper limit of the 90% CIs of the geometric means ratios were still contained within 0.8000 - 1.2500 bioequivalence interval for each comparison.

## Distribution

The applicant did not submit studies in distribution (see pharmacology discussion)

<div style=\"page-break-after: always\"></div>

## Elimination

The applicant did not submit studies in elimination (see pharmacology discussion)

## Dose proportionality and time dependencies

The applicant did not submit studies in dose proportionality and time dependencies (see pharmacology discussion)

## Special populations

The applicant did not submit studies in special populations (see pharmacology discussion)

## Pharmacokinetic interaction studies

The applicant did not submit studies in pharmacokinetic interaction studies (see pharmacology discussion)

## Pharmacokinetics using human biomaterials

The applicant did not submit studies in pharmacokinetic using human biomaterials (see pharmacology discussion)

## 2.4.3. Pharmacodynamics

## Mechanism of action

The applicant did not submit studies in mechanism of action (see pharmacology discussion)

## Primary and Secondary pharmacology

## Study MYL-1401H-1001

Concentration Data of ANC and CD34+ in Serum ANC

After administration of a single sc injection of 2 mg MYL-1401H, EU-Neulasta or US-Neulasta, mean ANC levels above baseline were first observed at 4 hours post-dose on Day 1. For all 3 treatments, a similar peak increase of approximately 8-fold compared to baseline was observed between Day 2 and Day 3 (24-48 hours post-dose; see Figure 2).

<div style=\"page-break-after: always\"></div>

Figure 2: Arithmetic Mean Change from Baseline ANC Serum Concentration-Time Profiles (MYL-1401H-1001)

<!-- image -->

Hours

<!-- image -->

Hours

Thereafter the mean ANC appeared to decrease in a multiphasic manner, with a relatively slow elimination phase between Day 6 and Day 9 (between 120 and 192 hours post-dose), before the ANC returned to values near baseline on Day 12 (264 hours post-dose). The mean ANC versus time profiles were very similar between the 3 treatments.

The combined individual change from baseline ANC versus time profiles showed minimal interindividual variability. However, for 2 subjects the increase in the ANC was very low (approximately 2fold compared to baseline) after administration of US-Neulasta in Period 2 compared to the other subjects. These minimal ANC increases were consistent with the relatively low PEG-GCSF concentrations observed for these subjects.

Mean CD34+ counts above baseline were first observed on Day 3. A maximum increase of approximately 9.5-fold compared to baseline was observed on Day 5 (96 hours post-dose; see Figure 3). Thereafter the mean CD34+ counts decreased to values near baseline on Day 12. The mean CD34+ versus time profiles were very similar between the 3 treatments.

The combined individual change from baseline CD34+ counts versus time profiles showed considerable inter-individual variability in the extent of increase in CD34+ counts over time.

<div style=\"page-break-after: always\"></div>

Figure 3: Arithmetic Mean Change from Baseline CD34+ Serum Concentration-Time Profiles (MYL-1401H-1001)

<!-- image -->

Hours

<!-- image -->

Hours

The primary PD parameters ANC Cmax and ANC AUC0-t were very similar across treatments. Also the secondary PD parameters CD34+ Cmax and CD34+ AUC0-t were comparable between these treatments (Table 10).

For MYL-1401H and EU-Neulasta the median ANC Tmax was 48 hours and for US-Neulasta the median ANC Tmax was 24 hours. For the CD34+ counts, the median CD34+ Tmax was 96 hours for all 3 treatments.

The inter-subject variability was much higher for the secondary CD34+ PD parameters (CV% up to ~80%) than for the primary ANC PD parameters (CV% up to ~30%).

Table 10: Summary of PD Parameters for ANC and CD34+ Count Data (Geometric Mean [CV%]) (MYL-1401H-1001)

| Parameter               | MYL-1401H N=204        | EU-Neulasta N=203      | US-Neulasta N=207      |
|-------------------------|------------------------|------------------------|------------------------|
| ANCPDParameters         | ANCPDParameters        | ANCPDParameters        | ANCPDParameters        |
| ANC AUCo-t (h·10%/L)    | 2784.356 (29.0%)       | 2792.623 (30.7%)       | 2744.700 (30.8%)       |
| ANC Cmax (10°/L)        | 22.507 (25.7%)         | 22.686 (25.9%)         | 22.546 (26.4%)         |
| ANC Tmax (h)            | 47.98 (12.00-96.00)    | 48.00 (12.00-96.00)    | 24.05 (8.00 - 72.03)   |
| CD34+PDParameters       | CD34+PDParameters      | CD34+PDParameters      | CD34+PDParameters      |
| CD34+AUCo-t(h·cells/μL) | 1652.305 (79.7%)       | 1633.532 (81.0%)       | 1598.443 (81.2%)       |
| CD34+ Cmax (cells/μL)   | 17.469 (76.5%)         | 17.681 (77.0%)         | 17.445 (77.1%)         |
| CD34+ Tmax (h)          | 96.00 (71.97 - 168.00) | 96.02 (72.00 - 192.00) | 96.00 (48.00 - 192.00) |

ANC=absoluteneutrophilcount;CV%=coefficientofvariation;PD=pharmacodynamic

For Tmaxthe median (range)is presented.

Source:Table15.3-3andTable15.3-4

<div style=\"page-break-after: always\"></div>

- Statistical Analysis of Pharmacodynamic Equivalence

## Primary PD Parameters

When comparing the primary PD parameters ANC AUC0-t and ANC Cmax between the 3 treatments (MYL-1401H, EU-Neulasta and US-Neulasta), GLM ANOVA results showed that the 95% CIs of the ratios of geometric means for these PD parameters ranged between 0.943 and 1.061 for each of the comparisons. The 95% CIs were therefore well contained within the predefined equivalence interval of 0.8500 - 1.1765 for each of the comparisons (Table 11). Likewise, the 90% CIs ranging between 0.950 and 1.054 were well contained within the 0.80 - 1.25 similarity range which was conducted as additional analysis. The intra-subject CV% was low for the primary PD parameters and comparable between ANC AUC0-t (22.3%) and ANC Cmax (17.7%).

Table 11: Summary of Equivalence Analysis for the Primary PD Parameters for ANC (MYL-1401H-1001)

|                             |                       | GeometricLSmeans   | GeometricLSmeans   | Ratio Test/Reference   | Ratio Test/Reference   | Ratio Test/Reference   |       |
|-----------------------------|-----------------------|--------------------|--------------------|------------------------|------------------------|------------------------|-------|
| Treatment Comparison        | PD                    |                    |                    |                        | 95% CI #               | 95% CI #               | Intra |
| (Test versus Reference)     | Parameter             | Test               | Reference          | Estimate               | Lower                  | Upper                  | CV%   |
| MYL-1401H/EU-Neulasta       | ANC AUCo-t (h·10%/mL) | 2794.628           | 2791.608           | 1.001                  | 0.959                  | 1.045                  | 22.3* |
|                             | ANC Cmax (10%/mL)     | 22.539             | 22.687             | 0.993                  | 0.960                  | 1.028                  | 17.7* |
| MYL-1401H / US-Neulasta?    | ANC AUCo-t (h·10%/mL) | 2794.628           | 2747.813           | 1.017                  | 0.974                  | 1.061                  |       |
|                             | ANC Cmax (10%/mL)     | 22.539             | 22.542             | 1.000                  | 0.966                  | 1.035                  |       |
| US-Neulasta? / EU-Neulasta? | ANC AUCo-t (h·10/mL)  | 2747.813           | 2791.608           | 0.984                  | 0.943                  | 1.027                  |       |
|                             | ANC Cmax (10%/mL)     | 22.542             | 22.687             | 0.994                  | 0.960                  | 1.028                  |       |

ANC = absolute neutrophil count; Cl = confidence interval; intra CV% = intra-subject coefficient of variation; LS =least squares; PD = pharmacodynamic

Natural log transformation of Cmax and AUCo-t was used for analysis. PROC general linear model (GLM) analysis of variance (ANOvA) with treatment sequence and period as fixed effects, and subject withinsequence asa randomeffect wasperformed for theseparameters.

Equivalence is established if the 95% Cl of the ratio is contained completely within acceptance range (0.8500 - 1.1765).

* The intra Cv% (within-subject variability) is displayed only once for each parameter, as it is equal for each comparison.

## Secondary PD Parameters

The estimates and corresponding 95% CIs of the geometric mean ratios were close to 1 for the secondary PD parameters CD34+ Cmax and CD34+ AUC0-t, with 95% CIs ranging between 0.915 and 1.104 for each of the comparisons (Table 12). The intra-subject variability was comparable between CD34+ Cmax (33.7%) and CD34+ AUC0-t (34.1%) across the 3 treatments. For the secondary PD parameters ANC Tmax and CD34+ Tmax, all estimates and corresponding 95% CIs were zero (0.000).

<div style=\"page-break-after: always\"></div>

Table 12: Summary of Statistical Analysis on Secondary PD Parameters for ANC and CD34+ Count Data (MYL-1401H-1001)

|                            |                            | Median                     | Median                     | Test Minus Reference       | Test Minus Reference       | Test Minus Reference       |
|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
| Treatment Comparison       |                            |                            |                            |                            | 95% C1                     | 95% C1                     |
| (Test versus Reference)    | PD Parameter               | Test                       | Reference                  | Estimate                   | Lower                      | Upper                      |
| Secondary ANC PD Parameter | Secondary ANC PD Parameter | Secondary ANC PD Parameter | Secondary ANC PD Parameter | Secondary ANC PD Parameter | Secondary ANC PD Parameter | Secondary ANC PD Parameter |
| MYL-1401H/ EU-Neulasta     | ANC Tmax (h)               | 47.975                     | 48.000                     | 0.000                      | 0.000                      | 0.000                      |
| MYL-1401H / US-Neulasta    | ANC Tmax (h)               | 47.975                     | 24.050                     | 0.000                      | 0.000                      | 0.000                      |
| US-Neulasta/ EU-Neulasta   | ANC Tmax (h)               | 24.050                     | 48.000                     | 0.000                      | 0.000                      | 0.000                      |
| Secondary CD34+ Parameter  | Secondary CD34+ Parameter  | Secondary CD34+ Parameter  | Secondary CD34+ Parameter  | Secondary CD34+ Parameter  | Secondary CD34+ Parameter  | Secondary CD34+ Parameter  |
| MYL-1401H/ EU-Neulasta     | CD34+Tmax (h)              | 96.000                     | 96.020                     | 0.000                      | 0.000                      | 0.000                      |
| MYL-1401H/ US-Neulasta     | CD34+Tmax (h)              | 96.000                     | 96.000                     | 0.000                      | 0.000                      | 0.000                      |
| US-Neulasta/ EU-Neulasta   | CD34+Tmax                  | 96.000                     | 96.020                     | 0.000                      | 0.000                      | 0.000                      |

(h)

|                               |                               | Geometric LS means            | Geometric LS means            | Ratio Test/Reference          | Ratio Test/Reference          | Ratio Test/Reference          |                               |
|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|
| Treatment Comparison          |                               |                               |                               |                               | 95% C1                        | 95% C1                        | Intra                         |
| (Test versus Reference)       | PD Parameter                  | Test                          | Reference                     | Estimate                      | Lower                         | Upper                         | CV%                           |
| Secondary CD34+ PD Parameters | Secondary CD34+ PD Parameters | Secondary CD34+ PD Parameters | Secondary CD34+ PD Parameters | Secondary CD34+ PD Parameters | Secondary CD34+ PD Parameters | Secondary CD34+ PD Parameters | Secondary CD34+ PD Parameters |
| MYL-1401H/EU-Neulasta         | CD34+ Cmax (cells/μL)         | 17.670                        | 17.701                        | 0.998                         | 0.936                         | 1.065                         | 33.7*                         |
|                               | CD34+AUC (h-cells/μL)         | 1655.336                      | 1638.707                      | 1.010                         | 0.946                         | 1.078                         | 34.1*                         |
| MYL-1401H/ US-Neulasta        | CD34+ Cmax (cells/μL)         | 17.670                        | 17.428                        | 1.014                         | 0.951                         | 1.081                         |                               |
|                               | CD34+AUCt (h-cells/μL)        | 1655.336                      | 1600.001                      | 1.035                         | 0.970                         | 1.104                         |                               |
| US-Neulasta/ EU-Neulasta      | CD34+ Cmax (cells/μL)         | 17.428                        | 17.701                        | 0.985                         | 0.924                         | 1.050                         |                               |
|                               | CD34+AUCt (h·cells/μL)        | 1600.001                      | 1638.707                      | 0.976                         | 0.915                         | 1.042                         |                               |

ANC = absolute neutrophil count; Cl = confidence interval; intra CV% = intra-subject coefficient of variation; LS = least squares; PD = phamacodynamic

Natural log transformation of Cmax and AUCot was used for analysis. PROC general linear model (GLM) analysis of variance (ANoVA) with treatment sequence and period as fixed effects, and subject within sequence as a random effect was perfomed for these parameters.

For Tmax a non-parametric Hodges-Lehmann method was performed on the non-transformed values.

+ The intra CV% (within-subject variability) is displayed only once for each parameter, as it is equal for each comparison.

Source:Table 15.3-6,and Table 15.3-7

- Relationship between Pharmacodynamics and Anti-Drug Antibodies

Descriptive statistics were used to summarise the PD parameters for ANC and CD34+ count by treatment and ADA status.

In addition, geometric mean ratios and corresponding 95% CIs for the 3 pairwise comparisons between 2 treatments were repeated by ADA status for the primary PD parameters for ANC and secondary PD parameters for ANC and CD34+ count data.

Minimal differences in the PD response were observed between ADA positive and negative subjects. For all 3 treatments, the primary PD response in terms of ANC AUC0-t appeared to be approximately 10% lower in ADA positive subjects compared to in ADA negative subjects.

<div style=\"page-break-after: always\"></div>

When excluding the ADA positive subjects from the comparison of the primary PD parameters in terms of ANC Cmax and ANC AUC0-t between the 3 treatments, results showed that the upper limit of the 95% CIs of the geometric means ratios were still contained within 0.8500 - 1.1765 equivalence interval for each comparison (Table 13).

Still in the smaller ADA positive subgroup the equivalence margin was met for the primary PD parameters. Also for the secondary PD parameters in this ADA negative subgroup, the estimates and corresponding 95% CIs of the geometric mean ratios were close to 1 for CD34+ Cmax and CD34+ AUC0-t, and the median difference was zero (0.000) for ANC Tmax and CD34+ Tmax.

Table 13: Summary of Equivalence Analysis for the Primary PD Parameters for ANC in ADA Negative Subjects (MYL-1401H-1001)

|                            |                        | GeometricLSmeans   | GeometricLSmeans   | RatioTest/Reference   | RatioTest/Reference   | RatioTest/Reference   |       |
|----------------------------|------------------------|--------------------|--------------------|-----------------------|-----------------------|-----------------------|-------|
| TreatmentComparison        | PD                     |                    |                    |                       | 95% CI#               | 95% CI#               | Intra |
| (TestversusReference)      | Parameter              | Test               | Reference          | Estimate              | Lower                 | Upper                 | CV%*  |
| MYL-1401H/EU-Neulasta?     | ANC AUCo-t (h·10%/mL)  | 2849.073           | 2892.386           | 0.985                 | 0.945                 | 1.027                 | 17.9  |
|                            | ANC Cmax (10%/mL)      | 22.675             | 22.945             | 0.988                 | 0.958                 | 1.020                 | 13.4  |
| MYL-1401H / US-Neulasta?   | ANC AUCo-t (h·10%/mL)  | 2849.073           | 2840.594           | 1.003                 | 0.962                 | 1.046                 |       |
|                            | ANC Cmax  (10%/mL)     | 22.675             | 23.090             | 0.982                 | 0.952                 | 1.013                 |       |
| US-Neulasta?/ EU-Neulasta? | ANC AUCo-t  (h·10%/mL) | 2840.594           | 2892.386           | 0.982                 | 0.942                 | 1.024                 |       |
|                            | ANC Cmax (10%/mL)      | 23.090             | 22.945             | 1.006                 | 0.975                 | 1.038                 |       |

ADA= anti-drugantibodies;ANC=absoluteneutrophilcount; CI = confidence interval; intra CV%= intra-subject coefficient of variation; LS =least squares;PD=pharmacodynamic

Natural log transformation of Cmax and AUCo-t was used for analysis. PROC GLM (general linear model)analysisofvariance(ANOvA)withtreatment sequence and period as fixedeffects,and subject withinsequenceasarandomeffectwasperformedfortheseparameters.

ADA status is defined as negative for subjects without any positive ADA response at any point during the study.

(0.8500 - 1.1765).

* The intra Cv% (within-subject variability) is displayed only once for each parameter, as it is equal for each comparison.

## Study MYL-1401H-1002

Trial MYL-1401H-1002 was a single-centre, randomised, open-label, repeated dose, parallel group trial intended to evaluate immunogenicity, PD, safety, and tolerability of the test product, MYL-1401H, compared with the reference product, US-licensed Neulasta, in healthy subjects.

<div style=\"page-break-after: always\"></div>

## Methods

Figure 4: Study design (MYL-1401-1002)

<!-- image -->

Each subject received 2 single sc. injections of 6 mg of either the test product, MYL-1401H, or the reference product, US-Neulasta, in 2 separate periods with a washout period of 4 weeks between study drug administrations. The sc. injections were given using a prefilled syringe.

As primary objective the immunogenicity between two sc injections of MYL-1401H and US Neulasta was descriptively compared. As secondary objective the safety and tolerability of MYL-1401H and US Neulasta after two sc injections (6 mg) in healthy volunteers was evaluated.

The sample size estimation is based on an 'expected immunogenicity event rate' as follows:

The expected immunogenicity event rate in this study was 13%. A total sample size of 44 normal healthy volunteers (22 per group) would provide 95% confidence to rule out an immunogenicity event rate of 13% or more in each treatment group if no events are observed.

## Results

## · Disposition of Subjects and Data Sets Analysed

Of the 85 subjects who were screened, 50 subjects were included in the study. Of these, 25 subjects received 6 mg MYL-1401H and 25 subjects received 6 mg US-Neulasta in the first treatment period. After dosing in Period 1, 6 subjects were withdrawn due to non-serious TEAEs. As a result, 23 of 25 subjects who received 6 mg MYL-1401H in the first treatment period received the same dose in the second treatment period, and 21 of 25 subjects who received 6 mg US-Neulasta in the first treatment period received the same dose in the second treatment period. In addition, Subject 004 withdrew consent in the second treatment period after receiving the second dose of US-Neulasta. A total 43 subjects completed the study and all were included in the PP set. The subject who withdrew consent after completion of dosing in Period 2 was included in the PP set as well, which consisted of 44 subjects in total. All 50 dosed subjects were included in the SAF set.

There were a few protocol deviations that were considered minor and not having affected the outcome of the study.

<div style=\"page-break-after: always\"></div>

## · Demographic and Other Baseline Characteristics

Based on Table 14, demographic characteristics are comparable between treatment groups.

Table 14: Summary of Demographic Characteristics (Safety Set)

| Parameter               | Parameter                       | Statistic / Category      | MYL-1401H (N=25)                | US-Neulasta (N=25)             | Total (N=50)                  |
|-------------------------|---------------------------------|---------------------------|---------------------------------|--------------------------------|-------------------------------|
| Gender                  | - Male                          | n (%)                     | 13 (52.0)                       | 11 (44.0)                      | 24 (48.0)                     |
|                         | - Female                        | n (%)                     | 12 (48.0)                       | 14 (56.0)                      | 26 (52.0)                     |
| Race                    | AmericanIndian or Alaska Native | n (%)                     | 0 (0.0)                         | 1 (4.0)                        | 1 (2.0)                       |
|                         | -Asian                          | n (%)                     | 1 (4.0)                         | 0 (0.0)                        | 1 (2.0)                       |
|                         | -Black orAfrican American       | n (%)                     | 1 (4.0)                         | 0 (0.0)                        | 1 (2.0)                       |
|                         | White                           | n (%)                     | 20 (80.0)                       | 22 (88.0)                      | 42 (84.0)                     |
|                         | - Multiple                      | n (%)                     | 3 (12.0)                        | 2 (8.0)                        | 5 (10.0)                      |
| Ethnicity               | -Hispanic or Latino             | n (%)                     | 0 (0.0)                         | 1 (4.0)                        | 1 (2.0)                       |
| Age (years)             | Age (years)                     | n (%) mean (SD) min - max | 25 (100.0) 34.7 (14.64) 19 - 65 | 24 (96.0) 41.4 (15.76) 19 - 64 | 49 (98.0) 38.0 (15.42) 19 -65 |
| Height (cm)             | Height (cm)                     | mean (SD) min-max         | 178.4 (11.36) 153 - 200         | 173.4 (8.47) 157-193           | 175.9 (10.23) 153 - 200       |
| Weight (kg)             | Weight (kg)                     | mean (SD)                 | 75.9 (11.85)                    | 74.4 (11.62)                   | 75.2 (11.64)                  |
|                         |                                 | min-max                   | 62 -113                         | 60 - 106                       | 60 - 113                      |
| Body Mass Index (kg/m²) | Body Mass Index (kg/m²)         | mean (SD)                 | 23.82 (2.40)                    | 24.66 (2.61) 19.60 - 29.00     | 24.24 (2.52)                  |
|                         |                                 | min-max                   | 20.60 - 28.50                   |                                | 19.60 - 29.00                 |

max = maximum; min = minimum; N (n) = number of subjects; SD = standard deviation

## · Pharmacodynamic Results

Samples for determination of ANC were taken each period on Day -1 (as part of the clinical laboratory assessments), on Days 2 (as part of the clinical laboratory assessments), 3, 8, 15, and 22, and at follow-up (as part of the clinical laboratory assessments). The Day 3 assessment was expected to be close to the time of maximum potential drug effect on ANC.

The mean ANC versus time profiles were relatively similar between the 2 treatments. An ANC elevation was observed at the first sampling time point of 24 hours after dosing of either the test product, MYL1401H, or the reference product, US-Neulasta. The strongest ANC response was observed 48 hours after the second dose; ANC levels were approximately 9-fold higher for both treatments compared with baseline. On subsequent days, ANC levels decreased and had returned to normal by 14 days after dosing. CD34+ counting was not performed.

<div style=\"page-break-after: always\"></div>

Figure 5: Mean Absolute Neutrophil Count Versus Time by Treatment (PerProtocol Set)

<!-- image -->

## 2.4.4. Discussion on clinical pharmacology

Study MYL-1401H-1001 demonstrated in an appropriate and sensitive model in a confirmatory way that 2 mg MYL-1401H and 2 mg reference MP (Neulasta EU sourced) were equivalent in terms of PK profiles and the co-primary PD endpoints ANC AUC0-t and ANC Cmax. This study also showed PD equivalence as to CD34+ count as a secondary parameter.

There were small differences in the PD response observed between ADA positive and negative subjects where responses in terms of ANC AUC0-t appeared to be approximately 10% lower in ADA positive subjects compared to in ADA negative subjects. Although the study MYL-1401H-1001 was not powered to evaluate equivalence of the primary PD parameters for ANC in a smaller subgroup of ADA negative subjects, these results indicate that the primary PD parameters continued to be equivalent between MYL-1401H and the reference treatments EU-Neulasta and US-Neulasta in a subgroup of subjects without any ADA positive response at any time point. Also the secondary PD parameters appeared to be similar between MYL-1401H and the reference treatments in this subgroup.

PD was also descriptively analysed in trial MYL-1401H-1002. The results reasonably support those of study 1001. In this study US-sourced Neulasta was used. The study results are relevant for the current application because an analytical bridge between US- and EU-sourced reference product has been established.

The applicant did not submit studies on distribution, elimination, dose-proportionality and time dependencies, special populations, pharmacokinetics interaction studies, pharmacokinetics using biomaterials and mechanism of action. This is acceptable as according to the guideline EMEA/CHMP/BMWP/31329/2005, these studies are not required.

Taken together, these results support the claim of biosimilarity between Fulphila and the reference product Neulasta.

<div style=\"page-break-after: always\"></div>

## 2.4.5. Conclusions on clinical pharmacology

The  clinical  pharmacology  has  been  well  described  for  Fulphila  and  the  claim  of  biosimilarity  is supported  by  the  primary  and  secondary  PK  parameters  which  were  fully  contained  within  the acceptance  interval  of  80.00-125.00%  in  the  study  MYL-1401H-1001  as  well  as  the  secondary  PD parameters where the GMR were close to 1.

Study MYL-1401H-1002 was supportive of the claim for biosimilarity.

Therefore,  overall  PK/PD  data  from  the  two  studies  show  that  similarity  between  Fulphila  and  the reference product Neulasta could be demonstrated.

## 2.5. Clinical efficacy

## 2.5.1. Dose response study(ies)

No specific dose-response studies were submitted with the initial application. The Applicant selected the dose based on the approved one for US- and EU-Neulasta a fixed SC dose of 6 mg, once per cycle.

## 2.5.2. Main study(ies)

## Study MYL-1401H-3001: A Multicenter, Double-Blind, Randomized, Comparative Efficacy and Safety Study of MYL-1401H and European Sourced Neulasta in Stage II/III Breast Cancer Patients Receiving Neoadjuvant or Adjuvant Chemotherapy

## Methods

## Study Participants

Inclusion criteria

1. Patients aged ≥18 years.
2. Women of child-bearing potential agreed to use effective methods of birth control during the treatment period from the first dose of study drug until 6 months following the last dose of study drug. Acceptable methods of contraception included nonhormonal intrauterine device and barrier methods (male condom, female condom, diaphragm, or cervical cap) with spermicide. Female patients who normally abstained from sexual activity were recruited, provided that they remained abstinent during the study or if they became sexually active, they agreed to use effective methods of birth control as described above.
3. Male patients without a vasectomy agreed to use a condom and their female partners of childbearing potential agreed to use another form of contraception (hormonal contraceptives, intrauterine device, diaphragm with spermicide, or cervical cap with spermicide) during the treatment period from the first dose of study drug until 6 months following the last dose of study drug.

<div style=\"page-break-after: always\"></div>

4. Newly diagnosed, pathologically confirmed breast cancer. Stage II or III breast cancer with adequate staging workup (National Comprehensive Cancer Network guidelines; Version 1.2014 and adequate surgery if receiving adjuvant therapy.
5. Patients planned/eligible to receive neoadjuvant or adjuvant treatment with TAC for their breast cancer. Cancer chemotherapy and radiotherapy naïve.
6. Eastern Cooperative Oncology Group (ECOG) performance status ≤1.
7. Absolute neutrophil count ≥1.5 × 10 9 /L.
8. Platelet count ≥100 × 10 9 /L.
9. Hemoglobin &gt;10 g/dL without blood transfusions or cytokine support during the 2 weeks previous to the hemoglobin level.
10. Adequate cardiac function (including left ventricular ejection fraction ≥50% as assessed by echocardiography) within 4 weeks prior to start of chemotherapy.
11. Adequate renal function, ie, creatinine &lt;1.5 × upper limit of normal (ULN).

## Exclusion criteria

1. Participation in a clinical trial in which they received an investigational drug within 28 days before randomization.
2. Previous exposure to filgrastim, pegfilgrastim, lenograstim, lipegfilgrastim, or other filgrastims on the market or in clinical development.
3. Received blood transfusions or erythroid growth factors within 2 weeks prior to first dose of chemotherapy.
4. Known hypersensitivity to any drugs or excipients that patients received during the study.
5. Known hypersensitivity to E. coli -derived products.
6. Known fructose intolerance (related with sorbitol excipient).
7. Underlying neuropathy of Grade 2 or higher.
8. Active infectious disease or any other medical condition which might have put the patient at significant risk to tolerate 6 courses of TAC chemotherapy (eg, recent myocardial infarction).
9. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;2.5 × ULN, ALT and/or AST &gt;1.5 × ULN with alkaline phosphatase (ALP) &gt;2.5 × ULN; any bilirubin &gt;ULN. Any alteration of liver function and/or ALP elevation, even within acceptance limits, was investigated before randomization to exclude any Stage IV disease.
10. Treatment with systemically active antibiotics within 5 days before first dose of chemotherapy.
11. Patients under treatment with lithium.
12. Chronic use of oral corticosteroids.
13. Splenomegaly of unknown origin by physical examination and/or computerized tomography scan or ultrasound and any condition which can cause splenomegaly, eg, thalassemia, glandular fever, hemolytic anemias, and malaria.
14. Myeloproliferative or myelodysplastic disorders, sickle cell disorders, and any illness or condition that in the opinion of the investigator might affect the safety of the patient or the evaluation of any study endpoint.

<div style=\"page-break-after: always\"></div>

15. Increased potential risk of Adult Respiratory Distress Syndrome.
16. Pregnant or nursing women.
17. Patients known to be seropositive for human immunodeficiency virus, or having an acquired immunodeficiency syndrome defining illness or a known immunodeficiency disorder.
18. A known active abuse of drugs or alcohol precluded patient participation and evaluation in the study.
19. Any known psychiatric conditions.
20. Any disease or physical condition that would have interfered with adequate performance of study assessments, such as lack of access to patient's domiciliary, and distance of patient's domiciliary from clinic site.

## Treatments

MYL-1401H 6 mg injection administered as a single sc dose, on Day 2 of each cycle, ie, 24 h (+ 2 h after) after the end of chemotherapy.

The planned duration for the entire study was approximately 28 weeks (from Screening to follow-up [24 weeks from the first dose of study drug]), assuming no delays in dosing.

The planned duration of patient treatment during the entire study was approximately 18 weeks (from the first day of chemotherapy [Day 1 Cycle 1] to the last scheduled assessment in Cycle 6), assuming no delays in dosing.

<!-- image -->

Abbreviations: CTX = cytotoxic chemotherapy; mg = milligram; n = chemotherapy cycle; sc = subcutaneous; w = weeks

Figure 6: Overview of Study Design MYL-1401H-3001

## Objectives

The primary objective of this clinical trial was to compare the efficacy of MYL-1401H versus Europeansourced Neulasta (EU-Neulasta) for the prophylactic treatment of chemotherapy-induced neutropenia

<div style=\"page-break-after: always\"></div>

in patients with Stage II/III breast cancer receiving docetaxel, doxorubicin, and cyclophosphamide (TAC) anti-cancer chemotherapy.

The secondary objectives of this clinical trial were as follows:

- to assess the safety of MYL-1401H and EU-Neulasta when administered through 6 cycles of TAC anti-cancer chemotherapy.
- to assess the potential immunogenicity of MYL-1401H and EU-Neulasta during chemotherapy and up to 24 weeks following the first administration.

## Outcomes/endpoints

## Primary Efficacy Endpoint:

The primary efficacy endpoint was the duration of severe neutropenia (DSN) in Cycle 1, defined as days with ANC &lt;0.5 × 10 9 /L.

## Secondary Efficacy Endpoints:

- [ ]  The frequency of the worst grade (Grade 3 or 4) neutropenia by cycle (Grade 3 defined as ANC &lt;1.0 × 10 9 /L and Grade 4 as ANC &lt;0.5 × 10 9 /L).

- [ ]  The depth of the ANC nadir in Cycle 1.

- [ ]  The time to the post-nadir ANC recovery (ANC ≥1.5 × 10 9 /L) in Cycle 1.

- [ ]  The ANC-time to nadir in Cycle 1 (ie, time from the beginning of chemotherapy to the occurrence of the ANC nadir).

- [ ]  The rate of febrile neutropenia (FN) defined by the European Society of Medical Oncology Clinical Practice Guidelines as ANC &lt;0.5 × 109/L, or expected to fall below 0.5 × 109/L, with a single oral temperature &gt;38.5°C or 2 consecutive readings of an oral temperature &gt;38.0°C for 2 h, by cycle and across all cycles.

- [ ]  The percentage of scheduled chemotherapy doses that were delivered.

- [ ]  The proportion of chemotherapy doses reduced, omitted, or delayed related to neutropenia, FN, or documented infections.

- [ ]  The number of days of delay of chemotherapy related to neutropenia, FN, or documented infection.

## Safety:

The following safety endpoints were evaluated:

- [ ]  The incidence, nature, and severity of adverse events (AEs) including adverse drug reactions.

- [ ]  The incidence, severity, and distribution of bone pain by brief pain inventory (BPI) form (Short Form) in Cycle 1 and Cycle 2 only.

- [ ]  The incidence, severity, and distribution of infections.

- [ ]  Injection site tolerance.

- [ ]  Incidence, titer, and neutralizing capacity of antibodies against MYL-1401H and EU-Neulasta.

<div style=\"page-break-after: always\"></div>

## Sample size

Approximately 189 patients were planned for enrolment into the study in a 2:1 ratio of the 2 treatment groups (126:63 in the MYL-1401H and EU-Neulasta arm, respectively).

A total sample size of 135 patients allocated in a 2:1 ratio (90 and 45 patients treated with MYL-1401H and Neulasta, respectively) is required to provide 90% power to declare that MYL-1401H is comparable to Neulasta in the analysis of DSN in cycle 1. This sample size assumes that the mean DSN will be 1.70 days in cycle 1 for both MYL-1401H and Neulasta.

The common SD is assumed to be 1.5 days. Equivalence will be declared if the two-sided 95% confidence interval (CI) of the difference between the mean DSNs falls wholly within a region defined as [-1, +1 day].

The region of [-1, +1 day] was established by analyzing historical Neulasta data and estimating a 50% retention of the Neulasta mean treatment benefit over placebo.

## Randomisation

Patients were randomised to receive either MYL-1401H or EU-Neulasta (in a 2:1 ratio, respectively), and were stratified based on their age and country.

## Blinding (masking)

The oncology pharmacist who prepared the doses and the person administering the drug (eg, study nurse, physician [other than the principal investigator or sub-principal investigator]) were the only individuals who had access or knowledge of the actual drug delivered. When administering the drug, the application syringes were covered in order to make them indistinguishable to the patient.

## Statistical methods

The ITT Population (ITT) consisted of all patients who were randomized into the study. Patients in the ITT population were categorized to the treatment as-randomized.

The per protocol (PP) population was defined at the end of Cycle 1 and was a subset of the ITT, including patients receiving treatment to which they were randomized and had no major protocol deviations.

The primary efficacy analysis was based on the PP population, an in the ITT as a sensitivity analysis.

An ANOVA model with treatment as independent variable, and country and age-group as factors, was used to produce a 2-sided 95% CI for the difference in least squares means DSNs. Equivalence was declared if the CI was completely within the range of ± 1 day.

The difference in mean DSN in Cycle 1 within the PP population was statistically compared with the following hypotheses:

H0: (μ MYL-1401H - μNeulasta ≤-1) or (μ MYL-1401H - μNeulasta ≥1)

```
H1: -1 day <(μ MYL-1401H - μNeulasta) <1 day,
```

where μ MYL-1401H and μNeulasta are the mean DSN for MYL-1401H and EU-Neulasta, respectively; calculated in days.

<div style=\"page-break-after: always\"></div>

An analysis of variance (ANOVA) model with treatment as an independent variable, and country and age-group as factors, was used to produce a 2-sided 95% confidence interval (CI) for the difference in least squares mean (LS Mean) DSNs. The 2-sided 95% CI is equivalent to two 1-sided tests at the 2.5% level. Equivalence was declared if the CI was completely within the range of ± 1 day.

Secondary endpoints were analysed descriptively.

A blinded interim analysis was conducted when 50% of the required patients had completed cycle 1. If the common SD had been estimated to be &gt; 1.5 days, then the sample size would have been adjusted accordingly. Since this evaluation is blinded, there was no impact on the overall type 1 error rate and no adjustment of the final analysis of the primary objective was required according to the applicant. Because the SD was less than 1.5 days, no adjustment to the sample size was made.

## Results

## Participant flow

Abbreviations:EU=EuropeanUnion;ITT=intent to treat;N=number ofpatients

<!-- image -->

## Recruitment

Actual: 194 patients were randomized and received study treatment; 127 patients were randomized to receive MYL-1401H and 67 patients were randomized to receive EU-Neulasta.

Completed: 186 patients completed the study.

<div style=\"page-break-after: always\"></div>

Analysed: 194 patients were included in the data analysis.

## Conduct of the study

Version 3.0 of the SAP (dated 25 September 2015) included information on additional immunogenicity assessments to be performed in anticipation of a protocol change. However, due to operational reasons, the protocol change was not initiated and as a consequence the additional immunogenicity assessments were not performed.

A summary of the major protocol deviations is presented in Table 15.

Table 15: Major protocol deviations (ITT population)

|                                                      | MYL-1401H (N=127)   | EU-Neulasta' (N=67)   |
|------------------------------------------------------|---------------------|-----------------------|
| Protocol Deviations                                  | n (%)               | n (%)                 |
| Number of Subjects Who Had Major Protocol Deviations | 34 (26.8%)          | 15 (22.4%)            |
| Protocol Deviation Description                       |                     |                       |
| Inclusion/Exclusion Criteria                         | 2 (1.6%)            | 0 (0.0%)              |
| Prohibited Concomitant Medication                    | 1 (0.8%)            | 0 (0.0%)              |
| Additional Protocol Deviations                       | 33 (26.0%)          | 15 (22.4%)            |
| Lab Testing Deviations                               | 15 (11.8%)          | 10 (14.9%)            |
| Special Testing Deviation                            | 11 (8.7%)           | 1 (1.5%)              |
| Other                                                | 6 (4.7%)            | 4 (6.0%)              |
| Dosing-Time Deviation                                | 3 (2.4%)            | 0 (0.0%)              |
| Subject Visit Window Deviation                       | 2 (1.6%)            | 0 (0.0%)              |
| Missed Subject Visit(s)                              | 1 (0.8%)            | 2 (3.0%)              |

Abbreviations: IT'T = intent-to-treat; N = mumber of patients, n = number of patients in the sample

## Baseline data

Out of the 194 (100.0%) patients with newly diagnosed, pathologically confirmed breast cancer 117 (60.3%) had undergone prior breast cancer surgery, 5 (2.6%) had undergone a lumpectomy, 43 (22.2%) had undergone partial or segmented mastectomy, 3 (1.5%) had undergone a simple or total mastectomy, 52 (26.8%) had undergone radical mastectomy, and 21 (10.8%) had undergone modified radical mastectomy.

<div style=\"page-break-after: always\"></div>

Table 16: Patient Demographics (ITT Population)

| Parameter                             | MYL-1401H (N=127)   | EU-Neulasta? (N=67)   | Overall (N=194)   |
|---------------------------------------|---------------------|-----------------------|-------------------|
| Age (years)                           |                     |                       |                   |
| Mean ± SD                             | 49.5 ± 10.61        | 50.1± 9.85            | 49.7± 10.33       |
| Median (min, max)                     | 49.0 (25, 79)       | 50.0 (29, 68)         | 50.0 (25,79)      |
| Age group (years), n (%)              |                     |                       |                   |
| 0S>                                   | 64 (50.4%)          | 32 (47.8%)            | 96 (49.5%)        |
| 50-65                                 | 56 (44.1%)          | 30 (44.8%)            | 86 (44.3%)        |
| >65                                   | 7 (5.5%)            | 5 (7.5%)              | 12 (6.2%)         |
| Sex, n (%)                            |                     |                       |                   |
| Male                                  | 1 (0.8%)            | 0 (0.0%)              | 1 (0.5%)          |
| Female                                | 126 (99.2%)         | 67 (100.0%)           | 193 (99.5%)       |
| Ethnicity, n (%)                      |                     |                       |                   |
| Hispanic or Latino                    | 0 (0.0%)            | 0 (0.0%)              | 0 (0.0%)          |
| Not Hispanic or Latino                | 127 (100.0%)        | 67 (100.0%)           | 194 (100.0%)      |
| Race, n (%)                           |                     |                       |                   |
| White                                 | 127 (100.0%)        | 67 (100.0%)           | 194 (100.0%)      |
| BlackorAfricanAmerican                | 0 (0.0%)            | 0 (0.0%)              | 0 (0.0%)          |
| Asian                                 | 0 (0.0%)            | 0 (0.0%)              | 0 (0.0%)          |
| AmericanIndian/Alaska Native          | 0 (0.0%)            | 0 (0.0%)              | 0 (0.0%)          |
| NativeHawaiian/Other Pacific Islander | 0 (0.0%)            | 0 (0.0%)              | 0 (0.0%)          |
| Other                                 | 0 (0.0%)            | 0 (0.0%)              | 0 (0.0%)          |

Abbreviations:N=number of patients;n=number of patients in the sample;SD=standard deviation

Source:Table 14.1.3.1

## Numbers analysed

## ITT Population:

The ITT population consisted of all patients who were randomized into the study. The ITT population consisted of a total of 194 (100%) patients.

## Safety Population:

The safety population included all patients who received at least 1 dose of study drug and consisted of 194 (100%) patients.

## Per Protocol Population:

The PP population was defined at the end of Cycle 1 and included a subset of the ITT population who started treatment without major protocol deviations and consisted of 193 (99.5%) patients.

## Outcomes and estimation

## Primary Efficacy Endpoint: Duration of Severe Neutropenia: Cycle 1 (PP population)

The mean (± SD) DSN in the MYL-1401H group was 1.2 (± 0.93), the median DSN was 1.0, and the DSN ranged from 0 to 5 days. In the EU-Neulasta group, the mean (± SD) DSN was 1.2 (± 1.10), the median DSN was 1.0, and the DSN ranged from 0 to 4 days. The DSN was 1 day for 51 (40.5%) patients in the MYL-1401H group and 17 (25.4%) patients in the EU-Neulasta group. The DSN was 0 days for 32 (25.4%) patients in the MYL-1401H group and for 24 [35.8%] patients in the EU-Neulasta

<div style=\"page-break-after: always\"></div>

group. The DSN was 2 days for 25 (27.8%) patients in the MYL-1401H group and for 17 (25.4.%) patients in the EU-Neulasta group (Table 17).

Table 17: Duration of Severe Neutropenia in Cycle 1 (PP Population)

| Parameter                              | MYL-1401H (N=126)                 | EU-Neulasta? (N=67)               |
|----------------------------------------|-----------------------------------|-----------------------------------|
| Durationofsevereneutropenia(days)      | Durationofsevereneutropenia(days) | Durationofsevereneutropenia(days) |
| Mean± SD                               | 1.2± 0.93                         | 1.2 ± 1.10                        |
| Median, (range)                        | 1.0, (0-5)                        | 1.0, (0-4)                        |
| LS Mean (SE)                           | 1.31 (0.139)                      | 1.30 (0.154)                      |
| LS Mean difference from Neulasta? (SE) | 0.01 (0.148)                      | 0.01 (0.148)                      |
| 95% CIa                                | (-0.285, 0.298)                   | (-0.285, 0.298)                   |
| Duration (days), n (%)                 | Duration (days), n (%)            | Duration (days), n (%)            |
| 0                                      | 32 (25.4%)                        | 24 (35.8%)                        |
| 1                                      | 51 (40.5%)                        | 17 (25.4%)                        |
| 2                                      | 35 (27.8%)                        | 17 (25.4%)                        |
| 3                                      | 7 (5.6%)                          | 8 (11.9%)                         |
| 4                                      | 0 (0.0%)                          | 1 (1.5%)                          |
| 5                                      | 1 (0.8%)                          | 0 (0.0%)                          |

Abbreviations:ANOVA= analysis of variance ; CI = confidence interval; N = total number of patients with available data in Cycle 1; n = number of patients in the sample; LS Mean = least squares mean; SD = standard deviation;

SE=standard error

Source: Table 14.2.1.1

a:The 95%CIfor thedifferenceinleast square means isbased on theresult of anANOVAmodelwith treatment group, country, and age group as factors. Comparable efficacy was declared if the 95% CI was completely within this range of (-1 day, +1 day)

The 95% CI (-0.285, 0.298) for the difference in least square mean DSN of MYL-1401H and EUNeulasta was found to be within the pre-specified equivalence range of [-1 day, +1 day] based on the ANOVA model with treatment group, country, and age group as factors. Therefore comparable efficacy of MYL-1401H and EU-Neulasta can be declared (null hypothesis that mean DSN in Cycle 1 on MYL1401H differs from mean DSN on EU-Neulasta by 1 day or more can be rejected).

In summary, trial MYL-1401H-3001 met its primary objective.

There were 19 out of 126 (15%) patients in the MYL-1401H group and 13 out of 67 (19.4%) in the EUNeulasta group who tested positive for anti-drug antibody (ADA) and 107 out of 126 (85%) patients in the MYL-1401H group and 54 out of 67 (80.6%) in the EU-Neulasta group who tested positive negative for anti-drug antibody (ADA). Results of DSN in this subgroup are presented in

<div style=\"page-break-after: always\"></div>

Table 18: Duration of severe neutropenia in cycle 1 in patients positive for antibody (based on assay with MYL-1401H) (PP population)

| Parameter                                | MYL-1401H (N=126)   | EU-Neulasta? (N=67)   |
|------------------------------------------|---------------------|-----------------------|
| Duration of severe neutropenia (days)    |                     |                       |
| n, Mean ± SD                             | 19, 1.5 ±0.77       | 13,0.9±0.95           |
| Median, (range)                          | 2.0, (0-3)          | 1.0, (0-3)            |
| LS Mean (SE)                             | 1.45 (0.311)        | 0.81 (0.314)          |
| LS Mean difference from EU-Neulasta (SE) | 0.64 (0.289)        | 0.64 (0.289)          |
| 95% CI                                   | (0.039,1.231)       | (0.039,1.231)         |
| Duration (days), n (%)                   |                     |                       |
| 0                                        | 2 (1.6%)            | 5 (7.5%)              |
| 1                                        | 7 (5.6%)            | 5 (7.5%)              |
| 2                                        | 9 (7.1%)            | 2 (3.0%)              |
| 3                                        | 1 (0.8%)            | 1 (1.5%)              |

Abbreviations: ANOVA = analysis of variance ; CI = confidence interval; N = total number of patients with available data in Cycle 1; n = mumber of patients in the sample; LS Mean = least squares mean; SD = standard deviation; SE = standard error a: The 95% CI for the difference in LS Mean is based on the result of an ANOVA model with treatment group, country, and age group as factors.

Table 19: Duration of severe neutropenia in Cycle 1 in patients negative for antibody (based on assay with MYL-1401H) (PP population)

| Parameter                                 | MYL-1401H (N=126)   | EU-Neulasta (N=67)   |
|-------------------------------------------|---------------------|----------------------|
| Duration of severe neutropenia (days)     |                     |                      |
| n, Mean ± SD                              | 107, 1.1 ±0.94      | 54,1.2±1.13          |
| Median, (range)                           | 1.0, (0-5)          | 1.0, (0-4)           |
| LS Mean (SE)                              | 1.20 (0.154)        | 1.32 (0.175)         |
| LS Mean difference from EU-Neulasta? (SE) | -0.12 (0.165)       | -0.12 (0.165)        |
| ,IO %56                                   | (-0.442,0.210)      | (-0.442,0.210)       |
| Duration (days), n (%)                    |                     |                      |
| 0                                         | 30 (23.8%)          | 19 (28.4%)           |
| 1                                         | 44 (34.9%)          | 12 (17.9%)           |
| 2                                         | 26 (20.6%)          | 15 (22.4%)           |
| 3                                         | 6 (4.8%)            | 7 (10.4%)            |
| 4                                         | 0 (0.0%)            | 1 (1.5%)             |
| 5                                         | 1 (0.8%)            | 0 (0.0%)             |

Abbreviations: ANOVA = analysis of variance ; CI = confidence interval; N = total number of patients with available data in Cycle 1; n = mumber of patients in the sample; LS Mean = least squares mean; SD = standard deviation; SE = standard error

a: The 95% CI for the difference in LS Mean is based on the result of an ANOVA model with treatment group, country, and age group as factors.

## Secondary (efficacy) endpoints

There were small numerical differences for secondary efficacy endpoints (depths of nadir, frequency of severe neutropenia, frequency of febrile neutropenia) not precluding a conclusion of biosimilarity.

<div style=\"page-break-after: always\"></div>

Table 20: Frequency, depth, and time of neutropenia in cycle 1 (PP population)

| Parameter                                                | MYL-1401H (N=126)                                        | EU-Neulasta? (N=67)                                      |
|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
| Frequency of the worst Grade 3 or 4 neutropenia, n (%6)* | Frequency of the worst Grade 3 or 4 neutropenia, n (%6)* | Frequency of the worst Grade 3 or 4 neutropenia, n (%6)* |
| Grade 3 or 4 neutropenia                                 | 114 (90.5%)                                              | 55 (82.1%)                                               |
| Grade 4 neutropenia                                      | 94 (74.6%)                                               | 43 (64.2%)                                               |
| Grade 3 neutropenia                                      | 20 (15.9%)                                               | 12 (17.9%)                                               |
| ANC nadir (10°/L)                                        | ANC nadir (10°/L)                                        | ANC nadir (10°/L)                                        |
| Mean (SD)                                                | 0.40 (± 0.47)                                            | 0.78 (± 1.43)                                            |
| Median (range)                                           | 0.21 (0.0-2.5)                                           | 0.27 (0.0-6.7)                                           |
| ANC-time to nadir (days)                                 | ANC-time to nadir (days)                                 | ANC-time to nadir (days)                                 |
| Mean (SD)                                                | 6.2 (±0.98)                                              | 6.3 (± 1.57)                                             |
| Median (range)                                           | 6.0 (0-12)                                               | 6.0 (1-14)                                               |
| Post-nadir ANC recovery, n (%o)                          | Post-nadir ANC recovery, n (%o)                          | Post-nadir ANC recovery, n (%o)                          |
| No                                                       | 0 (0.0%)                                                 | 0 (0.0%)                                                 |
| Yes                                                      | 125 (99.2%)                                              | 67 (100.0%)                                              |
| Not evaluable                                            | 1 (0.8%)                                                 | 0 (0.0%)                                                 |
| Time to post-nadir ANC recovery                          | Time to post-nadir ANC recovery                          | Time to post-nadir ANC recovery                          |
| n, Mean (SD)                                             | 125, 1.9 (±0.85)                                         | 67, 1.7 (± 0.91)                                         |
| Median (range)                                           | 2.0 (0-4)                                                | 2.0 (0-3)                                                |
| Time (day), n (%)                                        | Time (day), n (%)                                        | Time (day), n (%)                                        |
| 0                                                        | 6 (4.8%)                                                 | 9 (13.4%)                                                |
| ≤1                                                       | 38 (30.4%)                                               | 24 (35.8%)                                               |
| 2                                                        | 101 (80.8%)                                              | 56 (83.6%)                                               |
| 3                                                        | 121 (96.8%)                                              | 67 (100.0%)                                              |
| ≤4                                                       | 125 (100.0%)                                             | 67 (100.0%)                                              |

Abbreviations: ANC = absolute neutrophil count; L = liter; N = total number of patients with available data in

Cycle 1; n = mumber of patients in the sample; PP = per protocol; SD = standard deviation

<div style=\"page-break-after: always\"></div>

Table 21: Frequency of neutropenia by cycle (ITT population)

| Parameter Cycle                                          | MYL-1401H (N=127)                                        | EU-Neulasta (N=67)                                       |
|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
| Frequency of the worst Grade 3 or 4 neutropenia, n (%6)* | Frequency of the worst Grade 3 or 4 neutropenia, n (%6)* | Frequency of the worst Grade 3 or 4 neutropenia, n (%6)* |
| Grade 3 or 4 neutropenia                                 | 120 (94.5%)                                              | 56 (83.6%)                                               |
| Grade 4 neutropenia                                      | 103 (81.1%)                                              | 49 (73.1%)                                               |
| Grade 3 neutropenia                                      | 17 (13.4%)                                               | 7 (10.4%)                                                |
| Cycle 2                                                  |                                                          |                                                          |
| Grade 3 or 4 neutropenia                                 | 53 (42.4%)                                               | 29 (43.3%)                                               |
| Grade 4 neutropenia                                      | 19 (15.2%)                                               | 15 (22.4%)                                               |
| Grade 3 neutropenia                                      | 34 (27.2%)                                               | 14 (20.9%)                                               |
| Cycle 3                                                  |                                                          |                                                          |
| Grade 3 or 4 neutropenia                                 | 51 (41.1%)                                               | 28 (41.8%)                                               |
| Grade 4 neutropenia                                      | 34 (27.4%)                                               | 16 (23.9%)                                               |
| Grade 3 neutropenia                                      | 17 (13.7%)                                               | 12 (17.9%)                                               |
| Cycle 4                                                  |                                                          |                                                          |
| Grade 3 or 4 neutropemia                                 | 66 (53.2%)                                               | 30 (44.8%)                                               |
| Grade 4 neutropenia                                      | 30 (24.2%)                                               | 18 (23.9%)                                               |
| Grade 3 neutropemia                                      | 36 (29.0%)                                               | 12 (17.9%)                                               |
| Cycle 5                                                  |                                                          |                                                          |
| Grade 3 or 4 neutropemia                                 | 60 (48.8%)                                               | 26 (39.4%)                                               |
| Grade 4 neutropenia                                      | 38 (30.9%)                                               | 13 (19.7%)                                               |
| Grade 3 neutropenia                                      | 22 (17.9%)                                               | 13 (19.7%)                                               |
| Cycle 6                                                  |                                                          |                                                          |
| Grade 3 or 4 neutropemia                                 | 59 (49.2%)                                               | 28 (42.4%)                                               |
| Grade 4 neutropenia                                      | 34 (28.3%)                                               | 20 (30.3%)                                               |
| Grade 3 neutropenia                                      | 25 (20.8%)                                               | 8 (12.1%)                                                |

Abbreviations: n = number of patients in the sample; N = total mumber of patients with available data

Source: Table 14.2.3.2

*If a patient experienced more than 1 grade of neutropenia, only the highest grade was counted.

Table 22: Rate of febrile neutropenia (cycle 1) (ITT population)

| Parameter                          | MYL-1401H (N=127)   | EU-Neulasta (N=67)   |   P-value |
|------------------------------------|---------------------|----------------------|-----------|
| Rate of febrile neutropenia, n (%) | 5 (3.9%)            | 1 (1.5%)             |      0.35 |

Febrile neutropemia is defined as febrile neutropenia reported as an AE

Abbreviations: AE = adverse event; ITT = intent to treat; N = total mumber of patients with available data in Cycle 1; n = mumber of patients in the sample

<div style=\"page-break-after: always\"></div>

Table 23: Rate of febrile neutropenia by cycle (ITT population)

|                                            | MYL-1401H (N=127)   | EU-Neulasta (N=67)   |
|--------------------------------------------|---------------------|----------------------|
| Parameter                                  | n (%)               | n (%)                |
| Rate of febrile neutropemia for all cycles | 7 (5.5%)            | 1 (1.5%)             |
| Rate of febrile neutropenia in Cycle 1     | 5 (3.5%)            | 1 (1.5%)             |
| Rate of febrile neutropenia in Cycle 2     | 1 (0.8%)            | 0 (0.0%)             |
| Rate of febrile neutropemia in Cycle 3     | 1 (0.8%)            | 0 (0.0%)             |
| Rate of febrile neutropenia in Cycle 4     | 0 (0.0%)            | 0 (0.0%)             |
| Rate of febrile neutropenia in Cycle 5     | 0 (0.0%)            | 0 (0.0%)             |
| Rate of febrile neutropemia in Cycle 6     | 0 (0.0%)            | 0 (0.0%)             |

Febrile neutropenia is defined as febrile neutropenia reported as an AE.

Abbreviations: AE = adverse event; ITT = intent to treat; n = number of patients in the sample

## Ancillary analyses

Not applicable.

## Summary of main study(ies)

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Title: A Multicenter, Double-Blind, Randomized, Comparative Efficacy and Safety Study of MYL1401H and European Sourced Neulasta in Stage II/III Breast Cancer Patients Receiving Neoadjuvant or Adjuvant Chemotherapy

| Study identifier   | Study MYL-1401H-3001 EudraCT Number: 2014-002324-27                  | Study MYL-1401H-3001 EudraCT Number: 2014-002324-27                                                                                                                                                                                                                      |
|--------------------|----------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Design             | 25 Mar 2015 to 09 Feb 2016                                           | 25 Mar 2015 to 09 Feb 2016                                                                                                                                                                                                                                               |
| Design             | Duration of main phase: Duration of Run-in phase: Duration of study: | Patient treatment during the entire study was approximately 18 weeks (from the first day of chemotherapy [Day 1 Cycle 1] to the last scheduled assessment in Cycle 6) Not applicable 28 weeks (from Screening to follow-up [24 weeks from the first dose of study drug]) |
| Hypothesis         | Equivalence, Non-inferiority                                         | Equivalence, Non-inferiority                                                                                                                                                                                                                                             |
| Treatments groups  | Group 1: MYL-1401H                                                   | MYL-1401H 6 mg injection administered as a single sc dose, on Day 2 of each cycle, ie, 24 h (+ 2 h after) after the end of chemotherapy                                                                                                                                  |
| Treatments groups  | Group 2: Neulasta                                                    | EU-Neulasta 6 mg injection administered as a single sc dose, on Day 2 of each cycle, ie, 24 h (+ 2 h) after the end of chemotherapy.                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| Endpoints and definitions   | Primary endpoint   | mean duration of severe neutropenia (DSN) during Cycle 1                                      | The primary efficacy endpoint was the duration of severe neutropenia (DSN) in Cycle 1, defined as days with ANC <0.5 × 10 9 /L.                                                                                                                                                                                            |
|-----------------------------|--------------------|-----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Endpoints and definitions   | Secondary endpoint | Grade 3/4 Neutropenia                                                                         | The frequency of the worst grade (Grade 3 or 4) neutropenia by cycle (Grade 3 defined as ANC <1.0 × 10 9 /L and Grade 4 as ANC <0.5 × 10 9 /L).                                                                                                                                                                            |
| Endpoints and definitions   | Secondary endpoint | Time to ANC recovery                                                                          | The time to the post-nadir ANC recovery (ANC ≥ 1.5 × 10 9 /L) in Cycle 1.                                                                                                                                                                                                                                                  |
|                             | Secondary endpoint | Depth of ANC nadir                                                                            | The depth of the ANC nadir in Cycle 1                                                                                                                                                                                                                                                                                      |
|                             | Secondary endpoint | ANC- time to nadir                                                                            | The ANC-time to nadir in Cycle 1 (ie, time from the beginning of chemotherapy to the occurrence of the ANC nadir).                                                                                                                                                                                                         |
|                             | Secondary endpoint | Rate of Febrile Neutropenia                                                                   | The rate of febrile neutropenia (FN) defined by the European Society of Medical Oncology Clinical Practice Guidelines as ANC <0.5 × 109/L, or expected to fall below 0.5 × 109/L, with a single oral temperature >38.5°C or 2 consecutive readings of an oral temperature >38.0°C for 2 h, by cycle and across all cycles. |
|                             | Secondary endpoint | The incidence, nature, and severity of adverse events (AEs) including adverse drug reactions. | See safety.                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|                                                                                | Secondary endpoint                                       | The incidence, severity, and distribution of bone pain by brief pain inventory (BPI) form (Short Form) in Cycle 1 and Cycle 2 only.   | See safety.                  |
|--------------------------------------------------------------------------------|----------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|------------------------------|
|                                                                                | Secondary endpoint                                       | The incidence, severity, and distribution of infections.                                                                              | See safety.                  |
|                                                                                | Secondary endpoint                                       | Injection site tolerance.                                                                                                             | See safety.                  |
|                                                                                | Secondary endpoint                                       | Incidence, titer, and neutralizing capacity of antibodies against MYL-1401H and EU-Neulasta                                           | See safety.                  |
| Results and Analysis                                                           |                                                          |                                                                                                                                       |                              |
| Analysis description                                                           | Analysis description                                     | Analysis description                                                                                                                  | Analysis description         |
| Analysis population and time point description                                 | FAS                                                      | FAS                                                                                                                                   | FAS                          |
| Descriptive statistics and estimate variability                                | MYL-1401H Neulasta                                       | MYL-1401H Neulasta                                                                                                                    | MYL-1401H Neulasta           |
| Descriptive statistics and estimate variability Effect estimate per comparison | Number of subject                                        | N=126                                                                                                                                 | N=67                         |
| Descriptive statistics and estimate variability Effect estimate per comparison | Primary endpoint Mean (SD)                               | 1.2±0.93                                                                                                                              | 1.2±1.10                     |
| Descriptive statistics and estimate variability Effect estimate per comparison | Median (Range)                                           | 1.0 (0.5)                                                                                                                             | 1.0 (0-4)                    |
| Descriptive statistics and estimate variability Effect estimate per comparison | LS Mean for difference La- MYL-1401H - Neulasta (95% CI) | 0.01 (0.148) (-0.285, 0.298)                                                                                                          | 0.01 (0.148) (-0.285, 0.298) |

<div style=\"page-break-after: always\"></div>

| Frequency of the worst Grade 3/4 Neutropenia (ITT) ; n (%)   | 120 (94.5%; 17 [13.4%] Grade 3 and 103 [81.1%] Grade 4   | 56 (83.6%; 7 [10.4%] Grade 3 and 49 [73.1%] Grade 4   |
|--------------------------------------------------------------|----------------------------------------------------------|-------------------------------------------------------|
| The depth of the ANC nadir in Cycle 1 ; Mean (std)           | 0.40 × 10 9 /L (± 0.474)                                 | 0.78 × 10 9 /L (± 1.426)                              |
| Time to ANC recovery (days); Mean (std)                      | 1.9 (± 0.85)                                             | 1.7 (± 0.91)                                          |
| ANC- time to nadir ; days (std)                              | 6.2 (± 0.98)                                             | 6.3 (± 1.57)                                          |
| Rate of febrile neutropenia; n(%)                            | 7/127 (5.5%)                                             | 1/67 (1.5%)                                           |

## Analysis performed across trials (pooled analyses and meta-analysis)

The applicant did not submit analyses across trials.

## Clinical studies in special populations

The applicant did not submit clinical studies in special populations (see clinical discussion).

## Supportive study(ies)

The applicant did not submit supportive studies (see clinical discussion).

## 2.5.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

The applicant has submitted the results of a parallel-group, active controlled, blinded trial to show equivalence in terms of DSN. The study design was in accordance with scientific recommendations as outlined in the respective EMA guideline currently in place.

There are minor criticisms on trial 3001 such as administering TAC to patients in neo-adjuvant intent, and not stratifying TAC for adjuvant/neo-adjuvant. These are, however, minor design and conduct issues which have, in essence, no effect on the biosimilar conclusion.

## Efficacy data and additional analyses

The primary analysis, as well as the sensitivity analyses, of the primary endpoint are robust and allow the conclusion which read:

The primary objective of the study was met, where the median DSN was 1.0 day (range 0-5) and EUNeulasta was 1.0 (0.4), the LS mean difference from Neulasta was 0.01 (95%CI -0.285, 0.298),

<div style=\"page-break-after: always\"></div>

determined by the ANOVA analysis (with treatment group, country, and age group as factors for the difference in least square mean DSNs of MYL-1401H and EU-Neulasta). The results were found to be within the pre-specified equivalence range of [-1 day, +1 day]. In fact, the 95% CIs were very narrow allowing a firm conclusion of similar efficacy. These results show that there are no significant differences between the two products in terms of DSN, supporting the claim for biosimilarity.

There were small numerical differences for secondary efficacy endpoints (depths of nadir, frequency of severe neutropenia, frequency of febrile neutropenia) not precluding a conclusion of biosimilarity. However, these were not considered clinically relevant. Secondary endpoints and the result of the frequency of neutropenia for cycle 2 to 6 lend overall support to the therapeutic equivalence between Fulphila and Neulasta.

## 2.5.4. Conclusions on the clinical efficacy

The clinical data in the trial MYL-1401H-3001 in patients undergoing cytotoxic chemotherapy has shown comparable efficacy between Fulphila and Neulasta in reducing the duration of severe neutropenia. Hence, MYL-1401H and Neulasta EU-sourced offer therapeutic equivalence which supports the claim for biosimilarity.

## 2.6. Clinical safety

Mylan has conducted 3 clinical studies that have evaluated the comparability of safety between MYL1401H and Neulasta: 2 studies in healthy subjects (MYL-1401H-1001 and MYL-1401H-1002) and 1 comparative safety and efficacy study in patients with Stage II/III invasive breast cancer (MYL-1401H3001).

Due to differences in the study dose, study design, and populations, the safety data from the 3 studies (MYL-1401H-1001, MYL-1401H-1002, and MYL-1401H-3001) have not been integrated.

The clinical trial specifically dedicated to immunogenicity is trial MYL-1401H-1002. However a thorough assessment of immunogenicity was conducted across the 3 clinical studies (see below).

## Patient exposure

A total of 232 healthy subjects and 127 patients diagnosed with breast cancer have received at least 1 dose of MYL-1401H.

In 3-way crossover Study MYL-1401H-1001, 216 healthy male and female subjects received at least one 2-mg SC injection of pegfilgrastim and 198 subjects received the planned 3 doses of pegfilgrastim: 207 subjects received at least 1 dose of MYL-1401H (test product), 208 subjects received at least 1 dose of EU-Neulasta and 207 subjects received atleast 1 dose of US-Neulasta.

In Study MYL-1401H-1002, 25 healthy male and female subjects received at least one 6-mg SC injection of MYL-1401H (test product) and 25 healthy male and female subjects received at least one 6-mg SC injection of US-Neulasta. Two 6-mg SC injections were received by 23 subjects in the MYL1401H group and 21 subjects in the US-Neulasta group.

In Study MYL-1401H-3001, 127 patients received at least one 6-mg SC injection of MYL-1401H (test product) and 67 patients received at least one 6-mg SC injection of EU-Neulasta. One hundred twenty (94.5%) patients in the MYL-1401H group and 66 (98.5%) patients received all 6 doses of study drug. During each cycle, the majority of patients received their study drug on Day 2 of the cycle as scheduled.

<div style=\"page-break-after: always\"></div>

## Adverse events

## Study MYL-1401H-1001

In Study MYL-1401H-1001, safety and tolerability were evaluated after the single 2-mg sc injection by evaluating all AEs, physical examinations, vital signs, ECGs, clinical laboratory, local tolerance, and immunogenicity (early development of ADA).

There were 1129 TEAEs reported by 200 (93%) subjects that were considered related to pegfilgrastim treatment with 177 (86%) subjects who received MYL-1401H, 182 (88%) subjects who received EUNeulasta, and 181 (87%) subjects who received US-Neulasta (Table 24).

Table 24: Overview of treatment-emergent adverse events during the study (1001)

|                                                     | MYL-1401H (N=207) n (%)   | EU-Neulasta (N=208) n (%)   | US-Neulasta (N=207) n (%)   |
|-----------------------------------------------------|---------------------------|-----------------------------|-----------------------------|
| Number of subjects with at least 1 TEAE             | 177 (86)                  | 182 (88)                    | 181 (87)                    |
| Number of subjectswith at least 1 related TEAE      | 156 (75)                  | 165 (79)                    | 157 (76)                    |
| Number of subjectswith at least 1 TEAE by severity: |                           |                             |                             |
| Grade 1 (mild) severity                             | 158 (76)                  | 172 (83)                    | 166 (80)                    |
| Grade 2 (moderate) severity                         | 86 (42)                   | 92 (44)                     | 84 (41)                     |
| Grade 3 (severe) severity                           | 0 (0)                     | 0 (0)                       | 1 (>0)                      |
| Number of subjectswithdrawn due to (S)AEs:          | 0 (0)                     | 2 (1)                       | 1 (>0)                      |
| SAE                                                 | 0 (0)                     | 0 (0)                       | 1 (>0)                      |
| AE                                                  | 0 (0)                     | 2 (1)                       | 0 (0)                       |

Abbreviations: AE = adverse event; EU = European Union; SAE = serious adverse event; TEAE = treatment-emergent adverse event; US =United States

In MYL-1401H-1001, the most commonly reported TEAE by preferred term (PT) were back pain (81% of the subjects), headache (63% of the subjects), pain in extremity (36% of the subjects) and nasopharyngitis (22% of the subjects). There were no relevant differences in the frequencies of TEAEs or percentages of subjects reporting TEAEs among MYL-1401H and the reference treatments (EUNeulasta and US-Neulasta).

## Study MYL-1401H-1002

A summary of all Treatment-Emergent Adverse Events is provided in Table 25 below.

<div style=\"page-break-after: always\"></div>

Table 25: Overview of Treatment-Emergent Adverse Events During the Study (1002)

|                                                     | MYL-1401H (N=25) n (%)   | US-Neulasta (N=25) n (%)   |
|-----------------------------------------------------|--------------------------|----------------------------|
| Number ofsubjects with atleast1TEAE                 | 24 (96.0%)               | 25 (100.0%)                |
| NumberofsubjectswithatleastlrelatedTEAE             | 24 (96.0%)               | 25 (100.0%)                |
| Number of subjectswith at least 1 TEAE by severity: |                          |                            |
| Grade 1 (mild)                                      | 23 (92.0%)               | 23 (92.0%)                 |
| Grade 2 (moderate)                                  | 19 (76.0%)               | 22 (88.0%)                 |
| Grade 3 (severe)                                    | 0 (0.0%)                 | 1 (4.0%)                   |
| Numberofsubjectswithdrawndueto(S)AEs:               | 2 (8.0%)                 | 4 (16.0%)                  |
| SAE                                                 | 0 (0.0%)                 | 0 (0.0%)                   |
| AE                                                  | 2 (8.0%)                 | 4 (16.0%)                  |

AE= adverse event;N=the#of subjects exposed to the treatment;n=the # of subjects that experienced the adverse event;SAE=serious adverse event;TEAE=treatment-emergent adverse event;%is calculated as (n/N)*100

There were 376 TEAEs reported by 49 (98%) subjects: 188 TEAEs by 24 (96.0%) subjects who received MYL-1401H and 188 TEAEs by 25 (100.0%) subjects who received the reference product USNeulasta.

Generally, most TEAEs reported during the study were consistent with the clinical data of pegfilgrastim (Neulasta). No serious AEs (SAEs) or unexpected TEAEs were reported.

The number of TEAEs and percentage of subjects reporting TEAEs was comparable between MYL1401H and the reference product US-Neulasta: 188 TEAEs reported by 24 (96.0%) subjects and 188 TEAEs reported by 25 (100.0%) subjects, respectively. The most frequently reported TEAEs by system organ class (SOC) (ie, reported by &gt;50% of the subjects) were musculoskeletal and connective tissue disorders (by 90.0% of the subjects), nervous system disorders (72.0%), and general disorders and administration site conditions (60.0%). The most frequently reported preferred terms (PTs) (ie, reported by ≥20% of the subjects) were back pain (80.0%), headache (70.0%), injection site pain (30.0%), fatigue (26.0%), myalgia (24.0%), non-cardiac chest pain (24.0%), pain in extremity (20.0%), and abdominal pain (20.0%). There were no relevant differences in the frequency of TEAEs or percentage of subjects reporting TEAEs between MYL-1401H and US-Neulasta.

## Study MYL-1401H-3001

In Study MYL-1401H-3001, 806 TEAEs were reported in 114 (89.8%) patients in the MYL-1401H group and 414 TEAEs were reported in 58 (86.6%) patients in the EU-Neulasta group. Among the patients with TEAEs, the majority had TEAEs that resolved during the study (104 [81.9%] patients in the MYL1401H group and 47 [70.1%] patients in the EU-Neulasta group). An overview of TEAEs in Study MYL1401H-3001 is provided in Table 26.

<div style=\"page-break-after: always\"></div>

Table 26: Overview of treatment-emergent adverse events during the study (3001)

|                                                         | MYL-1401H (N=127) n (%)   | US-Neulasta (N=67) n (%)   |
|---------------------------------------------------------|---------------------------|----------------------------|
| Number of TEAEs                                         | 806                       | 414                        |
| Number of patients with at least 1 TEAE                 | 114 (89.8)                | 58 (86.6)                  |
| Number ofpatientswith atleast1pegfilgrastim-relatedTEAE | 57 (44.9)                 | 24 (35.8)                  |
| Number ofpatientswith atleast1 TEAEbyseverity:          |                           |                            |
| Grade 1 (mild) severity                                 | 34 (26.8)                 | 15 (22.4)                  |
| Grade2(moderate)severity                                | 56 (44.1)                 | 35 (52.2)                  |
| Grade3(severe)severity                                  | 24 (18.9)                 | 8 (11.9)                   |
| Number of patients withSAE(s):                          |                           |                            |
| Notrelated                                              | 8 (6.3)                   | 1 (1.5)                    |
| Related                                                 | 0                         | 0                          |
| Number ofpatients withdrawn due to(S)AEs:               |                           |                            |
| Grade 1 (mild) severity                                 | 0                         | 0                          |
| Grade2(moderate)severity                                | 3 (2.4)                   | 0                          |
| Grade 3 (severe)severity                                | 1 (0.8)                   | 0                          |

Abbreviations:AE=adverse event;SAE=serious adverse event;TEAE=treatment-emergent adverse event; US=United States

The most commonly reported TEAE by preferred term was alopecia reported by 76 (59.8%) patients in the MYL-1401H group and 36 (53.7%) patients in the EU-Neulasta group. Of patients with this TEAE, most had CTCAE Grade 1 events (36 [28.3%] patients in the MYL-1401H group and 14 [20.9%] patients in the EU-Neulasta group) and Grade 2 events (36 [28.3%] patients in the MYL-1401H group and 22 [32.8%] patients in the EU-Neulasta group) (CSR MYL-1401H-3001). The events of alopecia were not considered related to the study drug by the investigator.

The TEAE of bone pain was reported for 51 (40.2%) patients in the MYL-1401H group and 24 (35.8%) patients in the EU-Neulasta group. Of the patients with this TEAE, most had CTCAE Grade 1 (21 [16.5%] patients in the MYL-1401H group and 10 [14.9%] patients in the EU-Neulasta group) and Grade 2 (26 [20.5%] patients in the MYL-1401H group and 13 [19.4%] patients in the EU-Neulasta group). Fifty (39.4%) patients in the MYL-1401H group and 23 (34.3%) patients in the EU-Neulasta group) had treatment-related TEAEs of bone pain. Bone pain was managed by simple analgetics, and no patients discontinued from the study as a result of their bone pain. The majority of the events of bone pain were reported in Cycle 1 (44 [34.6%] in the MYL-1401H group and 17 [25.4%] in the EUNeulasta group). However, a higher rate of use of naproxen was reported during Cycle 1 in the EUNeulasta group, 19 (28.4%) patients compared to 25 (19.8%) in the MYL-1401H group. Notably, the Brief Pain Inventory questionnaire, a sensitive and relevant measure of the intensity and interference of pain in the patient's life, was similar between the treatment groups.

There were 8 patients with thrombocytosis in the MYL-1401H group that were Grade 1 or 2 in severity and resolved without any intervention. The actual laboratory values of platelets were similar between the treatment groups (approximately 65 [51.2%] patients in the MYL-1401H group had at least 1 episode of elevated platelet count &gt;450 compared with 35 [52.2%] in the EU-Neulasta group and about half of these were single isolated episodes in both the groups). At the end-of-study visit, the mean and median platelets and the change from baseline in platelet counts were similar between the treatment groups. Additionally, the AE reporting of thrombocytosis appeared to be subjective, with only 3 of 24 sites reporting all the 8 events of thrombocytosis in the MYL-1401H group.

<div style=\"page-break-after: always\"></div>

## Serious adverse event/deaths/other significant events

## Study MYL-1401H-1001

In Study MYL-1401H-1001, 1 serious AE (SAE) of appendicitis in the US-Neulasta group occurred and resulted in subject withdrawal. The SAE was not considered to be related to pegfilgrastim.

## Study MYL-1401H-1002

No SAEs were reported in Study MYL-1401H-1002.

## Study MYL-1401H-3001

In Study MYL-1401H-3001, SAEs were infrequent. A total of 9 (4.6%) patients in the safety population had at least 1 SAE (8 [6.3%] patients in the MYL-1401H group and 1 [1.5%] patients in the EUNeulasta group. There were no SAEs considered by the investigator to be related to study drug.

Six of 127 (4.7%) patients had FN in the MYL-1401H group and 1 of 67 (1.5%) patients had FN in the EU-Neulasta group, which were considered to be SAEs. All the events of FN lasted less than 5 days, no documented infections nor sepsis events were observed during the events of FN, and all the FN events resolved without the use of rescue therapy. Of 7 patients with FN considered SAEs, only 3 patients met the ESMO definition for FN while 4 other patients had insufficient data. However, these patients were conservatively included under the category of FN.

There was 1 patient with an SAE of erysipelas and 1 patient with SAEs of hypokalemia and anemia in the MYL-1401H group, all of which were deemed resolved at the time of data analysis. All SAEs were deemed unrelated to the study drug by the investigator.

All SAEs of FN were deemed related to the chemotherapy and unrelated to treatment with MYL-1401H or EU-Neulasta by the investigator. There was no significant difference in the rate of FN between the treatment groups (p=0.35) based on a chi-square test comparing the proportion of patients with FN between the treatment groups. Given the 2:1 randomization, small sample size, and frequency of ANC assessments based on safety considerations, it is believed that these minor differences are incidental findings. All events of FN lasted less than 5 days, no documented infections or sepsis events were observed during the events of FN, and all FN events resolved without the use of rescue therapy.

No deaths occurred during any of the MYL-1401H clinical studies.

## Laboratory findings

In study MYL-1401H-1002 all clinical laboratory parameters were measured at screening and followup, and each period at baseline on Day -1 and on Day 2. Absolute neutrophil count was also measured on Days 3, 8, 15, and 22 as part of the PD assessments. For both treatments, mean ALP and LDH levels on Day 2 of both periods were elevated compared with baseline but remained below the ULN. Also individual ALP and LDH levels during the study remained below ULN. In summary, all observed hematological and clinical chemistry changes were expected and were primarily related to the PD effects of pegfilgrastim.

<div style=\"page-break-after: always\"></div>

## Summary of Hematology

Across all 3 studies (MYL-1401H-1001, MYL-1401H-1002, MYL-1401H-3001), there were no notable differences observed in the hematology measurements between the MYL-1401H groups and Neulasta groups. Across treatments, similar transient shifts in neutrophils and leukocytes occurred, and these parameters had returned to baseline levels by Day 13 and Day 15, respectively. White blood cell (counts of 100 × 10 9 /L or greater) have been observed in less than 1% of patients receiving Neulasta and are consistent with the PD effects of pegfilgrastim.

## Summary of Liver and Kidney Function Tests

Overall, there were no notable new differences observed in the liver or kidney function tests between MYL-1401H and Neulasta treatment groups. Liver function abnormalities are consistent with the PD effects of pegfilgrastim.

Vital signs, ECG, and physical findings in study 1002 can be summarized that they were insignificant for a population of healthy volunteers. There were no findings of splenomegaly or symptoms of splenic rupture during the physical examinations of the abdomen throughout the study. One subject (USNeulasta) had 'left side tenderness', which was considered to be of no clinical relevance.

Local tolerability (including ISR and VAS) in study 1002 was assessed each period at pre-dose and at 1, 4, 24 (Day 2), and 48 hours (Day 3) post-dose. Mostly, the ISR scores were 'none' (0). For 9 subjects that received MYL-1401H, at 1 or more time points following drug administration, a mild reaction was observed (ISR score of 1). This was mainly at 1 hour post-dose, but in some instances also at 4, 24, or 48 hours post-dose. For 5 subjects that received US-Neulasta, at 1 or more time points following drug administration, a mild reaction was observed (ISR score of 1). This was mainly at 1 hour post-dose, but in some instances also at 4, 24, or 48 hours post-dose. Most subjects had a score of 0 mm on a 0-100 mm VAS scale, indicating no pain at the injection site. There were 2 scores of 7 mm, all other scores were 4 mm or lower. The difference in the frequency of injection site reactions (ISR) 9/25 (36%; MYL-1401H) vs. 5/25 (20%; US-Neulasta) could reach statistical significance (not statistically analysed by the applicant). In trial 1001 identical but in 1002 different syringes were used. A higher frequency of injection site reactions (9/25 MYL-1401H vs 5/25 USNeulasta) has been observed and is noticeable in trial 1002 (all grade 1) but absent in pivotal 3001.

## Safety in special populations

N/A

## Immunological events

A thorough assessment of immunogenicity was conducted across the 3 clinical studies. The clinical program included Study MYL-1401H-1001 and Study MYL-1401H-1002, which were conducted in normal healthy volunteers, and Study MYL-1401H-3001, which was conducted in patients with breast cancer who were receiving chemotherapy. Serum samples were analyzed for the presence of ADA against MYL-1401H or Neulasta (either EU-Neulasta and/or US-Neulasta). Samples that were positive in the screening assay were further evaluated in a confirmatory assay. The samples confirmed as ADApositive were titrated to quantify the ADA response and were further evaluated for moiety characterization to determine if the antibodies were specifically directed against the PEG and/or the filgrastim moiety of the molecule.

<div style=\"page-break-after: always\"></div>

The immunogenicity assessment in the pivotal PK/PD Study MYL-1401H-1001 was limited. It evaluated a 2-mg dose, which is sub-therapeutic, and had a 3-way crossover design. Since subjects crossed over to other treatments, immunogenicity data from baseline through Day 29 in Period 1 (i.e., Period 2 pre-dose) are the most relevant for discussion, while data from Period 2 and Period 3 are potentially confounded.

A 7% (16 of 216 subjects overall) baseline frequency of ADA+ subjects is notable, as well as a small imbalance (9 (4%) subjects prior to administration of MYL-1401H, 4 (2%) subjects prior to EUNeulasta and 3 (1%) subjects prior to US-Neulasta). Most of these baseline ADAs were directed against PEG, or PEG and filgrastim, but not filgrastim alone. A volunteer having ADAs directed against neither the PEG nor the filgrastim portion of the molecule seems to be a false positive ADA result.

Prior to dosing on Day 1 of Period 2 (Table 27), which was Day 29 of Period 1 and the most relevant for immunogenicity assessment, 27 of the 208 (13%) subjects had positive ADA results at this time point with median ADA titre of 4 for each of the 3 treatments. Of the 27 subjects with confirmed positive results at pre dose in Period 2, 10 subjects had pre-existing ADAs at baseline and the other 17 (8%) subjects developed ADAs after the first dose of study drug (5 subjects after MYL-1401H, 5 subjects after EU-Neulasta, and 7 subjects after US-Neulasta). For these 17 subjects, the increased ADAs were considered to be treatment-induced positive ADA results. Thus, the incidence of treatment induced ADA positivity was similar across all the 3 dosing groups (7.2-9.7%) in Period 1.

Table 27: Summary of subjects with treatment-induced anti-drug antibodies at pre-dose in period 2 (1001)

|                      | ADA Results at Predose (Day 1) in Period 2, by Administration of the First Dose   | ADA Results at Predose (Day 1) in Period 2, by Administration of the First Dose   | ADA Results at Predose (Day 1) in Period 2, by Administration of the First Dose   | ADA Results at Predose (Day 1) in Period 2, by Administration of the First Dose   |
|----------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| FirstdoseinPeriod1   | Totalconfirmed positive for ADAS n                                                | Treatment-induced ADAsb n (%)                                                     | treatment- induced positives\"                                                     | Mean titer ofPredosepositiveswith >3-fold ADA titer increase n (%)                |
| MYL-1401H (N=69)*    | 11                                                                                | 5 (7.2)                                                                           | 4                                                                                 | 1 (1.4)                                                                           |
| EU-Neulasta? (N=67)a | 7                                                                                 | 5 (7.5)                                                                           | 2                                                                                 | 1 (1.5)                                                                           |
| US-Neulasta? (N=72)a | 9                                                                                 | 7 (9.7)                                                                           | 9                                                                                 | 1 (1.4)                                                                           |
| Total (N=208)        | 27                                                                                | 17 (8.2)                                                                          |                                                                                   | 3 (1.4)                                                                           |

Abbreviations: ADA = anti-drug antibody; EU = European Union; N = number of patients; n = number of patients in the sample;US=United States

The number of subjects shown and used for the calculation of percentages in this table are the number of subjects with data available at Period 2 predose (Study Day 29).

Subjects who were confirmed positive ADA prior to administration of the first dose in Period 1 were excluded

Prior to dosing in Period 3, 13 of the 198 (6%) subjects continued to have positive ADA results. The median ADA titers were comparable across treatments (median titer: 2, 4, and 4 for MYL-1401H, EUNeulasta and US-Neulasta, respectively).

At follow up, a total of 14 of the 213 (6%) subjects were found positive for ADA that included 6 subjects with ADAs present prior to the first dose of study drug and 8 subjects that were considered to have treatment-induced positive ADA results (including 4, 1, and 3 subject[s] who received MYL1401H, EU-Neulasta, or US-Neulasta as first dose of study drug, respectively). All ADA titers were &lt;30 at follow up.

<div style=\"page-break-after: always\"></div>

The follow-up result make clear why a cross-over design is all but optimal for testing immunogenicity: The treatments actually consisted of 6 different sequences of 3 different products.

Samples that were ADA positive were further assessed for NAb. A total of 72 subjects with ADA positive samples were analyzed for NAbs (Table 28).

The term '72 subjects with ADA positive samples' gives approximately the same proportion of 'immunogenicity' as in trial 1002 the wording 'ADA was positive at 1 or more time points for 8 of 25 (32.0%) subjects who received MYL-1401H and for 8 of 25 (32.0%) subjects who received USNeulasta'. 72/216 (see above) is 33.3%. Thus, this 'phenomenon' is not dose related.

Table 28: Summary of neutralizing antibodies by visit (1001)

| Visit          | NAb Assay         | MYL-1401H (N=72) n (%)   | EU-Neulasta (N=72) n (%)   | US-Neulasta (N=72) n (%)   | Total (N=216) n (%)   |
|----------------|-------------------|--------------------------|----------------------------|----------------------------|-----------------------|
| Period1Predose |                   |                          |                            |                            |                       |
| (Day 1)        | Total#of samples  | 72                       | 72                         | 72                         | 216                   |
|                | Negative          | 5 (6.9)                  | 3 ( 4.2)                   | 3 ( 4.2)                   | 11 ( 5.1)             |
|                | Positive          | 4 (5.6)                  | 1 (1.4)                    | 0 (0.0)                    | 5 (2.3)               |
|                | Not Reportable    | 0 (0.0)                  | 0 (0.0)                    | 0 (0.0)                    | 0 (0.0)               |
|                | No Assay          | 63 (87.5)                | 68 (94.4)                  | 69 (95.8)                  | 200 (92.6)            |
| Period 1 Day 8 | Total #of samples | 72                       | 72                         | 72                         | 216                   |
|                | Negative          | 18 (25.0)                | 16 (22.2)                  | 21 (29.2)                  | 55 ( 25.5)            |
|                | Positive          | 3 (4.2)                  | 3 ( 4.2)                   | 3 ( 4.2)                   | 9 ( 4.2)              |
|                | Not Reportable    | 0 (0.0)                  | 0 (0.0)                    | 0 (0.0)                    | 0 (0.0)               |
|                | No Assay          | 51 (70.8)                | 53 (73.6)                  | 48 (66.7)                  | 152 ( 70.4)           |
| Period2Predose |                   |                          |                            |                            |                       |
| (Day 1)        | Total #of samples | 69                       | 67                         | 72                         | 208                   |
|                | Negative          | 7 (9.7)                  | 4 ( 5.6)                   | 9 ( 12.5)                  | 20 (9.3)              |
|                | Positive          | 4(5.6)                   | 2 (2.8)                    | 0 (0.0)                    | 6 (2.8)               |
|                | Not Reportable    | 0 (0.0)                  | 1 (1.4)                    | 0 (0.0)                    | 1(0.5)                |
|                | No Assay          | 58 (80.6)                | 60 (83.3)                  | 63 (87.5)                  | 181 (83.8)            |

Abbreviations: ADA = anti-drug antibody; EU =European Union; N = number of patients; n = number of patients in the sample; NAb = neutralizing antibodies; US = United States

Note: Day 8 of Period 1 immunogenicity samples consist of pooled pharmacokinetic samples that were collected on Day8 and Day 9of Period1. There are 2 subjects with samples collected on Day7 and Day8due to missing visit on Day 9.

Study MYL-1401H-1002 was specifically designed to assess immunogenicity and evaluated a 6-mg repeated dose in normal healthy volunteers. It also evaluated both an early (IgM) and late (IgG) immunogenic response in a controlled setting.

Samples for determination of ADA were taken each period on Day -1, on Days 8, 15, and 22, and at follow-up.

Based on the SAF set, the confirmatory assay for ADA was positive at 1 or more time points for 8 of 25 (32.0%) subjects who received MYL-1401H and for 8 of 25 (32.0%) subjects who received USNeulasta. There was no time-dependent increase in ADA titre following dosing of either MYL-1401H or US-Neulasta. Two Subjects (MYL-1401H) and one Subject  (US-Neulasta) had a positive ADA result before first dosing on Day -1 of the first period.

Two subjects (MYL-1401H) continued to have positive ADA results at all time points measured, including follow-up, whereas one Subject  (US-Neulasta) had no positive ADA results after dosing. Positive ADA results at follow-up were seen for 4 subjects who received MYL-1401H and 2 subjects who received US-Neulasta. A maximum titer of 30 was measured once for one Subject  (on Day 15, MYL-1401H) and once for other Subject (at follow-up, US-Neulasta).

Based on the per-protocol (PP)  set (subjects who received both doses of study drug), at the majority of the 9 time points measured, subjects who received MYL-1401H had slightly more positive ADA results than subjects who received US-Neulasta.

<div style=\"page-break-after: always\"></div>

All samples confirmed as positive for ADA (mainly against PEG) were further analyzed for NAb using a validated cell-based assay.

Based on the PP set (subjects who received both doses of study drug), no positive NAb results were seen for any of the subjects. Based on the SAF set however, positive NAb results were seen for one Subjects (MYL-1401H) and one subject (US-Neulasta).

One Subject  (in the MYL-1401H arm) had positive ADA results at 4 time points in Period 1 (pre-dose [Day -1], Day 8 and Day 15, and at follow up after Period 1). At the first 3 of these time points (with ADA titers of 7 [pre-dose], 4, and 30), the NAb results were also positive. This subject was withdrawn after the first period due to a treatment-emergent adverse event (TEAE) of headache and was not included in the PP set; therefore, the subject had a follow-up visit after Period 1. At this follow-up visit, the subject was not positive for NAb.

One subject  had a treatment-emergent, positive ADA result at 1 time point (with an ADA titer of 2 at Period 1, Day 8) at which time the NAb results were also positive. The subject did not have positive ADA prior to study start and therefore, her ADA and NAb positivity was treatment-emergent. As with one Subject, this subject was also withdrawn from the study after Period 1 due to a TEAE of headache and therefore was not included in the PP set.

ADA = anti-drug antibody

<!-- image -->

## Figure 7: Percentages of Subjects with Positive ADA Versus Time by Treatment (PP set)

- Relationship Between Immunogenicity and Pharmacodynamic Results

For the 2 subjects that had a maximum ADA titre of 30, one Subject  (Day 15, MYL-1401H) and other Subject (follow-up, US-Neulasta), the effect of pegfilgrastim treatment on ANC levels appeared not to be different from the subjects that had no positive ADA counts or positive ADA counts with lower titers. Based on this it appeared that the formation of ADA had no effect on the PD effects of pegfilgrastim.

Finally, immunogenicity was also evaluated in the relevant patient population within Study MYL-1401H3001, in which patients with breast cancer received multiple doses of MYL-1401H or Neulasta in addition to their chemotherapeutic dosing regimen. Thus, the overall immunogenicity assessment includes evaluation of early and late immune response, response after multiple dosing in healthy volunteers as well as in patients, and response after low and therapeutic doses of MYL-1401H and Neulasta.

Table 29 and Table 30 summarize the immunogenicity data at the sample and subject levels integrated across the 3 studies.

<div style=\"page-break-after: always\"></div>

The proportions of ADA-positive samples were similar in MYL-1401H and EU-Neulasta groups (8.38.7%) and slightly higher (12.7%) in US-Neulasta group. At a subject level, 22.3% and 23.7% of subjects were positive at least once in MYL-1401H and EU-Neulasta arm respectively, while the proportion was slightly higher at 33% in the US-Neulasta arm. Data from US-Neulasta is only from healthy subjects and it could have contributed to higher proportion of ADA positive response in that arm. Both at subject and sample level, most of the ADA positivity was against the PEG moiety of the molecule across the 3 groups.

Table 29: Integrated summary of all immunogenicity results by sample (1001, 1002, 3001, ITT population)

| Parameter                          | MYL-1401H   | EU-Neulasta   | US-Neulasta   |
|------------------------------------|-------------|---------------|---------------|
| Total #of Samples                  | 1050        | 545           | 417           |
| Positive ADA samples at least once | 91 (8.7)    | 45 (8.3)      | 53 (12.7)     |
| PEG+ only at least once            | 46 (4.4)    | 31 (5.7)      | 33 (7.9)      |
| GCSF+ only at least once           | 13 (1.2)    | 1 (0.2)       | 0 (0.0)       |
| PEG+ & GCSF+ at least once         | 23 (2.2)    | 10 (1.8)      | 16 (3.8)      |
| PEG-& GCSF- at least once          | 9 (0.9)     | 3 (0.6)       | 4 (1.0)       |
| NAb+ at least once                 | 12 (1.1)    | 1 (0.2)       | 1 (0.2)       |

Abbreviations: ADA=antidrug antibody; NAb=neutralizing antibody

Table 30: Integrated summary of all immunogenicity results by subject (1001, 1002, 3001, ITT population)

| Parameter                     | MYL-1401H   | EU-Neulasta   | US-Neulasta   |
|-------------------------------|-------------|---------------|---------------|
| Total # of Subjects           | 224         | 139           | 97            |
| PositiveADAsamplesatleastonce | 50 (22.3)   | 33 (23.7)     | 32 (33.0)     |
| PEG+ only at least once       | 29 (12.9)   | 27 (19.4)     | 23 (23.7)     |
| GCSF+ only at least once      | 3 (1.3)     | 1 (0.7)       | 0 (0.0)       |
| PEG+ & GCSF+ at least once    | 17 (7.6)    | 7 (5.0)       | 11 (11.3)     |
| PEG-& GCSF- at least once     | 8 (3.6)     | 3 (2.2)       | 4 (4.1)       |
| NAb+ at least once            | 6 (2.7)     | 1 (0.7)       | 1 (1.0)       |

Abbreviations: ADA=antidrug antibody; NAb=neutralizing antibody

It is known that healthy subjects and patients are exposed to PEG-containing chemicals in the environment, and that anyone has a potential to develop antibodies against this moiety. This was apparent based on the pre-dose positive samples across each of the 3 studies. Table 30 summarises the pre-dose ADA-positive samples across the studies.

The proportions of samples that were ADA-positive were similar in the MYL-1401H and EU-Neulasta groups (13.5% and 11.5%, respectively) but was quite low in the US-Neulasta group (4.1%), which appears to be a chance finding. Many of the subjects who were ADA-positive prior to dosing continued to remain positive throughout the study. The majority of these subjects had antibodies against the PEG moiety of the molecule.

<div style=\"page-break-after: always\"></div>

Table 31: Integrated summary of pre-dose immunogenicity results by sample (1001, 1002, 3001, ITT population)

| Parameter                     | MYL-1401H   | EU-Neulasta   | US-Neulasta   |
|-------------------------------|-------------|---------------|---------------|
| Total #of Samples             | 223         | 139           | 97            |
| Positive ADA samples pre-dose | 30 (13.5)   | 16 (11.5)     | 4 (4.1)       |
| PEG+ only                     | 14 (6.3)    | 13 (9.4)      | 3 (3.1)       |
| GCSF+ only                    | 2 (0.9)     | 0 (0.0)       | 0 (0.0)       |
| PEG+& GCSF+                   | 9 (4.0)     | 3 (2.2)       | 1 (1.0)       |
| PEG-& GCSF-                   | 5 (2.2)     | 0 (0.0)       | 0 (0.0)       |

Abbreviations:ADA=antidrug antibody;NAb=neutralizing antibody

To assess the treatment-induced impact on immunogenicity, an analysis was conducted to evaluate the post-dose ADA-positive results excluding the subjects who were ADA-positive at baseline. The data at the sample and subject level is presented in Table 32 and Table 33.

Table 32: Integrated summary of post-dose immunogenicity results from subjects who were ADA-negative at baseline by sample (1001, 1002, 3001, ITT population)

| Parameter                      | MYL-1401H   | EU-Neulasta   | US-Neulasta   |
|--------------------------------|-------------|---------------|---------------|
| Total #ofSamples               | 723         | 350           | 306           |
| Positive ADA samples post-dose | 36 (5.0)    | 22 (6.3)      | 44 (14.4)     |
| PEG+ only                      | 23 (3.2)    | 15 (4.3)      | 29 (9.5)      |
| GCSF+ only                     | 1 (0.1)     | 1 (0.3)       | 0 (0.0)       |
| PEG+& GCSF+                    | 9 (1.2)     | 4 (1.1)       | 11 (3.6)      |
| PEG-& GCSF-                    | 3 (0.4)     | 2 (0.6)       | 4 (1.3)       |
| NAb+                           | 2 (0.3)     | 0 (0.0)       | 0 (0.0)       |

Abbreviations:ADA=antidrugantibody;NAb=neutralizing antibody

Table 33: Integrated summary of post-dose immunogenicity results from subjects who were ADA-negative at baseline by subject (1001, 1002, 3001, ITT population)

| Parameter                      | MYL-1401H   | EU-Neulasta   | US-Neulasta   |
|--------------------------------|-------------|---------------|---------------|
| Total # of Subjects            | 192         | 123           | 93            |
| Positive ADA samples post-dose | 20 (10.4)   | 17 (13.8)     | 28 (30.1)     |
| PEG+ only                      | 13 (6.8)    | 13 (10.6)     | 20 (21.5)     |
| GCSF+ only                     | 1 (0.5)     | 1 (0.8)       | 0 (0.0)       |
| PEG+&GCSF+                     | 7 (3.6)     | 4 (3.3)       | 8 (8.6)       |
| PEG-& GCSF-                    | 3 (1.6)     | 2 (1.6)       | 4 (4.3)       |
| NAb+                           | 2 (1.0)     | 0 (0.0)       | 0 (0.0)       |

Abbreviations:ADA=antidrug antibody;NAb=neutralizingantibody

The data indicate that at the sample level, 5.0% and 6.3% of post-dose samples were treatmentemergent ADA-positive in the MYL-1401H and EU-Neulasta groups, respectively.

<div style=\"page-break-after: always\"></div>

The proportion was higher (14.4%) in the US-Neulasta group. At a subject level, the proportions of subjects with post-dose treatment-emergent ADA-positive data were also similar for MYL-1401H and EU-Neulasta groups (10.4% and 13.8%, respectively), while it was 30.1% in the US-Neulasta group. Although the proportion of subjects who were treatment-emergent ADA-positive was higher in the USNeulasta group, the ADA in most cases were against only the PEG moiety, the titers were very low, and the antibodies were non-neutralizing. Only 2 subjects (1 each in the MYL-1401H and EU-Neulasta groups) had antibodies against the GCSF moiety only.

Two subjects were NAb-positive in the MYL-1401H group while none were NAb-positive in either Neulasta group. Table 34 presents the post-dose ADA-positive results excluding the subjects who were NAb-positive at baseline. This analysis is slightly different from analysis in Table 45 as it includes subjects who might have been ADA-positive but NAb-negative prior to dosing. The data indicate that there were 2 subjects who were treatment-emergent NAb-positive in the MYL-1401H group, 1 subject who was NAb-positive in the EU-Neulasta group, and 1 subject who was NAb-positive in the USNeulasta group.

Table 34: Integrated summary of post-dose immunogenicity results from subject Nabnegative at baseline by subject (1001, 1002, 3001, ITT population)

| Parameter                         | MYL-1401H   | EU-Neulasta   | US-Neulasta   |
|-----------------------------------|-------------|---------------|---------------|
| Total # of Subjects               | 218         | 139           | 97            |
| Positive ADA Sample at least once | 26 (11.9)   | 21 (15.1)     | 31 (32.0)     |
| PEG+ only at least once           | 15 (6.9)    | 16 (11.5)     | 21 (21.6)     |
| GCSF+only atleastonce             | 3 (1.4)     | 1 (0.7)       | 0 (0.0)       |
| PEG+& GCSF+ at least once         | 8 (3.7)     | 6 (4.3)       | 11 (11.3)     |
| PEG-&GCSF-at least once           | 4 (1.8)     | 3 (2.2)       | 4 (4.1)       |
| NAb+ at least once                | 2 (0.9)     | 1 (0.7)       | 1 (1.0)       |

Abbreviations: ADA=antidrug antibody; NAb=neutralizing antibody

## Safety in special populations

The applicant did not submit safety in special populations (see clinical safety).

## Safety related to drug-drug interactions and other interactions

The applicant did not submit safety related drug-drug interactions (see clinical safety).

## Discontinuation due to adverse events

Discontinuation from MYL-1401H due to TEAEs was infrequent. In Study MYL-1401H-1001 , 3 TEAEs led to subject withdrawal (rash and abnormal liver function test in 2 subjects after EU-Neulasta, and a SAE of appendicitis in 1 subject after US-Neulasta).

In Study MYL-1401H-1002 , 6 subjects were withdrawn from the study due to TEAEs after dosing in Period 1 (vomiting in 1 subject and headache in 3 subjects in the US-Neulasta group and pain in extremity and headache in 1 subject each in the MYL-1401H group).

<div style=\"page-break-after: always\"></div>

In Study MYL-1401H-3001 , a Grade 2 TEAE of influenza led to discontinuation of MYL-1401H. The event was considered resolved at the time of data analysis. A Grade 3 TEAE of erysipelas led to discontinuation of the patient from the study, although it was considered resolved at the time of data analysis. A Grade 2 TEAE of pneumonitis led to discontinuation of MYL-1401H and from the study. The event was considered resolved at the time of data analysis. Among the patients who received EUNeulasta, a Grade 3 TEAE of increased ALT led to the discontinuation from the study drug. The event was considered resolved at the time of data analysis.

None of the described events were deemed related to the study drug by the investigator.

## Post marketing experience

There is no post marketing experience with Fulphila.

## 2.6.1. Discussion on clinical safety

To assess clinical safety of MYL-1401H intended to be bio-similar to Neulasta (EU) based on the dossier submitted has several challenges.

Trial MYL-1401H-1001 , has a cross-over design and therefore mainly period 1 can contribute to immunogenicity and safety assessment. For immunogenicity, results at the end of period 1 suggest that MYL-1401H is comparable to the reference product.

Trial MYL-1401H-1002 , in healthy volunteers was specifically dedicated to investigate immunogenicity. Healthy subjects are in fact considered a more sensitive model to compare immunogenicity of two pegfilgrastims than immunosuppressed patients, although differences in the frequency of AEs have to be large to be detected in a small trial such as 1002. The confirmatory assay for ADA was positive at 1 or more time points for 8 of 25 (32.0%) subjects who received MYL-1401H and for 8 of 25 (32.0%) subjects who received Neulasta suggesting comparable immunogenicity of both products. Of note, this study used US-sourced Neulasta. The data are however relevant for the present application since an analytical bridge has been established between EU- and US-reference product.

Trial MYL-1401H-3001 , a phase III trial with parallel group design comparing Fulphila with Neulasta EU sourced during 6 cycles of TAC showed similar ADRs that occurred at similar frequencies for Fulphila and Neulasta.

Overall, the AE profile of test and reference appeared similar. There is a high frequency of injection site reactions for MYL-1401H in study 1002. The relative high frequency of injection site reactions (grade 1) in the MYL-1401H arm of trial 1002 was is an isolated finding in the smallest clinical trial and hence is not clinically relevant.

Immunogenicity data derived from the 3 studies suggest similar immunogenicity profiles of test and EU reference. In the integrated analysis, immunogenicity appeared to be higher with US-reference which may be due to the fact that US-Neulasta was only administered to healthy subjects that are more likely to mount an immune response to an antigen than immunocompromised patients on chemotherapy as treated in study 3001. Most of the ADA positivity, including that at predose, was directed against the PEG moiety of the molecule across the 3 groups, which is unsurprising as it is known that exposure to PEG-containing chemicals in the environment may lead to development of antibodies against this moiety.

From the safety database all the adverse reactions reported in clinical trials have been included in the Summary of Product Characteristics.

<div style=\"page-break-after: always\"></div>

## 2.6.2. Conclusions on the clinical safety

Overall, the results from the 3 clinical studies did not show any relevant difference in ADRs or immunogenicity following Fulphila administration compared to Neulasta. The safety of Fulphila supports the claim for similarity with Neulasta.

## 2.7. Risk Management Plan

## Safety concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                                                                                                                                                                                                                 |
|------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | • Severe splenomegaly / splenic rupture • Cutaneous vasculitis • Sweet's syndrome • Anaphylactic reaction • Capillary leak syndrome • Serious pulmonary adverse events (including interstitial pneumonia and acute respiratory distress syndrome) • Sickle cell crisis in patients with sickle cell disease • Musculoskeletal pain-related symptoms • Leukocytosis • Thrombocytopenia • Glomerulonephritis |
| Important potential risks    | • Acute myelogenous leukaemia/ myelodysplastic syndrome • Cytokine release syndrome • Medication errors including overdose • Drug interaction with lithium • Off-label use • Immunogenicity (incidence and clinical implications of anti-G-CSF antibodies) • Extramedullary haematopoiesis                                                                                                                 |
| Missing information          | • Use in paediatric patients • Use during pregnancy and breastfeeding                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

## Pharmacovigilance plan

There is no planned or ongoing additional study in the pharmacovigilance plan.

Routine pharmacovigilance activities are sufficient to address the safety concerns of this medicinal product.

## Risk minimisation measures

| Safety concern                                                                                              | Risk minimisation measures                                                                                             | Pharmacovigilance activities                                            |
|-------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|
| Important identified risks                                                                                  | Important identified risks                                                                                             | Important identified risks                                              |
| Severe splenomegaly / splenic rupture                                                                       | Routine risk minimization measures: SmPC sections: 4.2, 4.4, 4.8 and 5.3. Additional risk minimisation measures: None. | Routine pharmacovigilance activities.                                   |
| Cutaneous vasculitis                                                                                        | Routine risk minimization measures: SmPC sections: 4.2 and 4.8. Additional risk minimisation measures: None.           | Routine pharmacovigilance activities.                                   |
| Sweet's syndrome                                                                                            | Routine risk minimization measures: SmPC sections: 4.2 and 4.8. Additional risk minimisation measures: None.           | Routine pharmacovigilance activities.                                   |
| Anaphylactic reaction                                                                                       | Routine risk minimization measures: SmPC sections: 4.2, 4.3, 4.4 and 4.8. Additional risk minimisation measures: None. | Routine pharmacovigilance activities.                                   |
| Capillary leak syndrome                                                                                     | Routine risk minimization measures: SmPC sections: 4.2, 4.4 and 4.8. Additional risk minimisation measures: None.      | Routine pharmacovigilance activities, including follow up questionnaire |
| Serious pulmonary adverse events (including interstitial pneumonia and acute respiratory distress syndrome) | Routine risk minimization measures: SmPC sections: 4.2, 4.4. and 4.8. Additional risk minimisation measures: None.     | Routine pharmacovigilance activities.                                   |
| Sickle cell crisis in patients with sickle cell disease                                                     | Routine risk minimization measures: SmPC sections: 4.2, 4.4. and 4.8. Additional risk minimisation measures: None.     | Routine pharmacovigilance activities.                                   |
| Musculoskeletal pain- related symptoms                                                                      | Routine risk minimization measures: SmPC sections: 4.2 and 4.8. Additional risk minimisation measures: None.           | Routine pharmacovigilance activities.                                   |
| Leukocytosis                                                                                                | Routine risk minimization measures:                                                                                    | Routine pharmacovigilance                                               |

<div style=\"page-break-after: always\"></div>

| Safety concern                                                                 | Risk minimisation measures                                                                                        | Pharmacovigilance activities                                            |
|--------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|
|                                                                                | SmPC sections: 4.2, 4.4, 4.8 and 5.3. Additional risk minimisation measures: None.                                | activities.                                                             |
| Thrombocytopenia                                                               | Routine risk minimization measures: SmPC sections: 4.2, 4.4 and 4.8. Additional risk minimisation measures: None. | Routine pharmacovigilance activities.                                   |
| Glomerulonephritis                                                             | Routine risk minimization measures: SmPC sections: 4.4 and 4.8. Additional risk minimisation measures: None.      | Routine pharmacovigilance activities.                                   |
| Important identified risks                                                     | Important identified risks                                                                                        | Important identified risks                                              |
| Acute myelogenous leukaemia/ myelodysplastic syndrome                          | Routine risk minimization measures: SmPC sections: 4.2 and 4.4. Additional risk minimisation measures: None.      | Routine pharmacovigilance activities.                                   |
| Cytokine release syndrome                                                      | Routine risk minimization measures: SmPC sections: 4.2. Additional risk minimisation measures: None.              | Routine pharmacovigilance activities, including follow up questionnaire |
| Medication errors including overdose                                           | Routine risk minimization measures: SmPC sections: 4.2. Additional risk minimisation measures:                    | Routine pharmacovigilance activities, including follow up questionnaire |
| Drug interaction with lithium                                                  | Routine risk minimization measures: SmPC sections: 4.2. and 4.5. Additional risk minimisation measures: None.     | Routine pharmacovigilance activities, including follow up questionnaire |
| Off-label use                                                                  | Routine risk minimization measures: SmPC sections: 4.1, 4.2, 4.4. Additional risk minimisation measures: None.    | Routine pharmacovigilance activities, including follow up questionnaire |
| Immunogenicity (incidence and clinical implications of anti-G- CSF antibodies) | Routine risk minimization measures: SmPC sections: 4.2 and 4.4. Additional risk minimisation measures: None.      | Routine pharmacovigilance activities, including follow up questionnaire |
| Extramedullary haematopoiesis                                                  | Routine risk minimization measures: SmPC sections: 4.2 and 5.3. Additional risk minimisation measures: None.      | Routine pharmacovigilance activities.                                   |

<div style=\"page-break-after: always\"></div>

| Safety concern                         | Risk minimisation measures                                                                                             | Pharmacovigilance activities                                           |
|----------------------------------------|------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|
| Missing information                    | Missing information                                                                                                    | Missing information                                                    |
| Use in paediatric patients             | Routine risk minimization measures: SmPC sections: 4.1, 4.2, 4.8 and 5.2. Additional risk minimisation measures: None. | Routine pharmacovigilance activities.                                  |
| Use during pregnancy and breastfeeding | Routine risk minimization measures: SmPC sections: 4.2 and 4.6. Additional risk minimisation measures: None.           | Routine pharmacovigilance activities including follow up questionnaire |

Routine risk minimisation measures are considered sufficient to minimise the safety concerns of this medicinal product.

## Conclusion

The CHMP and PRAC considered that the risk management plan version 2 is acceptable.

## 2.8. Pharmacovigilance

## Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the applicant fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

## Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.9. Product information

## 2.9.1. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

## 2.9.2. Additional monitoring

Pursuant to Article 23(1) of Regulation No (EU) 726/2004, Fulphila (pegfilgrastim) is included in the additional monitoring list as it is a biological product.

<div style=\"page-break-after: always\"></div>

Therefore the summary of product characteristics and the package leaflet includes a statement that this medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information. The statement is preceded by an inverted equilateral black triangle.

## 3. Biosimilarity assessment

## 3.1. Comparability exercise and indications claimed

The claimed indication is identical to the reference product Neulasta: 'Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes)'. Clinical studies supporting the application were carried out in healthy volunteers as part of the biosimilarity exercise as well as a phase III clinical trial in breast cancer patients.

The claim of biosimilarity is based on comparative analytical, nonclinical and clinical data.

## Quality:

To establish biosimilarity of Fulphila to EU Neulasta on the quality level, a comprehensive analytical comparability exercise was performed comparing Fulphila to EU Neulasta. Up to 12 batches of Fulphila and up to 34 batches of EU Neulasta were included in the analytical similarity studies.

## Non-clinical:

Comparative in vitro and in vivo non-clinical studies were performed in order to demonstrate biosimilarity between Fulphila and the reference product Neulasta. In addition, one comparative 28 day repeat dose toxicity study in neutropenic rats was performed.

## Clinical:

With the present application (EMEA/H/C4915) the applicant provides study results from 3 clinical trials, of which MYL-1401H-1001 is the pivotal PK/PD study.

MYL-1401H-1001 was a single centre, randomized, double-blind, 3-period, 3 treatments, 3-way crossover trial to evaluate the PD, PK, safety and tolerability of pegfilgrastim from test product (MYL1401H) compared to reference products EU- and US-Neulasta in healthy subjects. Primary objectives were comparison of PK and PD profiles after a single injection of a 2 mg dose of MYL-1401H and a single injection (2 mg) of EU- and US-Neulasta.

Trial MYL-1401H-1002 was a single-centre, randomized, open-label, repeated dose, parallel group trial intended to evaluate immunogenicity, PD, safety, and tolerability of the test product, MYL-1401H, compared with the reference product, US-licensed Neulasta. Healthy subjects received 2 single SC injections of 6 mg of either the test product, MYL-1401H, or the reference product, US-Neulasta, in 2 separate periods with a washout period of 4 weeks between study drug administrations.

The phase III trial MYL-1401H-3001 was a multicentre, randomized, double-blind, therapeutic equivalence study in breast cancer patients receiving 6 cycles TAC for adjuvant or neo-adjuvant treatment. The primary objective of the study was to compare the efficacy of MYL-1401H versus Neulasta during chemotherapy cycle 1 using duration of severe neutropenia (DSN), defined as days with ANC &lt; 0.5 × 10 9 /L, as endpoint.

<div style=\"page-break-after: always\"></div>

## 3.2. Results supporting biosimilarity

## From a quality perspective:

With respect to primary, secondary and higher order structures comparability of Fulphila with the reference product EU Neulasta has been confirmed. Fulphila has been demonstrated to have an overall similar purity and impurity profile compared to Neulasta which refers in particular to oxidized and reduced, deamidated and charged variants, dimers, di-PEGylated variants and aggregates of pegfilgrastim as well as free filgrastim.

In addition, analytical similarity of Neulasta sourced from US and EU was established.

## From a non-clinical perspective:

The results of in vitro and in vivo studies underline comparability between the two products. In addition, no relevant differences were observed in the 28 day repeat dose toxicity study in neutropenic rats.

## From a clinical perspective:

- Pharmacokinetics and Pharmacodynamics
- Study MYL-1401H-1001 demonstrated similar PK profiles of Neulasta-EU sourced, Neulasta-US sourced, and MYL-1401H (in all comparison-pairs).
- For the comparison test vs. EU reference, the 90% CIs of the primary PK endpoints Cmax and AUC0-inf ([0.984; 1.16] and [0.979; 1.12], respectively] lay well within the predefined acceptance range of 0.8 to 1.25.
- The PD profiles were also similar between the 3 treatments.
- For the comparison test vs. EU reference, the 95% CIs of the primary PD parameters ANC Cmax and ANC AUC0-t ([0.960; 1.028] and [0.959; 1.045], respectively) were well contained within the predefined equivalence range of 0.8500 - 1.1765. Also the 95% CIs of the secondary PD parameters CD34+ Cmax and CD34+ AUC0-t met these margins, further supporting biosimilarity.
- The PD parameters of all three products tested demonstrate that they are equivalent in terms of PD.
- Although study MYL-1401H-1001 was not powered to evaluate equivalence of the primary PD parameters for ANC in a smaller subgroup of ADA negative subjects, these results indicate that the primary PD parameters continued to be similar between MYL-1401H and the reference treatments EU-Neulasta and US-Neulasta in a subgroup of subjects without any ADA positive response at any time point. Also the secondary PD parameters appeared to be similar between MYL-1401H and the reference treatments in this subgroup.
- There were no clinically relevant differences in immunogenicity as shown in the trial MYL1401H-1002 where there were no detectable neutralizing antibodies detected.
- A secondary PD endpoint, however, was ANC which was descriptively analysed and supported the primary endpoints (Cmax and AUC of ANC) as of trial MYL-1401H-1001. The study 1002 is considered supportive of the overall biosimilarity of Fulphila
- Efficacy
- Trial MYL-1401H-3001 met its primary objective. The mean (± SD) DSN in the MYL-1401H group was 1.2 (± 0.93), the median DSN was 1.0, and the DSN ranged from 0 to 5 days.

<div style=\"page-break-after: always\"></div>

- Safety
- The safety and immunogenicity profiles of MYL-1401H and EU-sourced Neulasta appeared generally similar in all 3 studies. The applicant presented within this application an integrated immunogenicity analysis which provided supportive evidence on the similarity of the immunogenicity profile.

## 3.3. Uncertainties and limitations about biosimilarity

There are no remaining uncertainties and limitations that have an impact on the conclusion of biosimilarity of Fulphila and Neulasta.

## 3.4. Discussion on biosimilarity

Analytical similarity of MYL-1401H to the reference product Neulasta (EU) has been shown in a satisfactory manner. Likewise, analytical similarity of Neulasta sourced from EU and US was also demonstrated. Therefore, results obtained in comparison to US-reference product can be bridged and are relevant in supporting the overall biosimilarity exercise in this application.

## Non-clinical

In vitro assays are considered more sensitive than in vivo studies to detect potential differences between test and reference product and hence, the results have shown equivalent similarity between the two products. Results from the in vitro study support a conclusion of functional similarity. The in vivo studies can be considered supportive of the biosimilarity.

## Clinical

The clinical pharmacology studies have shown that the PK and PD data were within the acceptance range for the criteria for biosimilarity and immunogenicity was comparable between Fulphila and Neulasta. In addition, the clinical efficacy and safety data support the claim for biosimilarity as demonstrated by showing equivalent DSN and rates of febrile neutropenia as well as comparable safety profiles between the two products.

Therefore,  considering  the  totality  of  the  evidence  on  the  quality,  non-clinical  and  clinical  data, biosimilarity of Fulphila with the reference product EU Neulasta can be concluded.

## 3.5. Extrapolation of safety and efficacy

The claimed indication is the only indication currently approved for EU-Neulasta ('Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy [with the exception of chronic myeloid leukaemia and myelodysplastic syndromes']).

## 3.6. Additional considerations

Not applicable.

In the EU-Neulasta group, the mean (± SD) DSN was 1.2 (± 1.10), the median DSN was 1.0, and the DSN ranged from 0 to 4 days. The 95% CI (-0.285, 0.298) for the difference in least square mean DSN of MYL-1401H and EU-Neulasta was found to be within the prespecified equivalence range of [-1 day, +1 day].

<div style=\"page-break-after: always\"></div>

## 3.7. Conclusions on biosimilarity and benefit risk balance

Based on the review of the submitted data, Fulphila is considered biosimilar to Neulasta. Therefore, a benefit/risk balance comparable to the reference product can be concluded.

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of Fulphila is favourable in the following indication:

Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

The CHMP therefore recommends the granting of the marketing authorisation subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

## Other conditions and requirements of the marketing authorisation

## Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

<div style=\"page-break-after: always\"></div>

Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States

Not applicable.